

# **Environmental Assessment for Investigational Use of *Aedes aegypti* OX513A**

In support of a proposed field trial of genetically engineered (GE) male *Ae. aegypti* mosquitoes of the line OX513A in Key Haven, Monroe County, Florida under an investigational new animal drug exemption

**August 5, 2016**

**Prepared by**

**Center for Veterinary Medicine**

**United States Food and Drug Administration**

**Department of Health and Human Services**

# 1 Table of Contents

1	Table of Contents .....	2
2	List of Figures .....	8
3	List of Tables .....	9
4	List of acronyms, abbreviations, and technical terms .....	10
5	List of definitions.....	14
6	List of appendices .....	15
7	Executive Summary.....	16
8	Purpose and Need.....	18
8.1	Alternative action.....	20
9	Overview of the rDNA construct in the <i>Ae. aegypti</i> mosquito .....	21
9.1	Description of the product.....	21
9.1.1	Putative mechanism by which tTAV causes developmental failure in <i>Ae. aegypti</i> .....	22
9.2	The rDNA construct used for transformation .....	22
9.2.1	Potential for transposon-mediated remobilization .....	24
9.2.2	Assessment of the introduced genetic elements for their likelihood to pose potential hazards	24
9.2.3	Production of the OX513A line .....	25
9.2.4	Molecular characterization of the #OX513 rDNA construct .....	26
9.2.5	Confirmation of a single insertion site.....	26
9.2.6	Detecting the absence of the plasmid backbone in OX513A <i>Ae. aegypti</i> .....	27
9.2.7	Conclusion .....	27
10	Product.....	28
10.1	Product Identity .....	28
10.2	Proposed Product Claim.....	28
10.3	Conditions for use .....	28
10.4	Product sources .....	29
10.4.1	General overview of <i>Ae. aegypti</i> OX513A production .....	29
10.4.1.1	Mosquito life cycle .....	29
10.4.1.2	Mosquito breeding and husbandry.....	30

10.4.1.3	Mosquito production for investigational use .....	31
10.4.1.4	Egg production .....	33
10.4.1.5	Blood feeding females for egg production .....	34
10.4.1.6	Shipment of eggs to the United States .....	34
10.4.2	Activities based in the United States .....	35
10.4.2.1	Production of adults.....	35
10.4.2.2	Disposal of female insects.....	37
10.4.2.3	Release devices .....	37
10.4.2.4	Transport to release site .....	37
11	Investigational Field Trial .....	38
11.1	Proposed Field Trial .....	38
11.2	Data collection .....	40
11.3	Sample Analysis and Disposal .....	40
11.3.1	Ovitrap analysis.....	40
11.3.2	Adult analysis .....	41
11.3.3	Testing of functional adult mortality .....	41
11.3.4	Estimating <i>Ae. aegypti</i> suppression at the proposed trial site .....	41
12	Environmental Risk Analysis .....	42
12.1	Accessible environments .....	42
12.1.1	<i>Aedes aegypti</i> habitat .....	42
12.1.1.1	Aquatic habitats .....	42
12.1.1.2	Terrestrial habitats.....	43
12.1.2	Monroe County, Florida .....	43
12.1.2.1	Occurrence of natural disasters.....	44
12.1.2.2	Biological and ecological properties .....	45
12.1.2.2.1	Threatened and endangered species .....	45
12.1.2.2.2	National Wildlife Refuges (NWR).....	46
12.1.2.2.3	Conclusion.....	48

12.1.2.3	Proposed release site .....	48
12.1.2.3.1	Environment .....	49
12.1.2.3.2	Water .....	50
12.1.2.3.3	The HRU site.....	51
12.2	Survivability.....	53
12.2.1	Influence of abiotic factors on survivability of OX513A <i>Ae. aegypti</i> .....	53
12.2.1.1	Sensitivity to tetracycline.....	54
12.2.1.1.1	Dose-response study to tetracycline .....	54
12.2.1.1.2	Conclusion.....	57
12.2.1.2	Longevity of OX513A reared on/off tetracycline .....	58
12.2.1.2.1	The evaluation of the potential for changes in penetrance of the introduced traits on exposure to high doses of tetracycline in blood feeding.....	59
12.2.1.2.2	Conclusion.....	61
12.2.1.3	Susceptibility to chemical insecticides .....	61
12.2.1.4	Temperature .....	63
12.2.1.4.1	Study on the temperature response of OX513A .....	64
12.2.1.4.2	Conclusion.....	64
12.2.2	Biotic factors affecting survivability.....	65
12.2.2.1	Reproduction .....	65
12.2.2.1.1	Insemination capacity of OX513A males .....	66
12.2.2.2	Mating competitiveness of the OX513A <i>Ae. aegypti</i> mosquito.....	67
12.2.2.2.1	Mating competitiveness in the laboratory .....	67
12.2.2.2.2	Mating competitiveness in the field .....	68
12.2.2.2.3	Conclusions .....	70
12.3	Dispersion .....	70
12.3.1	Dispersal of the OX513A <i>Ae. aegypti</i> mosquito.....	70
12.3.2	Data obtained from field release on dispersal of OX513A .....	71

12.3.3	Conclusion .....	73
13	Evaluation of Potential Impacts .....	73
13.1	What is the likelihood for inadvertent release of OX513A mosquitoes outside of the proposed trial site? .....	73
13.1.1	Containment measures .....	73
13.1.2	Conclusions .....	76
13.2	What is the likelihood for establishment of OX513A mosquitoes at the proposed trial site? ...	76
13.2.1	Lifecycle parameters .....	76
13.2.2	Mating competitiveness .....	77
13.2.3	Conclusions .....	78
13.3	What is the likelihood of dispersal of OX513A mosquitoes and their progeny from the proposed trial site? .....	78
13.3.1	Conclusions .....	79
13.4	What is the likelihood that the rDNA construct could be transferred to humans or other organisms? .....	79
13.4.1	Likelihood of sexual transfer of rDNA construct .....	79
13.4.2	Likelihood of non-sexual transfer of the rDNA construct .....	80
13.4.2.1	Acquisition of genes through oral ingestion or biting .....	80
13.4.3	Conclusions .....	82
13.5	What is the likelihood that release of OX513A mosquitoes would have an adverse effect on non-target species at the proposed trial site? .....	82
13.5.1	Competition with other mosquito species (conspecifics) .....	83
13.5.2	Predators of <i>Ae. aegypti</i> .....	84
13.5.2.1	Predatory mammals .....	85
13.5.2.2	Predatory birds .....	85
13.5.2.3	Predatory amphibians .....	86
13.5.2.4	Predatory invertebrates .....	86
13.5.2.5	Studies on mosquito predators .....	87
13.5.2.5.1	Studies on <i>Toxorhynchites</i> species .....	87
13.5.2.5.2	Study on fish ( <i>Poecilia</i> species) .....	87
13.5.3	<i>Ae. aegypti</i> and parasitoids .....	88

13.5.4	<i>Ae. aegypti</i> as a decomposer.....	89
13.5.5	<i>Ae. aegypti</i> as a resource for decomposers.....	89
13.5.6	<i>Ae. aegypti</i> as a pollinator.....	89
13.5.7	<i>Ae. aegypti</i> and threatened and endangered species.....	90
13.5.8	Introgression of traits from OX513A to local wild-type <i>Ae. aegypti</i> at release site.....	90
13.5.9	Conclusions.....	91
13.6	What is the likelihood that the rDNA expression products in OX513A mosquitoes would have adverse effects on humans or other animals?.....	91
13.6.1	Bioinformatics studies of the novel proteins expressed in OX513A.....	91
13.6.1.1	tTAV potential toxicity and allergenicity assessment.....	92
13.6.1.2	DsRed2 potential toxicity and allergenicity assessment.....	93
13.6.1.3	Bioinformatics assessment results.....	95
13.6.2	Analysis of expression of the introduced proteins in female mosquito saliva.....	96
13.6.2.1	Study on detection of tTAV and DsRed2 in the saliva of OX513A females.....	96
13.6.3	Conclusions.....	97
14	What are the likely consequences to, or effects on the environment of the U.S. associated with the proposed investigational use of OX513A mosquitoes?.....	97
14.1	Consequences for the environment.....	97
14.2	Consequences for human and non-target animal health.....	99
14.3	Conclusions.....	103
14.4	Consequences of the No Action Alternative.....	103
14.5	Cumulative Impacts.....	103
15	Measures used to minimize potential impacts.....	104
15.1	Physical containment.....	104
15.1.1	ACL2: Standard practices.....	104
15.1.1.1	Safety equipment (Primary barriers).....	107
15.1.1.2	Facilities (Secondary barriers).....	107
15.2	Biological containment.....	108
15.2.1	Potential for the failure of the biological containment.....	109
15.3	Geographical/geophysical containment.....	110
15.3.1	Temperature.....	110

15.3.2	Water storage and rainfall .....	111
15.3.3	Salinity of the ocean surrounding the release site .....	111
15.3.4	Tetracycline in the environment.....	111
16	Risk assessment .....	113
16.1	Uncertainties in the risk assessment .....	121
17	Conclusions .....	122
18	Listing of agencies and persons consulted.....	124
19	References .....	125

## 2 List of Figures

Figure 1. Map of the vector plasmid pOX513 and the helper plasmid #265. ....	25
Figure 2. Schematic of restriction enzyme strategy for Southern Blots. ....	27
Figure 3. General overview of the lifecycle of <i>Ae. aegypti</i> OX513A. ....	30
Figure 4. A schematic of the production process for producing males for release. ....	32
Figure 5. Process flow for UK egg production. ....	33
Figure 6. Process flow for male production for release. ....	35
Figure 7. Temperature vs Precipitation, Key West, FL. Jan 2014 - Mar 2016. ....	44
Figure 8. Storm surge flooding map for Key West. ....	45
Figure 9. Proposed trial area on Key Haven. ....	49
Figure 10. The HRU site at the FKMCD Marathon base. ....	52
Figure 11. Relationships between the proposed site of the HRU and the field trial location. ....	52
Figure 12. Summary of results of tetracycline-loaded blood study. ....	60
Figure 13. Insemination capacity of OX513A males (from (Bargielowski et al. 2011a)). ....	66
Figure 14. Summary of mating competitiveness results against wild-type <i>Ae. aegypti</i> strains worldwide in the laboratory. ....	68
Figure 15. Review of reported mean distance travelled (m) for wild-type and OX513A <i>Ae. aegypti</i> and observed dissemination of #OX513 rDNA construct from male release. ....	72
Figure 16. Amino acid sequence of the tTAV protein. ....	93
Figure 17. Amino acid sequences of the DsRed2 protein. ....	94
Figure 18. Summary schematic of containment measures for egg production facility in the U.S. ....	108

### 3 List of Tables

Table 1. Genetic elements, their donor organisms, and function in #OX513.....	23
Table 2. Average values for male pupae in batches from trials in Cayman, Brazil, and Panama. ....	37
Table 3. Dose-response of hemizygous OX513A larvae to different concentrations of tetracycline.....	55
Table 4. Mosquito mortality recorded 24 hours after exposure to insecticide.....	62
Table 5. Summary of mating competitiveness evaluation of the Oxitec OX513A males in the wild.....	69
Table 6. Potential routes for impacts, consequences, and control strategies for the transport of OX513A mosquitoes from the HRU to the release site. ....	75
Table 7. Summary of guilds potentially exposed to the OX513A <i>Ae. aegypti</i> . ....	84
Table 8. Summary of <i>P. reticulata</i> mortality, length, and weight after 14-day oral exposure to <i>Aedes aegypti</i> . ....	88
Table 9. Risk assessment.....	115

#### 4 List of acronyms, abbreviations, and technical terms

ACL	Arthropod Containment Level
AMCA	American Mosquito Control Association
ASTMH	American Society of Tropical Medicine and Hygiene
BLAST	Basic Local Alignment Search Tools
Bs	<i>Bacillus sphaericus</i>
Bt	<i>Bacillus thuringiensis</i>
Bti	<i>Bacillus thuringiensis israelensis</i>
CFR	Code of Federal Regulations
CFSAN	Center for Food Safety and Applied Nutrition (FDA)
CDC	Centers for Disease Control and Prevention
CVM	Center for Veterinary Medicine (FDA)
DDT	Dichloro-diphenyl-trichloroethane
DNA	Deoxyribo Nucleic Acid
DSP	Daily Survival Probability
DsRed2	Red Fluorescent marker gene from <i>Discosoma</i> species
EA	Environmental Assessment
EIP	External Incubation Period
EST	Expressed Sequence Tag
FAO	Food and Agriculture Organization
FARRP	Food Allergy Research and Resource Program
FASTA	Fast-ALL (DNA and protein sequence format)
FDA	U.S. Food and Drug Administration
FEMA	Federal Emergency Management Agency

FL	Florida
FL DOH	Florida Department of Health
Ft	feet
KH	Key Haven, Florida
FKAA	Florida Keys Aquifer Authority
FKMCD	Florida Keys Mosquito Control District
GE	Genetically Engineered
HRU	Hatching and Rearing Unit
HSE	Health and Safety Executive, UK
HSV	Herpes Simplex Virus
HVAC	Heating, Ventilation and Air Conditioning
IAEA	International Atomic Energy Authority
IBC	Institutional Biosafety Committee
IPM	Integrated Pest Management
INAD	Investigational New Animal Drug
INSP	Instituto Nacional Salud Publica México
L1	1 <sup>st</sup> instar larva
L4	4 <sup>th</sup> instar larva
LPS	Larval Pupal Sorter
LSTM	Liverpool School of Tropical Medicine, UK
LOER	Lowest Observable Effect Rate
Kdr	Knockdown resistance
mRNA	messenger Ribo Nucleic Acid
NA	Native Area
NAS	National Academy of Sciences, USA

NCBI	National Center for Biotechnology Information
NEPA	National Environmental Policy Act
NLAA	Not Likely to Adversely Affect
NOAA	National Oceanic and Atmospheric Administration
NOER	No Observable Effect Rate
NRC	National Research Council, USA
NST	Non-Sexual Transfer
NWR	National Wildlife Reserve
OSTP	Office of Science and Technology Policy, U.S. Office of the Executive
PCR	Polymerase Chain Reaction
PCT	Patent Cooperation Treaty (148 Countries worldwide)
RNA	Ribo Nucleic Acid
piRNA	P-element Induced Wimpy testis- interacting Ribo Nucleic acid
QC	Quality Control
RIDL	Release of Insects with Dominant Lethal (trait)
rDNA	recombinant Deoxyribo Nucleic Acid
RO	Reverse Osmosis
SEM	Standard Error of Mean
SI	Stock Island, Florida Keys
SIT	Sterile Insect Technique
SE	South Eastern
TA	Treated Area
tTA	tetracycline-Transcriptional Activator
tRE	tetracycline Response Element
tTAV	tetracycline-Transcriptional Activator Variant

TetO	Tetracycline Operator
TetR	Tetracycline Repressor
UCA	Untreated Comparator Area
UK	United Kingdom
ULV	Ultra-Low Volume
USDA	United States Department of Agriculture
USFWS	United States Fish and Wildlife Service
U.S.	United States of America
VP16	Viral Protein 16 (tegument protein also called Alpha-TIF from Herpes Simplex Virus1)
v/v	volume per volume
WT	Wild-Type
WHO	World Health Organization
WWTP	Waste Water Treatment Plant

## 5 List of definitions

<b>Term</b>	<b>Definition</b>
Conditional lethal	Survival is dependent on the absence of the dietary antidote; absence of the dietary antidote is the condition that results in lethality; also known as self-limiting
Diploid	An organism having two complete sets of chromosomes
Eclosion	The emergence of an adult insect from a pupal case
Fitness	The extent to which an organism is adapted to or able to survive and reproduce in a particular environment for which the organism is selectively adapted
Gene	Part of a chromosome that controls the expressions of certain biological characteristics of an organism; a portion of DNA that directs the synthesis of a protein
Gene construct	The recombinant DNA introduced into the organism to alter its phenotype
Genotype	An organism's heredity information, even if not expressed
#OX513	Gene construct used in the genetic engineering of the OX513A line
Plasmid	DNA employed in the molecular cloning of DNA fragments
Penetrance	The proportion of individuals of a given genotype that exhibit the phenotype typical of that genotype.
Protein coding sequence	DNA sequence of a gene that is transcribed into mRNA and subsequently translated into protein
PIWI interacting RNA	P-element Induced Wimpy in testis (PIWI)-interacting RNAs (piRNAs) are endogenous small noncoding RNAs
Regulatory sequence	DNA sequence that is not translated into protein (non-protein coding) and acts to control the expression of a gene.
rDNA construct	The regulated article that is composed of regulatory and coding sequences introduced into an organism to alter its structure and function.
Sialome	The set of messages and proteins expressed in saliva glands

## 6 List of appendices

APPENDIX A	Adequate response letter from Centers for Disease Control and Prevention
APPENDIX B	Threatened and endangered species analysis for Monroe County, FL.
APPENDIX C	CBI-deleted Copy of PH-2013-4-v3a Investigating the tetracycline dose response of <i>Aedes aegypti</i> OX513A
APPENDIX D	CBI-deleted Copy of PH-2013-5-V3a Investigating the effects of larval rearing temperature on the phenotype of <i>Aedes aegypti</i> OX513A
APPENDIX E	Report ITF/2011/001 Liverpool Insect Testing Establishment study on insecticide resistance.
APPENDIX F	CBI-deleted Copy of PH-2013-3-V3a Assessment of heterozygous OX513A individuals surviving without provision of tetracycline in the diet: Longevity and Fecundity.
APPENDIX G	CBI-deleted Copy of PH-2013-2-v2 Ingestion of tetracycline by adult female <i>Aedes aegypti</i> does not affect penetrance of the OX513A transgenic phenotype.
APPENDIX H	A laboratory prolonged toxicity study to determine the effects of ingestion of larvae and pupae of the genetically modified sterile mosquito strain <i>Aedes aegypti</i> OX513A towards the guppy <i>Poecilia reticulata</i> ( <i>Actinopterygii: Poeciliidae</i> ); according to OECD No. 204 (1984) modified for oral route of exposure.
APPENDIX I	Expert opinion on toxicity and allergenicity of introduced proteins (2015).
APPENDIX J	Bioinformatics analysis for risks of allergenicity and toxicity of proteins encoded by the two genes introduced into GE mosquitoes ( <i>Ae. aegypti</i> ) strain OX513A for production of sterile males to reduce vector transmission of important human diseases (2013).
APPENDIX K	CBI-deleted Copy of Study Report SR-00004 ED 2.b Western blot analysis of <i>Aedes aegypti</i> OX513A saliva for the detection of tTAV and DsRed2 proteins.
APPENDIX L	Larval mosquito surveillance at the Key Haven sewage treatment plant, Monroe County, FL during the 2004-2015 period.
APPENDIX M	Expert opinion on composition of mosquito saliva and introduction into human host during biting.

## 7 Executive Summary

Oxitec Ltd. (“Oxitec”) has developed a mosquito control program which is an adaptation of the Sterile Insect Technique (SIT), a methodology that has successfully controlled several insect species in different countries over the last 50 years using radiation based sterilization. The Oxitec mosquito control program involves the repeated controlled release of genetically engineered (GE) male *Aedes aegypti* mosquitoes (line OX513A), expressing a conditional lethality trait and a fluorescent marker. The line was first constructed in 2002, and a publication about it was published in a peer-reviewed scientific journal in 2007 (Phuc et al. 2007). This line has been characterized for over 10 years. Male OX513A mosquitoes mate with the wild females of their own species only, leading to a reduction in the population of the local population of *Ae. aegypti*. Male mosquitoes do not bite humans or animals and therefore are unable to transmit or vector viruses or other saliva constituents. Oxitec mosquitoes can be used in two ways: to reduce the *Ae. aegypti* population in an area, and/or to prevent its recurrence once control in the area has been achieved.

The purpose of this proposed investigational field trial is to evaluate the mating ability of released OX513A mosquitoes with local wild-type *Ae. aegypti* females, to assess the survival of the resultant progeny in order to estimate mortality related to inheritance of the #OX513 recombinant DNA (rDNA) construct, and to determine the efficacy of sustained releases of OX513A mosquitoes for the suppression of a local population of *Ae. aegypti* in the defined release area in the Florida Keys, specifically an area known as Key Haven, in Monroe County, which is within the jurisdiction of the Florida Keys Mosquito Control District for mosquito control.

Released adult OX513A mosquitoes are homozygous for an rDNA construct that confers both late-acting lethality to the line in the absence of tetracycline as a dietary supplement (tTAV), and a gene that encodes a fluorescent marker (DsRed2), stably integrated at a specific site in this specific line of the *Ae. aegypti* mosquito. Penetrance<sup>1</sup> of expression of the lethality trait is > 95% (i.e., 95% of the GE mosquitoes containing the lethality trait exhibit the associated lethal phenotype). Eggs for the proposed field trial would be produced in the UK for shipment to the Hatching and Rearing Unit (HRU) located in Marathon, Florida. Once introduced into the secured HRU, the mosquitoes would be hatched and reared to pupae, which would be sorted mechanically to ensure accuracy of sorting does not exceed a maximum of 0.2% females using the difference in size between male and female pupae (sexual dimorphism). Males, which do not bite, blood feed, or transmit disease, would be used for the release.

As a framework for this environmental assessment, we have developed several risk-based questions listed below:

---

<sup>1</sup> Penetrance is the proportion of the population that carries the conferred trait and exhibits the phenotype associated with this trait. 95% penetrance means that 95% of the population with the gene (in this case tTAV) also expresses the introduced trait (i.e. also has the tTAV-associated lethality phenotype).

- What is the likelihood of inadvertent release of OX513A mosquitoes outside of the proposed trial site?
- What is the likelihood of establishment of OX513A mosquitoes at the proposed trial site?
- What is the likelihood of dispersal of OX513A mosquitoes and their progeny from the proposed trial site?
- What is the likelihood that the rDNA construct could be transferred to humans or other organisms?
- What is the likelihood that release of OX513A mosquitoes would have adverse effects on non-target species at the proposed site?
- What is the likelihood that the rDNA expression products in OX513A mosquitoes would have adverse effects on humans or other animals?
- What are the likely consequences to, or effects on the environment of the United States associated with the investigational use of OX513A mosquitoes?

In risk assessment, risk [R] may be defined as the joint probability of exposure [P(E)] **and** the conditional probability of harm (H; i.e., adverse effects) given that the exposure to a hazard has occurred [P(H|E)]:  $R = P(E) \times P(H|E)$  or Risk = Exposure x Adverse Effect. If either one of the parameters is determined to be negligible (close to zero), then the likelihood of a significant impact is likely to be negligible as well, because the outcome is the two probabilities multiplied by each other. Data and information presented in this EA to address these risk-related questions are based on semi-field and field studies, laboratory studies, and published literature.

The likelihood of escape, survival, and establishment of OX513A would be highly unlikely due to a combination of physical, geophysical, geographic, and biological measures that would be in place during egg production, transport, local rearing, and release. Physical measures would include premises that conform with the Arthropod Containment Guidelines<sup>2</sup> to prevent escape; use of screens, filters, traps, and multiple levels of containment; devices for transport that have multiple layers of containment; as well as use of trained personnel to ensure containment is appropriately implemented. Geographic containment would be provided by the siting of the egg production unit in the UK, which is beyond the isothermal range of the mosquito (i.e., it is too cold for *Ae. aegypti* to survive outside the climate controlled environment of the laboratory). Geophysical containment would be provided by the island location of the proposed release site, which is predominantly surrounded by ocean, and the mosquito in any life stage cannot survive due to the high salinity of the waters. Biological containment would be afforded by the introduction of the conditional lethality trait into the OX513A *Ae. aegypti* line, where on mating with the local females of the same species, >95% of the progeny will not survive to functional

---

<sup>2</sup> The Arthropod Containment Guidelines have been developed by the American Committee on Medical Entomology and American Society for Tropical Medicine and Hygiene to provide risk-based guidelines for arthropod containment and to safeguard individuals coming into contact with arthropods. They have been adopted by most institutions working with arthropods as the operating standard for containment, and can be found online at <http://www.astmh.org/subgroups/acme#arthropod> [Accessed June 21, 2016].

adulthood in the absence of tetracycline (Harris et al. 2011), leading to the overall reduction in the population of *Ae. aegypti* at a given site.

The consequences of escape, survival, and establishment of OX513A in the environment have been extensively studied: data and information from those studies indicates that there are unlikely to be any adverse effects on non-target species, including humans. Risk of establishment or spread has been determined to be negligible. The trial is short in duration and any unanticipated adverse effects are unlikely to be widespread or persistent in the environment. Most importantly, the status of the environment is restored when releases are stopped (i.e., the released mosquitoes all die, and the environment reverts to the pre-trial status). Overall, the environmental assessment concludes that the production, rearing, and short term release of the *Ae. aegypti* line OX513A for investigational use in Key Haven, Florida would be unlikely to result in adverse effects on the environment or human health.

## 8 Purpose and Need

The U.S. Food and Drug Administration (FDA)'s Center for Veterinary Medicine (CVM, we) has received a proposal for Oxitec's proposed field trial of genetically engineered (GE) male *Ae. aegypti* mosquitoes of the line OX513A in Key Haven, Monroe County, Florida under an investigational new animal drug (INAD) exemption (21 CFR 511.1(b)). *Ae. aegypti* is a known vector for the human diseases associated with Zika, dengue, and chikungunya viruses. OX513A have been genetically engineered to express a gene that encodes a conditional or repressible lethality trait (also known as self-limiting) (see below for discussion of how this function operates) and a red fluorescent marker protein to aid in the identification of GE mosquitoes. The field trial would be carried out in conjunction with the Florida Keys Mosquito Control District (FKMCD) to evaluate the use of male *Ae. aegypti* OX513A line to reduce the population of local *Ae. aegypti*.

Oxitec Ltd. intends to ship eggs from the OX513A line of *Ae. aegypti* mosquitoes for a study in Key Haven, Monroe County, Florida. In conjunction with the FKMCD, Oxitec proposes to conduct an open field release trial for the OX513A *Ae. aegypti* male mosquitoes to determine whether such releases can reduce the population of local *Ae. aegypti*. Data collected during this study may be used in support of the New Animal Drug Application for this product.

Local transmission of dengue fever, a viral disease transmitted by the mosquito vector *Ae. aegypti* was reported in the Florida Keys in 2009 and 2010, with 22 people diagnosed in 2009 and a further 66 people in 2010, with other cases in Miami-Dade and Broward counties (CDC 2010; Radke et al. 2012). Case counts for locally-acquired dengue and those imported from other countries can be found in the weekly surveillance report of the Florida Department of Health<sup>3</sup>. A CDC report issued in 2010 (CDC 2010) estimated that nearly 1,000 people in the Florida Keys had been exposed to the virus (approximately 5% of the population). 2009 saw the first occurrence of locally-acquired dengue in the Keys since the 1930s;

---

<sup>3</sup> <http://www.doh.state.fl.us/Environment/medicine/arboviral/surveillance.htm> [Accessed June 20, 2016].

no locally acquired cases were reported in 2011, although in September 2012, one case of local transmission was recorded in Miami-Dade County (FLDOH 2012). In 2013, further cases of locally acquired dengue were reported in Martin County, Florida, where a total of 28 individuals were identified as infected (FLDOH 2013). In 2014, the Florida Department of Health confirmed locally acquired cases of chikungunya fever in Miami-Dade, St. Lucie, and Palm Beach Counties as well as 4 cases of locally acquired dengue. Thus far in 2016, the Florida Department of Health has confirmed one locally-acquired case of dengue in a visitor to Key West, Monroe County.<sup>4</sup> Frequent air travel to dengue endemic countries, transport of goods and trade, along with the continued presence of the vector species and human behaviors that facilitate mosquito bites means that dengue and chikungunya virus transmission is therefore a consistent public health threat in this area (Teets et al. 2014).

Control of the *Ae. aegypti* mosquito, also known as vector control, is currently the most effective way of reducing the incidence of dengue<sup>5</sup>. Vector control is currently carried out by a variety of means including chemical control, source reduction such as removal of mosquito breeding sites, and use of trapping methods, and combinations thereof, known as integrated pest management (IPM). Even a well-organized mosquito control program, using integrated mosquito management measures, cannot always be effective against the mosquitoes as it is not possible to access all of the breeding sites with the current control measures.

The FKMCD is interested in assessing the utility of new tools to manage *Ae. aegypti* populations. Based on promising results elsewhere, including the Cayman Islands (Harris et al. 2011; Harris et al. 2012); Brazil (Carvalho et al. 2015), where the Brazilian National Biosafety Commission (CTNBio) determined in 2014 that the Oxitec OX513A mosquito is safe for use in Brazil<sup>6</sup>, and Panama (Gorman et al. 2016), FKMCD is seeking to assess the utility of the OX513A *Ae. aegypti* mosquito for *Aedes aegypti* vector control in Monroe County.

Oxitec Ltd. as the Sponsor would conduct the trial in collaboration with FKMCD<sup>7</sup>. This document constitutes the Environmental Assessment (EA) that considers the potential consequences that such an investigational field trial might have on the environment and human and animal health.

---

<sup>4</sup> <http://monroe.floridahealth.gov/newsroom/2016/06/160601-Dengue.html> [Accessed June 15, 2016].

<sup>5</sup> Currently there are several clinical trials of vaccines against dengue, but the results have not indicated effective immunity against all strains of dengue (Halstead 2012; Swaminathan et al. 2013)

<sup>6</sup> <http://ctnbio.mcti.gov.br/documents/566529/686098/Thecnical+Report+3964-2014+-+Commercial+Release+of+strain+OX513A+of+Aedes+aegypti+-+Process+01200.002919-2013-77/be405f52-a1a5-4c01-97a6-5cd95e058e53> [Accessed June 20, 2016].

<sup>7</sup> FKMCD's role in the trial is as a collaborator. They are supplying resources and facilities to Oxitec for the conduct of the field trial.

## 8.1 Alternative action

Under the National Environmental Policy Act (NEPA), 42 U.S.C. § 4321 et seq., and its implementing regulations, all EAs should include a brief discussion of alternatives to the proposed action as well as environmental impacts of these alternatives. This section focuses on the “No Action” alternative and discusses its potential impact on the quality of the human environment in the United States.

A “No Action” alternative in this case would be for Oxitec not to carry out the field trial in Key Haven, Florida. The plausible outcomes of this decision are that Oxitec could continue development and commercialization of the product at locations outside of the United States with no intent to conduct a field trial in the United States, or they could select another location in the United States to conduct the field trial(s). With respect to the former, Oxitec may seek regulatory approval from other countries interested in its product. For example, Oxitec has performed several open field release trials in various countries including the Cayman Islands, Malaysia, Panama, and Brazil. Should Oxitec wish to select another location in the United States to conduct a field trial, it would prepare a separate environmental assessment for that investigational release.

In the event of this alternative, the FKMCD would continue to use its existing control measures for the *Ae. aegypti* mosquitoes without also conducting the investigational field trial. (FKMCD will continue its current vector control program whether the field trial proceeds or not.) Currently, FKMCD utilizes integrated mosquito management practices, which involve a variety of methods to reduce *Ae. aegypti* mosquitoes including adulticides, larvicides, source reduction, and biological controls.

The primary method of control of the *Ae. aegypti* mosquito is source reduction, involving domestic inspectors throughout the Florida Keys, and aerial larvicide application (by helicopter) primarily in Key West. The inspectors’ primary responsibility is to find and eliminate domestic breeding habitats. Where this is not possible, inspectors treat containers by hand. The larvicide utilized is largely dependent upon the species, juvenile life stage (instar) of the mosquito, and container size and type in which the mosquito larvae are found. Larvicides include *Bacillus thuringiensis israelensis* (Bti), *Bacillus sphaericus* (Bs), methoprene, temephos, and Spinosad, or oil dispersants such as Kontrol or CocoBear. These products are rotated to avoid prolonged exposure of mosquito larvae to a particular larvicide’s mode of action. Standard treatment of larval *Ae. aegypti* is Bti if the larvae are 1st through 3rd instar. The mosquitofish, *Gambusia affinis*, is also used as a larvicide in permanent water bodies such as cisterns, abandoned pools, and ornamental ponds.

The main delivery method of these larvicides is by helicopter, in the form of small droplets. However, backpack sprayers and direct treatments by hand; using granules, pellets, and tablets can also be utilized to treat smaller areas. The main larvicides utilized by inspectors by hand are methoprene and Spinosad due to the residual properties of these products. Methoprene is an insect growth regulator that inhibits mosquito larvae from developing into viable adults. Spinosad causes excitation of the mosquito's nervous system leading to paralysis and death. Backpack sprayers are employed in the treatment of tire piles and large groups of breeding containers with temephos. Temephos is an organophosphate larvicide used for control of *Ae. aegypti* larvae. Larval control is by far the most efficient means of *Ae. aegypti*

control; however, FKMCD also uses adult control methods when population numbers are high and disease is present.

Adult control of *Ae. aegypti* is extremely difficult due to the behavior of the species; therefore, adulticide treatments are not regularly employed. The most common and effective treatment for adult *Ae. aegypti* is the use of handheld ultra-low volume (ULV) sprayers. These are utilized by inspectors when *Ae. aegypti* are present during domestic inspections. The product used is a combination of sumithrin and prallethrin, which are classified as pyrethroids. In some instances, FKMCD uses the chemical Naled to control adult mosquitoes in an aerial program. The FKMCD is constantly monitoring for resistance of *Ae. aegypti* to all of these products to aid in the control of *Ae. aegypti*, the most effective means of control is source reduction and larviciding which is FKMCD's main emphasis. Even with these efforts, control of *Ae. aegypti* is at best 50% effective<sup>8</sup> and there is increasing resistance developing to these insecticides (Ranson et al. 2010).

## 9 Overview of the rDNA construct in the *Ae. aegypti* mosquito

### 9.1 Description of the product

The working product definition is

**“The single integrated copy of the OX513 rDNA construct, located at the OX513 site, directing expression of an insect-optimized tetracycline repressible transactivator protein (tTAV), intended to produce conditional lethality and decreased survival of resulting progeny and a red fluorescent protein (DsRed2), to aid detection of these mosquitoes, contained within a specific homozygous diploid line (OX513A) of mosquito, *Aedes aegypti*.”**

The *Ae. aegypti* mosquito has been engineered to express two traits: the overexpression of a synthetic protein leading to lethality of the mosquito under the control of a tetracycline repressible promoter, and a fluorescent marker protein to aid detection. The conditional lethality trait or “self-limiting” trait prevents progeny inheriting the #OX513 rDNA construct from surviving to functional adulthood in the absence of tetracycline. This is a similar concept as making insects sterile with irradiation. The sterile males compete with the wild-type males for female insects. If a female mates with a sterile male then it will have no offspring, reducing the next generation's population. Repeated release of irradiated insects can reduce the insect population to very low levels. Sterile Insect Technique has been widely used as a successful control tool in plant and animal pest species for over 50 years.

---

<sup>8</sup> <http://keysmosquito.org/wp-content/uploads/2015/05/2015-06-23-Reg-Mtg-Minutes.pdf> [Accessed March 4, 2016]

### 9.1.1 Putative mechanism by which tTAV causes developmental failure in *Ae. aegypti*

The tTAV (tetracycline transcriptional activator variant) protein binds to and activates expression from the tetracycline response element (tRE) which includes the specific DNA sequence to which tTAV binds (tetO), but in the presence of the antibiotic tetracycline or its analogues, it binds preferentially with high affinity to tetracycline preventing it from binding tRE DNA in the cell (Gossen and Bujard 1992), thus preventing the transcription of the gene regulated by that promoter.

Therefore, tTAV acts as a tetracycline regulated switch. High level expression of tTAV is deleterious to cells as it represses normal transcriptional function. Transcription is the process in the cell by which RNA is produced (the transcript), and the transcript is “translated” to make a protein. Developmental failure occurs when the cells cannot make the proteins they require to function normally which then causes cell death. This is known as transcriptional squelching and may be independent of the DNA binding action (Lin et al. 2007) of the transcriptional activator. tTA and its variants, such as tTAV, have been used in fungi, rodents, plants, and mammalian cultures with no known non-target adverse effects on the environment or human health<sup>9</sup>. Its wide use is due to the observation that it is well tolerated in eukaryotic systems (Zhu et al. 2002; Munoz et al. 2005; Stieger et al. 2009; Naidoo and Young 2012; Schonig et al. 2013).

## 9.2 The rDNA construct used for transformation

Genetic transformation of insects involves the stable integration of exogenous DNA into the genome of the insect. This requires a suitable method to get the DNA to insert itself into the genome. This is brought about by the use of non-autonomous transposons, which are genetic elements that will transpose, or move from one place to another in the genome, when an external source of an enzyme, referred to as a transposase is used. The non-autonomous transposons are incorporated into a gene construct along with the other genetic elements required to change the insect phenotype and are used for the transformation of the insect.

#OX513<sup>10</sup> is an rDNA construct consisting of regulatory sequences from *Ae. aegypti* and *Drosophila melanogaster* and protein coding sequences from tetracycline transcriptional activator variant known as tTAV (synthetic source; see Table 1) and DsRed2 (sourced from the *Discosoma* species of marine coral) and non-autonomous transposon inverted terminal repeat sequences from the *Trichoplusia ni piggyBac* transposable element. A full list of the genetic elements in #OX513, their originating donor organisms, and primary literature reference, is provided in Table 1. DNA sequences are not taken directly from the donor organism but from sequence databases and then optimized for expression in insects. Sequencing analysis, conducted by Oxitec, has confirmed the plasmid sequence is as expected.

---

<sup>9</sup> <http://www.tetsystems.com/science-technology/highlighted-publications/> [Accessed June 20, 2016].

<sup>10</sup> #OX513 is the designation Oxitec uses for the rDNA construct introduced into *Ae. aegypti*; OX513A refers to the resulting GE *Ae. aegypti* mosquito line.

**Table 1. Genetic elements, their donor organisms, and function in #OX513.**

Genetic Element	Location (bp) in plasmid pOX513	Size (bp)	Originating Donor Organism and Common name	Reference	Function
3' Inverted Terminal Repeat (ITR)	8508-8570	63	<i>Trichoplusia ni</i> (Cabbage looper moth)		Short related sequences in reverse orientation at the end of the <i>piggybac</i> transposon. Transposases recognize these to integrate the DNA into the chromosome.
<i>piggyBac</i> 3'	7524-8507	984	<i>Trichoplusia ni</i> (Cabbage looper moth)	(Cary et al. 1989; Thibault et al. 1999)	DNA transposable element with sequence deletions to prevent mobility.
Non-coding	7484-7523	40			
Actin5C	4833-7483	2651	<i>Drosophila melanogaster</i> (Vinegar fly)		Promoter element driving the expression of the marker gene.
Non-coding	4818-4832	15			
DsRed2	4134-4817	684	<i>Discosoma</i> (Coral)	(Matz et al. 1999; Lukyanov)	Red fluorescent protein marker gene.
Non-coding	4126-4133	8			
Drosomycin 3' UTR	3340-4125	786	<i>Drosophila melanogaster</i> (Vinegar fly)		Terminator region (polyadenylation signal).
Non-coding	3301-3339	39			
<i>tetOx7</i>	3005-3300	296	<i>Escherichia coli</i> (bacteria)	(Gossen and Bujard 1992)	Non-coding binding site for tTAV.
Non-coding	3000-3004	5			
<i>hsp70</i> minpro	2870-2999	130	<i>Drosophila sp.</i> (Vinegar fly)		Promoter element driving tTAV expression
Non-coding	2858-2869	12			
<i>adh</i> intron	2788-2857	70	<i>Drosophila sp.</i> (Vinegar fly)		Enhances gene expression.
Non-coding	2780-2787	8			
tTAV	1766-2779	1014	Synthetic DNA based on a fusion of sequences from <i>E. coli</i> (tetR - tetracycline repressor) and HSV-1 (VP16 transcriptional activator)	(Gossen and Bujard 1992; Gong et al. 2005)	Tetracycline repressible transcriptional activator.

Genetic Element	Location (bp) in plasmid pOX513	Size (bp)	Originating Donor Organism and Common name	Reference	Function
K10 terminator	934-1715	782	<i>Drosophila sp.</i> (Vinegar fly)		Terminator region (polyadenylation signal).
Non-coding	830-933	103			
<i>piggyBac</i> 5'	192-829	638	<i>Trichoplusia ni</i> (Cabbage looper moth)	(Cary et al. 1989)	DNA transposable element with sequence deletions to prevent mobility.
5' ITR	157-191	35	<i>Trichoplusia ni</i> (Cabbage looper moth)		Short related sequences in reverse orientation at the end of the <i>piggybac</i> transposon. Transposases recognize these to integrate the DNA into the chromosome.

### 9.2.1 Potential for transposon-mediated remobilization

The *piggyBac* transposable element is a non-autonomous transposon isolated from the cabbage looper moth *Trichoplusia ni*, which has been well studied and used to transform a wide range of insect taxa: Diptera, Lepidopteran, Coleoptera (Jasinskiene et al. 1998; Tamura et al. 2000; Handler 2002; Koukidou et al. 2006; Kuwayama et al. 2006; Labbé et al. 2010). A non-autonomous transposon, which has integrated into the genome, is prevented from moving within or outside the genome of its host because it does not encode or produce the associated transposase enzyme that is necessary for such movement. The integrated non-autonomous *piggyBac* vector is highly stable in the *Aedes* genome when exposed to exogenous transposase under a wide variety of conditions; numerous studies indicate that the inserted *piggyBac* elements are completely stable and unable to remobilize (O'Brochta 2003; Sethuraman et al. 2007; Palavesam et al. 2013). Arensburger et al. (2011) has proposed that the stability of the transposons in *Ae. aegypti* is the result of a low proportion of transposon-specific piRNAs. Therefore, transposon mediated remobilization is not expected in OX513A, nor has any instability in the transformed line, OX513A been observed to date in over 100 generation equivalents (see Section 9.2.3).


### 9.2.2 Assessment of the introduced genetic elements for their likelihood to pose potential hazards

The potential for the inserted genetic elements to pose potential risks to humans, non-target animals, or the environment has been evaluated in Section 13. In addition to the analysis reported in that Section, further scientific literature searches in the PubMed (NCBI) database maintained by the U.S. National Library of Medicine were conducted to address the issue of whether the introduction of these mosquitoes could likely have a direct or indirect impact on human health. The database was queried as to whether the source of the gene or sequence used in the #OX513 rDNA construct is a common cause of allergy or toxicity or is linked to pathogenicity. The scientific literature review determined that there were no sequences in the construct that are directly or indirectly likely to be toxic, allergenic, or pathogenic to humans, animals, or the environment. The release would use >99% male OX513A mosquitoes (sorted to a level of accuracy that ensures no more than 0.2% are females) which cannot bite

humans. However, to assess the potential risk of a bite from a female OX513A mosquito, Oxitec performed a study to determine whether the synthetic proteins tTAV and DsRed2 are detectable in the female OX513A mosquito saliva (Section 13.6.2).

### 9.2.3 Production of the OX513A line

The OX513A line was produced in 2002 (Phuc et al. 2007) by microinjecting the #OX513 rDNA construct with a transposase helper plasmid (#265) into individual embryos of *Ae. aegypti* from a Rockefeller strain background (Figure 1). The transposase helper plasmid provides a source of *piggyBac* transposase, to allow the rDNA construct to be integrated into the germline of *Ae. aegypti*. The non- autonomous transposon has no endogenous source of transposase in mosquitoes and has had no further translocation.



**Figure 1. Map of the vector plasmid pOX513 and the helper plasmid #265.**

Survivors from the microinjection ( $G_0$ ) were back-crossed to wild-type *Ae. aegypti* and the females were allowed to lay eggs ( $G_1$ ). Hatched  $G_1$  larvae were screened for the fluorescent marker gene. Two independent GE strains were recovered from approximately 200 fertile  $G_0$  back crosses. The line designated LA513A in the paper describing transformation (Phuc et al. 2007) and subsequently renamed as OX513A, was selected for further development due to the strong expression of the fluorescent marker gene and the high penetrance (>95%) of the lethality trait when reared in the absence of tetracycline. This line has been maintained in culture at Oxitec since that time, often in pooled rearing, where eggs are collected at particular time points allowing egg storage for extended periods. *Ae. aegypti* development time varies with temperature, so along with the egg storage, this leads to a time-based estimate of the rate of progress through generations rather than a discrete, generation-based rearing. Consequently, generations are referred to as “generational equivalents” based on time rather than discrete generations.

The line was made homozygous by repeated back-crossing and then the insert was introgressed into an *Ae. aegypti* Latin strain background from Instituto Nacional de Salud Publica (INSP), Mexico. The line has been maintained by Oxitec in a continuously cycling insect colony for the equivalent of over 100 generations.


#### **9.2.4 Molecular characterization of the #OX513 rDNA construct**

Inverse PCR has been used to identify the genomic sequence adjacent to the insertion site of OX513A according to the method of Handler et al. (1998). Restriction enzymes were chosen that cut in the *Ae. aegypti* genome approximately every 500 bp-5 kb. The fragments were circularized and amplified using primer sequences in opposite orientation within the *piggyBac* restriction site and terminus for each junction (5' and 3'). The products were gel purified, cloned, and sequenced. PCR products were compared to *piggyBac* terminal sequences by DNA alignment and BLAST analysis to identify genomic insertion sites. The results revealed the expected *piggyBac* inverted terminal repeats sequences immediately adjacent to a TTAA tetranucleotide sequence characteristic of all *piggyBac* integrations and flanking sequences of 307 bp and 315 bp at either side of the insertion site. The combined flanking sequence was compared with the relatively poorly annotated *Ae. aegypti* genome sequence (publically available via Vectorbase <https://www.vectorbase.org>), transcript and EST databases using the BLAST tool.

The sequence was compared in both orientations at the nucleotide level and at the translated sequence level in all six reading frames with amino acid sequences in the database. The flanking sequence shows 94.6% identity across its length to a single genome sequence contig (1.859), giving an unambiguous match. No new open reading frames were found in all six possible reading frames, inferring that no genes appear to be disrupted by the #OX513 rDNA construct insertion and no new genes are created.

#### **9.2.5 Confirmation of a single insertion site**

Southern blot analysis was used to detect the number of insertion sites. Southern blot hybridization was conducted on genomic DNA extracted from individuals of the OX513A line from generational equivalent 96. Three restriction enzymes (*AgeI*, *BglII*, and *Sall*) were chosen such that they cleaved the DNA only once in area of the rDNA construct recognized by the chosen probes (A5C+DsR and TetR) as shown in Figure 2.



**Figure 2. Schematic of restriction enzyme strategy for Southern Blots.**

*AgeI* cleaves within the *piggyBac* 3' of the rDNA construct at 853 bp and further downstream in the genomic DNA to produce a band expected to be more than 7565 bp. *BglIII* cleaves within the Act5C promoter sequence at 1286 bp and so is expected to produce a fragment of more than 7131 bp. *Sall* cleaves within the tTAV sequence at 6566 bp and 6817 bp to produce a band expected to be more than 6566 bp on the Southern Blot. Following gel electrophoresis and probing of the membrane with the specific probes, bands of the expected sizes were obtained.

The entire integrated #OX513 rDNA construct insertion in the insect has been sequenced and compared to the sequence of the injected plasmid rDNA construct. There was 100% identity between the sequenced fragments and the #OX513 vector plasmid and genomic flanking sequences indicating no re-arrangements have occurred.

Both of these tests confirm that there is a single, complete copy of the rDNA construct in OX513A *Ae. aegypti* at a single discrete genomic integration site.

### 9.2.6 Detecting the absence of the plasmid backbone in OX513A *Ae. aegypti*

The backbone sequence of the #OX513 rDNA construct includes an ampicillin resistance gene and a bacterial origin of replication to allow growth in *E.coli*. Sequencing of the flanking genomic DNA showed no evidence of the plasmid backbone at the site of the rDNA construct insertion.

### 9.2.7 Conclusion

The molecular characterization of the OX513A line has shown that the sequence of the insert in the GE insect is as intended without re-arrangements. Based on flanking sequence analysis, the insert does not interrupt any genes and, based on flanking sequence analysis, no additional proteins apart from the

intended ones are likely to be produced. The GE insect does not contain plasmid backbone sequences as verified by PCR analysis. The non-autonomous transposable element used in the transformation is stable under a wide variety of conditions; published evidence is available to indicate that it would be refractory to movement, even if exposed to exogenous transposases (Section 9.2.1). Additionally, the insert has been shown to be stable and a complete single copy insertion. Genotyping of generational equivalents at G<sub>60-64</sub> and G<sub>100</sub> showed that the genotype has been consistent across 36 generational equivalents. No sequences have been inserted that encode for pathogens, toxins, or allergens as evidenced by both literature searches and bioinformatics studies (Section 13.6.1).

Therefore, we conclude there are unlikely to be potential risks to the animal (OX513A *Ae. aegypti*) from the genetic engineering, apart from the intended effect of lethality in the absence of tetracycline.

## 10 Product

### 10.1 Product Identity

Oxitec is currently operating under the following working product definition:

**“The single integrated copy of the #OX513 rDNA construct, located at the OX513 site, directing the expression of an insect-optimized tetracycline-repressible transactivator protein (tTAV), intended to produce conditional lethality and decreased survival of resulting progeny, and a red fluorescent protein (DsRed2), to aid detection of these mosquitoes, contained with a specific homozygous diploid line (OX513A) of mosquito, *Aedes aegypti*.”**

### 10.2 Proposed Product Claim

A working claim, against which this investigational use will be assessed, in order to validate the proposed claim has been determined as:

**“OX513A males mate with local wild-type, non-GE female *Aedes aegypti* in a population so that the resulting progeny carry a copy of the #OX513 rDNA construct and produce at least a 2-fold increase in mortality of these #OX513 rDNA construct-bearing progeny relative to local non-GE progeny before they reach functional adulthood.”**

As this is a working claim, and it is the purpose of the investigational use proposed to test the claim, it is subject to change.

### 10.3 Conditions for use

This investigational use includes all processes regarding the import, rearing, and field release of OX513A *Ae. aegypti* for the conduct of the proposed trial. OX513A eggs would be produced at Oxitec Ltd., UK and shipped by air in multiple shipments to the U.S.<sup>11</sup> for rearing to adults in a specialized facility, known

---

<sup>11</sup> See Section 10.4.1.6 for a more complete description of import permits.

as the Hatching and Rearing Unit (HRU), located in Marathon, FL. Adult male mosquitoes would be released up to three times per week over a time period of up to 22 months for the evaluation of the efficacy of the control of local, wild-type populations of *Ae. aegypti* at the specific site identified in Key Haven, Monroe County, FL, although the trial might be concluded earlier if the operational objectives have been met.

#### **10.4 Product sources**


##### **10.4.1 General overview of *Ae. aegypti* OX513A production**

A general overview of *Ae. aegypti* lifecycle and the methods used in the productions of *Ae. aegypti* OX513A is given below.

###### **10.4.1.1 Mosquito life cycle**

*Ae. aegypti* undergoes complete metamorphosis, i.e., the juvenile form is anatomically different from the adults. Juveniles live in a different habitat, eat different foods, and pass through both a larval and pupal stage. Transformation to the adult form takes place during the pupal stage. The larval and pupal stages are aquatic, where the adult phase is land-based. Eggs are laid by females on the water surface, or close to the water-line where they will be flooded. The lifecycle is described in Figure 3 below.

## Reproductive biology of OX513A *Aedes aegypti*



■ Tetracycline used during this phase of rearing to suppress dominant lethal gene expression

**Figure 3. General overview of the lifecycle of *Ae. aegypti* OX513A.**

The eggs can remain viable as ‘dried’ eggs (not submerged in water) for several months. The eggs of *Ae. aegypti* hatch when submerged in water, the larvae then go through 4 molts (L1-L4), growing between each molt. As pupae they metamorphose into adults and emerge onto the water’s surface after about 48 hours. Males and females mate and the females take a blood meal to get nutrients to develop eggs. When rearing OX513A from egg to adult, tetracycline is added to the water during the larval phase to suppress the conditional lethal gene expression. In adults, the #OX513 rDNA construct is inherited by all the offspring creating a true breeding line for the #OX513 rDNA construct.

### 10.4.1.2 Mosquito breeding and husbandry

**General environmental conditions:** OX513A mosquitoes are reared in temperature- and humidity-controlled facilities. For eggs and larvae, temperature generally has the greatest effect on survival and development rate. Insectary conditions vary slightly depending on location but generally have a light:dark cycle of 12:12 hours and a temperature of 27°C +/-4°C and a high relative humidity.

**Mosquito eggs:** OX513A mosquito eggs require approximately 48 hours to complete embryogenesis and become fully developed un-hatched larvae, although if a water source is present they can hatch immediately. After they have matured, the eggs can remain viable in a dried state for several months.

Storage of eggs is accomplished by maturing for at least five days after being laid to ensure embryogenesis has completed and the chorion of the egg has matured to prevent desiccation. After maturing, eggs are processed into batches and stored.

**Hatching eggs:** Eggs hatch most readily when oxygen levels in the water are low, and can be induced by applying a vacuum, which decreases oxygen concentration in the water.

#### **Rearing Conditions**

**Larvae:** Larvae are reared in water containing nutrients, such as fish food, and tetracycline to suppress the conditional lethal gene expression. Larvae can be reared in many different types of containers but generally a surface area in the range 400 to 800 cm<sup>2</sup> and minimum depth of 1 cm are required. The amount of daily nutrient to be fed to the larvae is calculated taking into account the density of the larvae, temperature, and water quality. Larvae go through four stages of molting over about 7-10 days; at each molt they grow in size but are essentially identical in morphology.


**Pupae:** Approximately two days after the fourth molt, larvae develop into pupae. The smaller male pupae develop faster than the larger female pupae, providing the underlying mechanism for sorting pupae by sex. Development times are mainly dependent on temperature, density of larvae, and dietary resources.

**Adults:** Pupae undergo metamorphosis into adults over a 48 hour period after which they emerge onto the water's surface by breaking out of the pupal casing. Adults are placed into cages that provide space for flying, mating, and resting, as well as sugar water (10% v/v sucrose) for energy, and where necessary, blood for females to feed on.

**Oogenesis (egg production):** Females feed on the blood provided, which enables development and laying of eggs. No blood feeding would be conducted in the HRU in Florida as eggs would not be produced there; only rearing of eggs to adults would occur at this facility.

#### **10.4.1.3 Mosquito production for investigational use**

There are two production sites: a UK-based egg production site to produce *Ae. aegypti* OX513A eggs and a local facility (the HRU) in the U.S. in Marathon, Florida, which would rear eggs to adults for release. In the UK egg production facility, eggs are continually produced from a cycling colony of homozygous OX513A parent mosquitoes. The eggs would be shipped in multiple shipments throughout the course of the investigation to the HRU facility near the trial site where they would be reared through to pupae, sex sorted to select male pupae, the males matured to adults, and then released at the pre-designated trial site (summarized in Figure 4; the associated process flows for egg production and production of males for release are shown, respectively, in Figure 5 and Figure 6).




■ Tetracycline used during this phase of rearing to suppress tTAV gene expression

**Figure 4. A schematic of the production process for producing males for release.**

The following sections of the EA describe the main production processes for each of the facilities in the UK and the US.

The process used to produce eggs in the UK is summarized in Figure 5.



**Figure 5. Process flow for UK egg production.**

Oxitec Ltd. has dedicated rearing production facilities for its insects in the UK. The facility is licensed by the UK Health and Safety Executive (HSE) for the holding of GE organisms in contained use, under the UK Genetically Modified Organisms (Contained Use) Regulations (HSE 2014). The facility is inspected annually by the HSE for compliance with these regulations. HSE conducted the last inspection in March 2016 and, from a verbal close out meeting, no deficiencies were noted.

#### 10.4.1.4 Egg production

In the egg production facility, male and female pupae are added to a cage and allowed to emerge as adults over a 3-4 day period. Female mosquitoes require a blood meal to provide the nutrients to produce each batch of eggs and, therefore, require a blood meal between each laying cycle. They are fed twice a week for 4-6 weeks to have the necessary dietary resources to produce eggs. Approximately three days after blood feeding, female mosquitoes develop a batch of eggs and are ready to oviposit (lay eggs). A damp substrate (e.g., seed germination paper in a container half-filled with water) is provided for the females to lay eggs. The eggs take about five days to mature, at which time they can be dried and

stored under insectary conditions. Insectary conditions are generally maintained at temperatures of +27°C/-4°C and a high relative humidity.

#### **10.4.1.5 Blood feeding females for egg production**

Animal blood (defibrinated horse blood, TCS Biosciences Ltd) is used in a heated membrane feeding system as the source of blood meals for the female mosquitoes. An aluminum plate is sealed on one side with a thin membrane such as Parafilm and blood is added between the membrane and the aluminum plate. The plate is then placed membrane side down on top of the cage and a heat source provided to heat the blood to approximately 37°C. Female mosquitoes readily feed through the mesh of the cage and engorge on blood. Animal blood is supplied through an authorized supplier and is tested for quality control including sterility and haemolysis. Defibrinated blood is collected using sterile apparatus and processed aseptically from a closed herd of healthy horses permanently housed in the UK, under regular veterinarian supervision, that are screened for equine infectious anemia (EIA) and equine viral arteritis (EVA) among other pathogens, to minimize the potential for contamination of the blood by virus, bacteria, or other pathogenic agents. In the future, mosquito breeding requirements could require testing of blood for arboviruses, but at this time the host range of *Aedes aegypti* and *Aedes albopictus* does not extend to the UK (Kraemer et al. 2015) so the risk of transmission of arbovirus such as dengue and chikungunya to these horses is negligible. As a result, the blood collected from the horses would be free of such arboviruses.


#### **10.4.1.6 Shipment of eggs to the United States**

Shipping from the UK to the U.S. will be conducted in accordance with the requirements of 7 CFR Part 340, 9 CFR Part 122, 42 CFR 71.54, and 21 CFR Part 511, including obtaining valid permits from the USDA Animal and Plant Health Inspection Service (APHIS) and the CDC. Oxitec and/or FKMCD would obtain all necessary permits and make required notifications prior to shipment. Eggs from the UK production facility would be packed in at least two levels of shatterproof containment (e.g., sealed plastic bags/polystyrene container/cardboard boxes) and with all the relevant permits and permit stickers attached to outer shipment containers, as required by the regulations cited above. Boxes would be shipped through a courier service that has a tracking facility to ensure the whereabouts of the shipment is known at all times. Shipping from the UK to the USA would need to occur regularly (probably weekly) prior to and during the investigational use. Shipments would be labelled with directions to be kept above 10°C and to only be opened by inspection officials or Oxitec and/or FKMCD staff to prevent inadvertent release. Eggs are a non-motile life stage of *Ae. aegypti* and under the correct conditions can remain viable for several months.

On receipt by Oxitec or FKMCD, shipments would only be opened by authorized staff and within the designated facility (the HRU). Rearing would be performed as described in Section 10.4.2 and the associated SOPs. Shipping materials would be disposed of by freezing at ≤ -15°C for at least 12 hours to kill any remaining eggs prior to disposal via incineration by an external contractor.

### 10.4.2 Activities based in the United States

The process used to produce mosquitoes for release is shown in Figure 6.



**Figure 6. Process flow for male production for release.**

Production of adults in the U.S. would be in the HRU. This is a dedicated, containment facility for the production of OX513A male adults for release. The proposed HRU is located within an existing FKMCD site in Marathon and would be accessible only to authorized FKMCD or Oxitec staff. The HRU has been inspected by CDC under 42 CFR 71.54, where some minor departures from recognized safety standards were noted. These have all been corrected and a letter of satisfactory response has been issued by CDC (*Appendix A*).

#### 10.4.2.1 Production of adults

All egg production would take place in the UK, the HRU would rear to adulthood for release at the trial site eggs produced in the UK and shipped to the HRU. The following procedures would be employed:

### **Egg hatch**

Eggs would be weighed, added to water, and hatched under vacuum. Vacuum hatching assists with synchronous hatching of the eggs, and eggs normally hatch within an hour under vacuum.

### **Larvae rearing**

Following egg hatching, first instar larvae (L1 as shown in Figure 3) would be put into rearing trays containing water with tetracycline (30 µg/ml) to allow the insects to survive to adulthood as tetracycline switches off the repressible lethality system. To give a consistent density in each tray (of approximately 3000 larvae/liter) the L1 larvae would be counted and aliquoted volumetrically. The larval diet would be added daily. Most of the male larvae would pupate at Days 7 and 8 post hatching.

### **Pupal processing**

Pupae would be processed when the optimum numbers of male larvae have reached the pupal stage (~8-9 days). Pupal processing would consist of two steps; separation of larvae from pupae, followed by separation of male from female pupae.

### **Larvae separation from pupae**

Pupae would be separated from larvae using a proprietary wire sorter device (pending PCT Patent number US2015/0008163A1<sup>12</sup>) known as a Larval Pupal Sorter (LPS) that separates larvae from pupae based on size; the gap size can be adjusted so that larvae can pass through but pupae cannot. The trials in the Cayman Islands and Panama and current operations in Brazil have used an earlier model of this type of wire sorter device; however, Oxitec has improved the device over time, including improvements to the sorting accuracy and improvements based on experience of using it with trained staff. The proposed trial in Key Haven would use an improved version of the device used in previous trials in other countries.

### **Sex separation of male and female pupae**

Mechanical size separation would be used to separate sexes as the majority of female pupae are larger than males (Sharma et al. 1972; Ansari et al. 1977). Using the proprietary method above, it is possible to separate males from females with a sorting accuracy of >99.9% (Table 2) (Harris et al. 2012; Carvalho et al. 2014). Quality control processes would be established to ensure accuracy of the sorting does not exceed a maximum of 0.2% females. Two samples of 500 pupae would be taken for analysis and the number of female pupae in each sample would be counted by trained staff. The sample number would be based on the probability to achieve releases with as close to 100% males as possible. If more than 0.2% of the sorted population is female the batch would be re-sorted prior to release to ensure meeting the 0.2% criterion.

---

<sup>12</sup> [http://www.uspto.gov/web/patents/patog/week45/OG/classification/cpcClassGroup\\_B03.html](http://www.uspto.gov/web/patents/patog/week45/OG/classification/cpcClassGroup_B03.html) [Accessed June 22, 2016].

**Table 2. Average values for male pupae in batches from trials in Cayman, Brazil, and Panama.**

Study	Cayman	Brazil	Panama
% Sex sorting efficiency	99.93%	99.98%	99.99%
Published reference	(Harris et al. 2012)	(Carvalho et al. 2014)	(Gorman et al. 2016)

#### **10.4.2.2 Disposal of female insects**

In the HRU after sorting the male from the female pupae, the female pupae and the larvae would be killed by freezing ( $\leq -15^{\circ}\text{C}$ ) for more than 12 hours and then disposed of by an external contractor by incineration.

#### **10.4.2.3 Release devices**

Male pupae would be placed into release devices to emerge and mature before release. Release devices are containers in which the pupae can be placed in about 1-2 cm depth of water, have enough space for adults to survive at the required density for up to five days (including pupation) and a mesh lid through which sugar water can be provided and the males released. The appropriate number of male pupae would be aliquoted into release devices volumetrically and water added to a depth of approximately 1 cm. Sugar would be provided as a 10% solution through a suitable wick (i.e., cotton wool or cotton dental sticks). After two days under insectary conditions, the water would be drained from the release device. Depending on the cycle of releases, the release devices can be maintained under insectary conditions for a further 1-3 days, and would be provided with the sugar solution. The release devices would be placed into a double-sealed container, labelled, and transported to the release site. At the appropriate release coordinates, a release device would be removed from double containment and the lid would be opened to release the mosquitoes. After release, individual release devices would be returned to double containment for transportation back to the rearing facility where they would be frozen ( $\leq -15^{\circ}\text{C}$ ) for over 12 hours to kill any remaining adults.

#### **10.4.2.4 Transport to release site**

Transport from the HRU facility to the release site would be by vehicle driven by authorized staff from either FKMCD or Oxitec. Release devices for adult release would be packed in the vehicle. Insects would be double contained for transport to the field site for release. One level of containment would be the release device itself and another would be a suitable container, such as a polystyrene box or sealed bag around the release devices. If temperatures are high, cooling devices such as ice packs may be used with the insects in the transport containers. A chain of custody protocol would require release devices to be signed out of the facility, and signed for upon receipt by authorized personnel at the field site. Outer containers would be labelled "Genetically engineered mosquitoes – only to be opened by FKMCD/Oxitec

staff". For transport of release devices back from the field site they would be placed back into the container or bag and frozen ( $\leq -15^{\circ}\text{C}$ ) when returned to kill any remaining adults. All life stages of OX513A mosquitoes not required for analysis that have been previously frozen would be discarded by incineration via an external contractor.

## 11 Investigational Field Trial

### 11.1 Proposed Field Trial

OX513A eggs would be produced by Oxitec in Oxford, UK and shipped to Marathon, Florida for rearing in the specialized HRU at the FKMCD facility. OX513A male mosquitoes reared from these eggs at the HRU in the FKMCD facility would be used for a proposed investigational open release field trial in Key Haven, Monroe County, Florida performed by FKMCD and Oxitec.

The proposed investigational trial has one primary and one secondary goal. The primary goal is comprised of two parts: part one aims to determine whether released OX513A males mate with local wild-type *Ae. aegypti* females resulting in their progeny inheriting a copy of the #OX513 rDNA construct and part two aims to determine whether these OX513A progeny inheriting the #OX513 rDNA construct exhibit at least a 2-fold proportional increase in mortality before reaching functional adulthood relative to the local non-GE *Ae. aegypti* progeny at the trial site. The secondary goal aims to determine whether sustained release of OX513A males results in a statistically significant ( $\geq 50\%$  with 95% Confidence Interval) suppression of the local population of *Ae. aegypti* in the treatment area (TA) relative to the untreated comparator area (UCA) (treated and control areas are described in greater detail in Section 12.1.2.3 of the EA).

OX513A male mosquitoes would be released in a systematic manner from a pre-determined georeferenced grid of release points up to three times a week to ensure even and consistent coverage of the TA. Release points will be spaced approximately 25-70 m apart, with a maximum spacing of 100 m. Release points will be georeferenced using Global Positioning System (GPS) coordinates and the area that is mapped with the spatial data will be incorporated into an appropriate Geographical Information System (GIS).

The trial will be divided into three phases:

- Phase I (Preparation Phase) would be used by Oxitec and the FKMCD to evaluate the initial density of the *Ae. aegypti* mosquito population at the proposed trial site and optimize the OX513A mosquito rearing methodology to local conditions in Florida. This phase of the investigational trial is expected to last 8 to 16 weeks.
- Phase II (Range finding Phase) would be used to address the two parts of the primary goal of the trial: "do released OX513A males mate with local wild-type *Ae. aegypti* females resulting in their progeny inheriting a copy of the #OX513 rDNA construct" and "is there at least a 2-fold increase in mortality of these #OX513 rDNA construct-bearing progeny relative to local non-GE progeny before they reach functional

adulthood.” During this phase, OX513A males would be released up to three times a week at a constant release rate as a function of the human population in the release area and current wild-type *Aedes aegypti* population estimated using surveillance and ovitrap data at the start of the releases. This phase would last from six to eight weeks and will determine the initial release rates for the next phase (Phase III- Suppression).

- Phase III (Suppression phase) would be used to evaluate the secondary goal of the trial: “does sustained release of OX513A result in statistically significant suppression ( $\geq 50\%$  with 95% CI) of the local *Ae. aegypti* population relative to the comparator area that is not treated with the released OX513A”. During this phase, OX513A male mosquitoes would be released up to three times a week at a rate that would be adjusted in accordance with changes in the local *Ae. aegypti* population (monitored every 6-8 weeks) to ensure that a mating fraction of  $\geq 0.5$  is maintained throughout this phase of the trial. This phase of the investigational trial would last up to 22 months (approximately 96 weeks).

FKMCD would continue its standard mosquito abatement procedures, including insecticide use, at the proposed investigational site during the entire duration of the trial.

The overall number of mosquitoes to be released depends on multiple factors including seasonality, egg banks, time of year, and rainfall and would be based on the estimates obtained from the initial six to eight week range finding phase i.e. the initial *Ae. aegypti* infestation level (Phase II). The number of OX513A mosquitoes released during the suppression phase (Phase III) of the trial would be a function of the release rate of OX513A mosquitoes in the previous phase (Phase II), the estimated mating fraction observed in Phase II, and the target Phase III mating fraction of  $\geq 0.5$ .<sup>13</sup> During Phase III the mating fraction would be determined periodically and monitored via ovitraps. Notwithstanding the variability in the number of OX513A that would be released based on the factors noted above, we are able to estimate the minimum number of OX513A mosquitoes that might be released based on 460 human residents in the TA (assuming four residents for each of approximately 115 houses within the designated TA), an eight-week duration for the range finding phase, and the maximum proposed period of 96 weeks for the suppression phase for a total of 104 weeks. Because this is a residential area with no commercial properties, population flux during the day is not expected to be substantial enough to alter the total number of humans in the TA significantly. Based on these assumptions, the minimum number of OX513A mosquitoes that would be released is estimated at 14,352,000 over the 104 week period (estimates for eight week range finding phase plus 96 week suppression phase under high initial infestation conditions and not accounting for adaptive management adjustments in number of mosquitoes released during the suppression phase). Accordingly, the estimate for the number of females that would be released (under the same assumptions and 1 female for every 500 GE mosquitoes released) is less than 62 female mosquitoes released per person in the TA over a total of 104 weeks or

---

<sup>13</sup> Mating fraction is the proportion of red fluorescent (OX513A) to non-fluorescent (wild-type) larvae determined by analyzing content of ovitraps returned from the treatment area.

0.6 female mosquitoes per person per week (or 0.6 X 4 i.e., 2.4 female mosquitoes per household per week) at the highest initial infestation levels. The number of mosquitoes released will likely decrease over time if suppression is achieved due to adaptive management of releases.

## **11.2 Data collection**

All data obtained during the investigational trial would be collected using ovitraps (eggs) and BG-Sentinel (Biogents, Germany) (adults) traps.

An ovitrap is a device that mimics the preferred breeding site for container breeding mosquitoes such as *Ae. aegypti* and is routinely used to monitor the presence/absence of mosquitoes in an area of interest (Silver 2008). Oxitec states that a minimum of 60 ovitraps each would be used in the TA and the UCA respectively, with a trap density of 3-4 traps/ha. All trapping locations would receive a unique number and would be georeferenced using GPS coordinates. Oxitec or FKMCD employees would check traps every 6-8 days and collect the oviposition substrate for further analysis in the FKMCD laboratory in Marathon, Florida. Additional sentinel ovitraps will be placed outside the field trial area to monitor potential dispersion to urban areas located within a 400 m and an 800 m polygon from the edge of the TA in Key Haven and at the entrance to Key Haven from the Florida Keys Highway 1.

BG-Sentinel traps are designed to directly capture adults (Krockel et al. 2006). These traps are routinely used for monitoring *Ae. aegypti* populations and provide an indirect measure of *Ae. aegypti* abundance in the area (Williams et al. 2007; Ball and Ritchie 2010; Johnson et al. 2012). Oxitec's protocol states that a minimum of 20 different locations would be sampled in the TA and the UCA respectively, in parallel, once every week. All trapping locations would receive a unique number and would be georeferenced using GPS coordinates. These traps would be deployed overnight with the trap catch recovered the following day in both the TA and the UCA. The number of female *Ae. aegypti* captured from each BG-Sentinel trap would be recorded.

## **11.3 Sample Analysis and Disposal**

Samples from the field traps would be returned to a separate laboratory space in the FKMCD facility for analysis. These samples would include both OX513A and their progeny and local *Ae. aegypti* mosquitoes. All solid wastes from the field laboratory would be treated as GE waste and frozen ( $\leq -15^{\circ}\text{C}$ ) for over 12 hours prior to disposal by incineration by an external contractor. Liquid waste would be sieved to remove insect parts, which would be treated as solid wastes. Samples required for further analysis, such as PCR analysis, would be stored frozen in 70% ethanol prior to shipping to the UK or other suitable laboratory authorized by Oxitec to conduct the analysis, under the appropriate shipping conditions for the samples (e.g., dry ice, if necessary).

The samples returned from the field would be analyzed in a variety of ways:

### **11.3.1 Ovitrap analysis**

The eggs from the ovitraps would be hatched and the larvae analyzed for the fluorescent marker under a microscope with the appropriate filters for fluorescence. Larvae would be scored for fluorescence and

identified as either *Ae. aegypti* or non-*Ae. aegypti*. Larvae would be maintained until positive species identification can be conducted either at late larval stages or as adults using morphological features.

### 11.3.2 Adult analysis

The adult traps contain a bag to capture the mosquitoes that fly into them. These bags would be frozen to kill the mosquitoes following which *Ae. aegypti* mosquitoes would be separated from non-*Ae. aegypti* mosquitoes. The *Ae. aegypti* mosquitoes would be analyzed for their sex by trained staff and the numbers of females recorded.

### 11.3.3 Testing of functional adult mortality

Eggs from ovitraps, representing the progeny of matings with OX513A in the treatment area, would be hatched and tested for the presence of a functional #OX513 rDNA construct by rearing to adulthood. At least a 2-fold increase in mortality of these #OX513 rDNA construct-bearing progeny relative to local non-GE progeny is expected before they reach functional adulthood. Functional adulthood is defined as fully eclosed, live adults able to maintain flight. The mosquitoes caught in the traps would be analyzed by PCR; dead mosquito samples (all lifestages) from traps will be shipped to the UK for analysis to confirm their genotype by PCR as well. These mosquitoes would be expected to be either hemizygous for the #OX513 rDNA construct or without any copies of the #OX513 rDNA construct i.e., local wild-type *Ae. aegypti* or other non-*Ae. aegypti* mosquito species. It would be possible that some mosquitoes homozygous for the #OX513 rDNA construct would be detected<sup>14</sup>. These would likely be derived from mating between the small number of females (<0.2%) that might be co-released and the male OX513A mosquitoes they are released with (Section 10.4.2.1). However, any co-released OX513A female would live no longer than a wild-type *Ae. aegypti* and, because there are insufficient sources of tetracycline in the environment, progeny resulting from any matings of these females would die as described in Section 13.2.

### 11.3.4 Estimating *Ae. aegypti* suppression at the proposed trial site

Oxitec plans to estimate the suppression of *Ae. aegypti* at the trial site by calculating relative ovitrap and relative adult density indices based on the data collected from ovitraps and BG-Sentinel adult traps.

Ovitraps are a useful and effective tool for demonstrating the presence or absence of *Ae. aegypti* in the area of interest and a good indicator of changes in mosquito population (Silver 2008). As the size of the adult *Ae. aegypti* population decreases, the number of positive ovitraps and the number of eggs per ovitrap will decrease as well<sup>15</sup> (Dibo et al. 2008). Therefore, changes in the ovitrap index<sup>16</sup> over time and

---

<sup>14</sup> The PCR method developed by Oxitec is capable of discriminating between OX513A and wild-type mosquitoes and also between mosquitoes that are either hemi- or homozygous for #OX513.

<sup>15</sup> This relationship does not hold in studies/programs that involve removal of *Ae. aegypti* natural oviposition sites as decrease in available sites may lead to increase in the number of positive ovitraps and/or the number of eggs per ovitrap.

between the sites would be a good indicator of changes in the relative population of *Ae. aegypti* or relative population densities in compared areas (Morato et al. 2005; Devi 2013; Serpa et al. 2013). Previous studies involving OX513A mosquitoes conducted by Oxitec and published in peer-reviewed scientific literature (Harris et al. 2012; Carvalho et al. 2015) also used relative ovitrap index<sup>17</sup> to evaluate the change in size of the local *Ae. aegypti* population.

Using the same approach as for ovitrap data, relative abundance of adult density in the TA and UCA before and after the suppression phase also would be used as a measure of suppression of local wild-type *Ae. aegypti*.

## 12 Environmental Risk Analysis

### 12.1 Accessible environments

The environments and habitats that *Ae. aegypti* are found in are described below, along with a description of the environment found at the trial site.

#### 12.1.1 *Aedes aegypti* habitat

*Ae. aegypti* mosquitoes are a non-native mosquito species introduced into the United States with human migrations and international trade (Slosek 1986; Tabachnick 1991; Gubler et al. 2001). *Ae. aegypti* has limited interactions with ecological systems outside domestic settings in this habitat, although a sylvatic subspecies of *Ae. aegypti*—*Ae. aegypti formosa*—has been found in tree holes and more sylvan or rural settings in its native Africa (Brown et al. 2011; McBride et al. 2014). *Ae. aegypti* occupies two different habitats, aquatic or terrestrial, depending on the life stage of the mosquito. They are regarded as a uniquely domestic or anthropophilic species of mosquito tied closely to human habitations and urban areas; the presence of suitable breeding sites, along with the availability of a human blood meal, strongly influence both the habitat and geographic range of the mosquito.

##### 12.1.1.1 Aquatic habitats

*Ae. aegypti* eggs are preferentially laid on the surfaces of damp, man-made containers that hold clean still water or rainwater such as water storage containers, flowerpots, and waste materials such as tires, cans, and bottles. Breeding sites also can include those that might contain brackish water (defined as less than 30 parts per million (ppm) salinity or 3 g/L) such as boats, man-made containers at coastal edges, or on beaches (Ramasamy et al. 2011). *Ae. aegypti* maintains osmoregulation by increasing the

---

<sup>16</sup> The ovitrap index (OI) is a measure of mosquito abundance in the TA and the UCA. For a single time point of trap collection, the OI is defined as  $OI = \frac{L}{T}$  where L is the number traps from which one or more eggs positively identified as *Ae. aegypti* after hatching [fluorescent or non-fluorescent] and T is the total traps recovered.

<sup>17</sup> Relative ovitrap index (ROI) is defined as  $ROI = \frac{OI \text{ in TA}}{OI \text{ in UCA}}$ .

level of free amino acids in the haemolymph and has been reported to not survive in waters with salinity greater than 14 g/L; sea water salinity is generally in the range of 35 g/L (Clark et al. 2004). Other potential aquatic habitats could include standing waste water treatment areas such as septic tanks. A review of the literature in PubMed online conducted in July 2016 identified a few reports describing breeding of *Ae. aegypti* in septic tanks (Irving-Bell et al. 1987; Nwoke et al. 1993; Barrera et al. 2008; Mackay et al. 2009; Burke et al. 2010; Somers et al. 2011; Adeleke et al. 2013; Chadee and Martinez 2016). As best described by Burke et al. (2010) and Barrera et al. (2008), septic tanks were more productive breeding habitats for the mosquito when they were uncovered or cracked. A survey of productive containers for mosquitoes was undertaken in Monroe County in 2001 by FKMCD. The survey established that plastic buckets, trash cans, and discarded plastic containers were the most common mosquito breeding sites (Hribar et al. 2001). For these reasons, broken and cracked septic tanks are unlikely to be breeding sites in the trial area. Containers that were situated in areas with overhanging vegetation provided more favorable habitats as the breeding site is both shaded from intense sunshine and build-up of heat and provides a ready source of detritus for larval consumption. These containers are usually only sources of breeding sites for mosquitoes during the rainy season in countries with wet and dry seasons, but the eggs are resistant to desiccation and can remain in suitable containers until the following season's rains. Desiccated eggs that survive to hatch in the following season form the egg bank.

#### **12.1.1.2 Terrestrial habitats**

Adult *Ae. aegypti* occupies terrestrial (land-based) habitats. Male adults require three kinds of resources to survive and propagate: a) access to plant sugars for food, b) mates, and c) resting sites. Female adults require the same three resources as well as sources of blood meals and oviposition sites to lay eggs. All of these resources can be obtained in the domestic urban or peri-urban environments, without the need for the mosquito to fly long distances, which is probably why *Ae. aegypti* has become so well adapted to the human environment and rarely flies spontaneously for distances greater than 200 meters, as described in Section 12.3 of the EA.


#### **12.1.2 Monroe County, Florida**

Monroe County is at the southernmost tip of Florida and is composed of 3,737 square miles of which approximately 73% is water. Tourism is the main industry with over 106 million visitors to Florida in 2015, an increase of 8 percent over 2014<sup>18</sup>. Monroe County is comprised of portions of the Everglades National Park, Big Cypress National Preserve, and several other important biodiversity refuges (National Key Deer Refuge, Great White Heron National Wildlife Refuge, and the National Marine Park, which is comprised of sea-based biodiversity resources encompassing the majority of the Keys). Monroe County has a sub-tropical climate. Average monthly temperatures ranged from 68.5 °F to 86.4 °F and rarely fell

---

<sup>18</sup> <http://www.visitfloridamediablog.com/home/florida-facts/research/> [accessed June 15, 2016]

below 65°F at night between January 2014–March 2016 (Figure 7).<sup>19</sup> During the same period the amount of precipitation per month varied between 0.3 and 6.79 inches.



**Figure 7. Temperature vs Precipitation, Key West, FL. Jan 2014 - Mar 2016.**

### 12.1.2.1 Occurrence of natural disasters

Monroe County is one of the most vulnerable counties in the United States to hurricanes, with a historical average of a Category 1 or 2 hurricane passing within 50 nautical miles of Key West every eight years (Blake et al. 2011). The historical average for a Category 3 storm and higher passing within 50 nautical miles of the Keys, which requires mandatory resident evacuation, is every 18 years (Blake et al. 2011). Hurricane season extends from June to November with most of the hurricanes that make landfall in the Keys occurring in the month of September<sup>20</sup>. Storm surge as a result of hurricane activity has historically ranged from 6-17 ft in height, with little of Key West predicted as remaining un-flooded at the lower figure of 6 ft of storm surge (Figure 8). Key Haven was flooded following Hurricane Wilma in 2005 as were most of the “Lower Keys”<sup>21</sup>. There are more up-to-date FEMA interactive maps<sup>22</sup>

<sup>19</sup> Figure 7 summarizes temperature and precipitation data from the weather station located at the Key West International Airport provided by the NOAA’s National Centers for Environmental Information <https://www.ncdc.noaa.gov/cdo-web/datatools> [Accessed June 15, 2016].

<sup>20</sup> <http://www.aoml.noaa.gov/hrd/tcfaq/E20.html> [Accessed June 15, 2016]


<sup>21</sup> <http://www.srh.noaa.gov/key/?n=wilma> [Accessed June 15, 2016].

<sup>22</sup> <https://msc.fema.gov/portal/search?AddressQuery=key%20west%2C%20FL#searchresultsanchor> [Accessed June 20, 2016].

available for storm surge impacts but as most of the Keys are at or slightly above sea level, storm surge flooding is a potential hazard in all locations.

The HRU is located in Marathon, in a Category 4 hurricane-protected building, and a hurricane preparedness plan is in place where adult insects would be killed within 36 hours of a hurricane strike predicted by the U.S. National Weather Service.

A hurricane also has the potential to interrupt the investigational field trial for extended time periods. If this is the case, then either the timeframe of the study might need to be extended to allow sufficient sustained releases of OX513A to suppress the local population of *Ae. aegypti* or the investigational field trial would be abandoned, depending on the severity of the disruption encountered.



**Figure 8. Storm surge flooding map for Key West.**

Source: The image is re-drawn from Lower South East Florida Hurricane Evacuation Study Technical Assessment Summary for Monroe County Florida Keys 1991. Category 2 storm surge would cover the whole area (mid-grey) apart from the black; dark grey and white areas; a Category 3 storm would inundate the mid-grey area and include the black area of the map and a Category 5 storm would inundate the whole area with the exception of the small white areas in the black area.

### 12.1.2.2 Biological and ecological properties

#### 12.1.2.2.1 Threatened and endangered species

A threatened and endangered species habitat analysis has been carried out for Monroe County (*Appendix B*) and the proposed release area, Key Haven, also known as Raccoon Key. A total of 43 threatened, endangered, or candidate species were identified in this area, many of which were marine

species.<sup>23</sup> There was no overlap between the threatened and endangered species' habitat and the domestic or peri-domestic environment of *Ae. aegypti* in Key Haven. The Stock Island Tree Snail is the only species found in the physical vicinity of the proposed trial site. An assessment has been conducted according to the United States Fish and Wildlife Service (USFWS) criteria<sup>24</sup> to determine likely impacts from the study on this species. Using the criteria checklist from the Stock Island Tree snail Assessment guide, (reproduced below), it was determined that the use of OX513A is not likely to adversely affect (NLAA) the species as no removal or modification of habitat is proposed in this trial.

Criteria from the Stock Island Tree Snail Assessment Guide (USFWS):

*A. The parcel IS in a known location of the Stock Island tree snail, in the species focus area and/or on the RE parcel list..... go to B*

*B. The applicant proposes no removal or modification of the Stock Island tree snail's native habitat (hammock and beach berm)..... NLAA*

None of the critical habitats of the identified species overlap with the peri-domestic/domestic habitat of *Ae. aegypti*, meaning that released OX513A mosquitoes would not occupy the same habitat as these threatened and endangered species.

There would be no impact on the additional 42 threatened or endangered species' habitats because they are located outside the 200 m range that OX513A mosquitoes are capable of flying. While individual OX513A mosquitoes could migrate in a car, boat, or other conveyance, they would die within 2-3 days in the absence of tetracycline and, consequently, such individual mosquitoes are highly unlikely to impact the habitat of any threatened or endangered species. Additionally, even if any endangered species were to encounter OX513A mosquitoes, as discussed in Section 13.5.2, it is unlikely that OX513A mosquitoes would have a significant impact on predator species due in part to mosquitoes forming a small part of the predators' diet. Further, as discussed in Section 13.6, even if these species ingested an OX513A mosquito, the tTAV and DsRed2 proteins in the mosquitoes lack any toxic potential and, therefore, do not pose any significant risks to non-target animals, including endangered species.

#### **12.1.2.2.2 National Wildlife Refuges (NWR)**

The National Key Deer Refuge headquarters is located on Big Pine Key, which is 100-miles south of Miami and 30 miles north of Key West on Highway US-1, and 26 miles from Key Haven. It was

---

<sup>23</sup> Based on the search of the ECOS Environmental Conservation Online System maintained by the USFWS [http://ecos.fws.gov/tess\\_public/reports/species-by-current-range-county?fips=12087](http://ecos.fws.gov/tess_public/reports/species-by-current-range-county?fips=12087) [Accessed June 23, 2016].

<sup>24</sup> [http://www.fws.gov/verobeach/ConservationinKeysPDFs/20130729\\_updated%20Stock%20Island%20Tree%20Snail%20Assessment%20Guide.pdf](http://www.fws.gov/verobeach/ConservationinKeysPDFs/20130729_updated%20Stock%20Island%20Tree%20Snail%20Assessment%20Guide.pdf) [Accessed June 9, 2016].

established in 1957 to protect and preserve Key deer and other wildlife resources in the Florida Keys. The refuge is located in the lower Florida Keys and currently consists of approximately 9,200 acres of land that includes pine rockland forests, tropical hardwood hammocks, freshwater wetlands, salt marsh wetlands, and mangrove forests. These natural communities are critical habitat for hundreds of endemic and migratory species including 17 federally-listed species such as Key deer, lower Keys marsh rabbit, and the silver rice rat.

The Great White Heron Refuge is also administered as part of the Key Deer Refuge, and is only accessible by boat. It was established in 1938 as a haven for great white herons (which are only found in the Florida Keys), migratory birds, and other wildlife. The refuge is located in the lower Florida Keys and consists of almost 200,000 acres of open water and islands that are north of the primary Keys from Marathon to Key West. The islands account for approximately 7,600 acres and are primarily mangroves with some of the larger islands containing pine rockland and tropical hardwood hammock habitats. This vast wilderness area, known locally as the "backcountry," provides critical nesting, feeding, and resting areas for more than 250 species of birds.

The mosquito fauna of both National Deer Key and Great White Heron Refuges have been evaluated; *Ae. aegypti* was found "rarely," which is defined as a total of less than 20 specimens in the total refuge (Leal and Hribar 2010).

Three species of sea turtles rely on the backcountry for feeding and nesting. Endangered Green sea turtles and threatened Loggerhead sea turtles are the two documented species that successfully nest in the refuge. Hawksbill sea turtles are known to feed in seagrass beds throughout the refuge, but nesting has not been observed. Sea turtles mainly consume marine sponges, crustacea, and sea plants and are not known predators of *Ae. aegypti*. The Key West National Wildlife Refuge is another reserve that is administered as part of the Key Deer Refuge. It is only accessible by boat and comprises of more than 200,000 acres with only 2,000 acres of land. The area is home to more than 250 species of birds and is important for sea turtle nesting. The islands are predominately mangrove with a few beaches and salt ponds.

Another refuge that comes under the administration of the Key Deer Refuge is Crocodile Lake National Wildlife Refuge. It is located near Key Largo, approximately 40 miles south of Miami, and 94 miles from Key Haven. It was established in 1980 to protect critical breeding and nesting habitat for the endangered American crocodile and other wildlife. The refuge is located in North Key Largo and is currently comprised of 6,700 acres including 650 acres of open water. It contains a mosaic of habitat types including tropical hardwood hammock, mangrove forest, and salt marsh. These habitats are critical for hundreds of plants and animals including six federally-listed species. It is closed to general public use due to its small size and the sensitivity of the habitats and wildlife to human disturbance. Access to the refuge is by Special Use Permit only. The six federally endangered and threatened species indigenous to the refuge are highly susceptible to noise disturbance. The habitats they rely on for their survival can be adversely impacted by human traffic. It is highly unlikely that released mosquitoes could travel this far (i.e., tens of miles) as their dispersal by spontaneous flight is less than 200 m, and as there are no human

habitations in the refuge, it is unlikely to form an attractive habitat for *Ae. aegypti*, as *Ae. aegypti* is predominantly associated with human activity (Brown et al. 2011).

#### 12.1.2.2.3 Conclusion

***FDA concludes that release of OX513A would not affect threatened and endangered species or their habitats in Monroe County as there is no habitat overlap between the Key Haven release site for OX513A and the habitat of these species. Additionally, even if any endangered species were to encounter OX513A mosquitoes, it is unlikely that OX513A mosquitoes would have a significant impact on predator species due in part to mosquitoes forming a small part of the predators' diet. Further, even if these species ingested an OX513A mosquito, the tTAV and DsRed2 proteins in the mosquitoes lack toxic potential and, therefore, do not pose any significant risks to non-target animals, including endangered species.***

#### 12.1.2.3 Proposed release site


The proposed release site is located within Monroe County, on Key Haven, which has also been known as Raccoon Key (Figure 9)<sup>25</sup>. The release site is an island that is surrounded by sea water with a small land attachment to the main island highway and hence an area that is quite isolated from the potential immigration of other *Ae. aegypti* which could compromise the success of the investigational trial. The Key Haven site has been monitored for *Ae. aegypti* since 2012, using both ovitraps and adult traps. FKMCD indicates that all the current control measures (source reduction, larviciding, and adult insecticide) used over the entire Florida Keys achieve at best only 50% control of *Ae. aegypti*.<sup>26</sup>

The proposed site for evaluation of OX513A would be divided into two areas of similar size separated by a buffer zone (Figure 9). The area to receive releases of OX513A mosquitoes is identified as the Treatment Area (TA). The Untreated Comparator Area (UCA) is also identified in Figure 9, below. At its narrowest point, the buffer area is approximately 500 meters wide, which is sufficient to preclude the migration of the released OX513A mosquitoes from the TA into the UCA because *Ae. aegypti* rarely fly more than 200 meters (Suwonkerd et al. 2006; Maciel-de-Freitas and Lourenço-de-Oliveira 2009; Maciel de Freitas et al. 2010; Valerio et al. 2012).

---

<sup>25</sup> There is another island in the Keys known as Raccoon Key (24° 44'48"N, 81° 29'28"W) which is located northwest of Big Torch Key.

<sup>26</sup> <http://keysmosquito.org/wp-content/uploads/2015/05/2015-06-23-Reg-Mtg-Minutes.pdf> [Accessed March 4, 2016].



**Figure 9. Proposed trial area on Key Haven.**

Proposed site for investigational release of OX513A mosquitoes. Areas identified are Treated (TA), Buffer, and Untreated Comparator Areas (UCA), respectively. The location of the Waste Water Treatment Plant servicing Key Haven residents is marked with an arrow.

#### **12.1.2.3.1 Environment**

According to the Monroe County Master Plan for Future Development on Stock Island and Key Haven,<sup>27</sup> single family homes comprise 41% of the housing types in Stock Island (SI) and Key Haven (KH) communities, with 64% of those single family homes located in KH. KH is exclusively developed with single family homes. There are different land use zoning categories in the KH and SI communities. The main land use zoning categories are residential, commercial, industrial, and public, although KH does not have any industrial zoning due to the residential nature of the island. There is only one commercial zone on KH, being a single gas station on the north side of US1 at the entrance to Key Haven. SI industrial use is predominantly maritime (e.g., boat repair, launching and maintenance, recreational fishing etc.). The present-day size and development pattern of SI and KH are primarily a result of dredge and fill activities. Much of this filling and development occurred since 1950. Because the Islands' history is so heavily human-influenced, there are few truly "natural" areas or native plant or animal species except the tree snail and occasional crocodile or alligator. The American crocodile is a threatened species living in brackish or saltwater according to USFWS<sup>28</sup>; whereas alligators are a fundamental part of Florida's swamps, rivers, and lakes.

<sup>27</sup> <http://www.monroecounty-fl.gov/DocumentCenter/Home/View/1291> [Accessed June 16, 2016].

<sup>28</sup> <http://myfwc.com/wildlifehabitats/managed/american-crocodile/> [Accessed June 9, 2016].

Historically, Stock Island supported the largest population of Stock Island Tree Snails (*Orthalicus reses*), a tree-living snail. Habitat destruction and modification, pesticide use, and over-collection lead the U.S. Fish and Wildlife Service to include the tree snail on the list of threatened in July of 1978 (43 FR 28932). The population continued to decline through construction and increasing urbanization (USFWS South Florida Multi-Species Recovery Plan<sup>29</sup>). Beginning in October of 2000, the Stock Island Tree Snail had been relocated to public and private property throughout the Florida Keys and remaining populations are currently being monitored and tended to. USFWS<sup>30</sup> designates suitable habitat as hammock and beach berm. The USFWS species assessment guide has been utilized to determine if the proposed trial could have an impact on the Stock Island Tree Snail (see Section 12.1.2.2.1).

The Monroe County Planning Department brought in tiered land characterization in 2002 (Goal 105)<sup>27</sup> with a view to determining priority for acquisition of land by the County, either for conservation or for affordable housing. Tier 1 lands are classified as the most environmentally sensitive, Tier 3 land as the least environmentally sensitive, as it is predominantly built upon and is where future building infill is to be directed. Key Haven lands are predominantly classified as Tier 3, with a section in the Middle Key Haven zoned as Native area (NA) and red-flag wetlands<sup>31</sup>.

#### **12.1.2.3.2 Water**

The Florida Keys Aqueduct Authority (FKAA) is the provider of potable water for all of the Florida Keys. The main source of water for the FKAA is the Biscayne Aquifer with its well field located west of Florida City in Miami-Dade County providing most of the potable water for SE Florida, although the Biscayne Aquifer is designated as non-potable for the Keys due to the high chloride content. FKAA also operates a Reverse Osmosis (RO) plant on Stock Island, and is capable of producing 1.8 million gallons per day of water. The Monroe County Commissioners Resolution 426-2007<sup>32</sup> adopted the South Lower Key Regional Wastewater Treatment plant (WWTP) facilities plan, which was to include services at the Key Haven site. The location of the Key Haven WWTP is shown in Figure 9. Although it is noted in the plan that the Key Haven Utility is expected to be decommissioned in 2016 and its output flows are projected to be diverted to the Key West Resort Utilities WWTP, Key Haven WWTP is currently operational and

---

<sup>29</sup><http://www.fws.gov/verobeach/MSRPPDFs/StockIslandTreeSnail.pdf> [Accessed June 9, 2016].

<sup>30</sup>[http://www.fws.gov/verobeach/ConservationinKeysPDFs/20130729\\_updated%20Stock%20Island%20Tree%20Snail%20Assessment%20Guide.pdf](http://www.fws.gov/verobeach/ConservationinKeysPDFs/20130729_updated%20Stock%20Island%20Tree%20Snail%20Assessment%20Guide.pdf) [Accessed June 9, 2016].

<sup>31</sup>“Red-flag wetlands” are defined in the Keys Wetland Evaluation Procedure (KEYWEP) pursuant to Monroe County Code §118.10(4)(F)(1)(I)(AA) as “wetlands that clearly exhibit a high level of functional capacity and lack of disturbance prohibit development under any circumstances.”

<sup>32</sup><http://www.minutes-monroe-clerk.com/WebLink8/DocView.aspx?id=131444&page=18&dbid=0> [Accessed June 20, 2016].

services the residents of Key Haven. According to FCAA, Key Haven WWTP is expected to be decommissioned within the next 2-3 years.<sup>33</sup>

#### **12.1.2.3.3 The HRU site**

The HRU is located in Marathon (Figure 10). The relationship between the HRU in Marathon and the proposed release site is shown in Figure 11.

The distance between Key Haven and Marathon is approximately 50 miles along the main highway linking the Keys (the Overseas Highway-U.S Highway 1). The HRU is located in an industrial zone, with residential housing, close to Marathon Airport<sup>34</sup>. Marathon has piped potable water and a centralized sewerage system. The site is in sub-area 2 identified on the Marathon Master Plan<sup>35</sup>, and contains a mix of land uses. Behind the Airport is the state owned Blue Heron Park. This pristine tropical hardwood hammock and scrub mangrove area is known habitat for the white crown pigeon and the eastern indigo snake. The park is surrounded by established residential subdivisions and borders the airport property. The marine environment off the coast of Marathon is designated as a National Marine Sanctuary.

Imports of OX513A eggs from the UK would be shipped via international air carrier and then, once cleared through U.S. Customs and Border Protection at a major port, would be sent by air to Marathon. This is further described in Section 10.4.1.6.

---

<sup>33</sup> Phone conversation with FCAA, May 27, 2016.

<sup>34</sup> <http://cityofm.tikilive.com/download/download.php?id=795> [Accessed June 20, 2016].

<sup>35</sup> <http://cityofm.tikilive.com/download/download.php?id=2826> [Accessed June 20, 2016].



Figure 10. The HRU site at the FKMC D Marathon base.



Figure 11. Relationships between the proposed site of the HRU and the field trial location.

TA = treated area, UCA = untreated control area

## 12.2 Survivability

### 12.2.1 Influence of abiotic factors on survivability of OX513A *Ae. aegypti*

The insertion and expression of the repressible lethality trait to *Ae. aegypti* is intended to confer a strong selective disadvantage, i.e., lethality to the line. The penetrance of the introduced lethality trait in OX513A is approximately 95%, meaning that in the laboratory <5% of the progeny of OX513A males and wild-type females will survive if reared without the dietary antidote, tetracycline (Phuc et al. 2007). Laboratory conditions represent optimal conditions for the insects: field data indicates that survival is much lower. Mark release recapture studies with OX513A males were conducted in Malaysia (Lacroix et al. 2012) and the Cayman Islands (Winskill et al. 2014) to assess longevity of released males. Decay in recapture rate of males over time allowed estimation of daily survival probability (DSP), from which average life expectancy can be calculated as  $-1/\text{Log}_e(\text{DSP})$ .

In the Malaysian Study, OX513A average life expectancy was 2.0 (DSP=0.611) and 2.3 (DSP=0.646) days for the non-GE comparator, and therefore did not differ significantly from the non-GE laboratory strain co-released as part of a comparative evaluation. In the Cayman study, four separate mark release recapture studies were conducted with resulting estimates of average life expectancy ranging between 0.1 (DSP=0.001) to 1.6 (DSP = 0.53) days. No non-GE comparator was released in the Cayman study.

It is possible that survival of the line could be affected by exogenous tetracyclines in the environment. A review of the potential exogenous tetracycline concentrations that could be encountered in the environment has been conducted from the scientific literature, along with a dose response of the line to tetracycline under a variety of scenarios (*Appendix C*). The OX513A line was also examined for changes to the penetrance phenotype in the progeny when females were fed high doses of tetracycline in a blood meal (*Appendix G*), mimicking the potential concentrations of tetracyclines that could be present in blood, if humans or animals were receiving a therapeutic tetracycline dose. This study is described in Section 12.2.1.2.1 and used concentrations approximately 10 times higher than the highest dose found from the literature in human blood. The results showed that there was no increased survival of the OX513A mosquito female offspring if they were to take a blood meal from a human that has recently received a therapeutic dose of tetracycline.

Temperature is also a key factor in the survivability of the *Ae. aegypti*. Oxitec has evaluated the sensitivity of the line to a range of temperatures, including those outside the known isothermal range of the insect (the isothermal range is reported as between 10°C - 30°C ( 50°F - 86°F), with optimal survival at 25-27°C (77°F - 81°F) (Tun-Lin et al. 2000; Hemme et al. 2009) to determine if the use of the #OX513 rDNA construct in the insect has any impact on its sensitivity to temperatures and could therefore potentially allow an expansion of its geographic range. The study evaluated larval rearing temperatures of 9, 18, 24, 30, and 37°C (48, 64, 75, 86, and 98.4°F). No survival of OX513A to adulthood outside the *Ae. aegypti* isothermal range at temperatures of 9°C (48°F) and 37°C (98.4°F) was identified (*Appendix D*).

Resistance to current insecticides is a further potential factor that could impact not only on the survivability of the OX513A line, but also if the line was carrying novel insecticidal resistance alleles

that could be introgressed into the local population this could also impact existing control measures for *Ae. aegypti*. Consequently, Oxitec commissioned a study from the Liverpool School of Tropical Medicine to evaluate the susceptibility of the OX513A line to a range of current chemical control methods, using a standardized insecticide testing regime from the World Health Organization<sup>36</sup> as well as using literature information. The results showed that the OX513A line was susceptible to discriminating doses of insecticides (temephos, permethrin, deltamethrin, and malathion), and it showed significant resistance to bendiocarb. The level of resistance to bendiocarb was comparable to that seen in the New Orleans (control) strain used (*Appendix E*). A further study was conducted with the OX513A line in Malaysia (Nazni et al. 2009b) which reported that the OX513A was susceptible to the current insecticides in use in vector control programs. These studies are summarized in the sections below.

#### **12.2.1.1 Sensitivity to tetracycline**

Survival of the OX513A progeny is greatly reduced (to <5%) in the absence of the dietary antidote, tetracycline, due to the expression of the conditionally expressed lethal gene, tTAV. Hence, the response to tetracyclines in the environment can affect survivability of the line. In order to determine the response of the OX513A line to tetracyclines, Oxitec conducted a dose response study; the results were examined in light of potential exogenous tetracycline concentrations that might be encountered in the environment (*Appendix C*). Additionally, the line was examined for longevity without tetracycline in the diet, as the length of time the line survives in the environment contributes to overall survivability potential (*Appendix F*). Furthermore, the line was also examined for changes to the penetrance phenotype in the progeny when females were fed high doses of tetracycline in a blood meal (*Appendix G*), mimicking the potential concentrations of tetracyclines that could be present in blood if humans or animals were receiving a therapeutic dose. These studies and their results are presented in the sections below.

##### **12.2.1.1.1 Dose-response study to tetracycline**

The response of the OX513A line to different doses of tetracycline has been evaluated in the laboratory, with the objective of the study to identify the lowest concentration of tetracycline that allows for greater survival of OX513A progeny than when reared in the absence of tetracycline. The study evaluated twelve different concentrations of tetracycline in the rearing water ranging from 10 µg/mL to 1 µg/mL. Oxitec determined that concentrations of 3 ng/mL tetracycline yielded a small but statistically significant increase ( $p=0.212$ ) in the fraction of functional (flying) adults over those reared without tetracycline, with full rescue of the phenotype occurring above 1 µg/mL (as shown in Table 3). Therefore the no observable effect level (NOEL) was determined to be 1 ng/mL. Table 3 shows the dose response of hemizygous OX513A larvae to different concentrations of tetracycline. Percentages are means of first instar larva (L1) individuals reaching the specified stage based on initial counts of 200 L1s

---

<sup>36</sup> [http://whqlibdoc.who.int/hq/1998/WHO\\_CDS\\_CPC\\_MAL\\_98.12.pdf?ua=1](http://whqlibdoc.who.int/hq/1998/WHO_CDS_CPC_MAL_98.12.pdf?ua=1) [Accessed June 15, 2016].

per repeat. Confidence intervals are displayed in parentheses. “Non-viable adults” were defined as dead adults on the water surface, dead adults in the cage, and non-flying adults.

**Table 3. Dose-response of hemizygous OX513A larvae to different concentrations of tetracycline<sup>37</sup>.**

Tetracycline concentration	Dead pupae	Non-viable adults	Flying adults
1 µg/mL	0.8% (0.0%-1.6%)	6.7% (2.3%-11.1%)	60.9% (54.5%-67.3%)
300 ng/mL	0.4% (0.0%-1.0%)	7.0% (3.0-11.0%)	57.4% (50.4%-64.4%)
100 ng/mL	0.2% (0.0%-0.6%)	15.5% (10.0%-21.0%)	51.1% (44.6%-57.6%)
30 ng/mL	1.8% (0.5%-3.1%)	31.5% (25.9%-37.1%)	42.3% (34.6%-50.0%)
10 ng/mL	13.3% (8.0%-18.5%)	36% (33.3%-38.7%)	30.8% (26.9%-34.6%)
3 ng/mL	36.6% (28.4%-44.8%)	31.25% (29.0%-33.5%)	8.9% (6.6%-11.1%)
1 ng/mL	51.2% (47.4%-54.9%)	18.5% (16.3%-20.7%)	4.3% (3.2%-5.4%)
300 pg/mL	57.7% (52.6%-62.8%)	18.1% (14.7%-21.5%)	3.2% (2.3%-4.1%)
100 pg/mL	57.7% (49.3%-66.1%)	14.9% (10.8%-19.0%)	3.9% (2.4%-5.4%)
30 pg/mL	57.2% (53.0%-61.4%)	15.5% (12.8%-18.2%)	4.8% (4.1%-5.5%)
10 pg/mL	63% (52.9%-73.1%)	12.5% (9.0%-16.0%)	2.5% (1.3%-3.7%)
0	50.2% (45.0%-55.3%)	12.5% (9.2%-15.8%)	3.4% (2.4%-4.3%)

<sup>37</sup> Rows do not add up to 100% as dead larvae are not recorded in this table.

A survey of the literature found maximum reported concentrations of tetracyclines from field sites around the world as follows: tetracyclines 0.096 ng mL<sup>-1</sup> to 1.3 ng mL<sup>-1</sup> (e.g., chlortetracycline 0.04 ng mL<sup>-1</sup> to 0.97 ng mL<sup>-1</sup>, oxytetracycline 0.7 ng mL<sup>-1</sup> to 1.34 ng mL<sup>-1</sup> and doxycycline 0.07 ng mL<sup>-1</sup> to 0.4 ng mL<sup>-1</sup>) (McQuillan et al. 2002; Brown et al. 2006; Gulkowska et al. 2008; Watkinson et al. 2009; Le-Minh et al. 2010; Locatelli et al. 2011).

A review of environmental antibiotic degradation indicated that, in general, the highest sources of environmental tetracyclines (in the µg/L range) were from hospitals and municipal wastewater, whereas surface waters, and sea and ground waters were in the ng/L range (Homem and Santos 2011). Key Haven residences are serviced by the Key Haven Waste Water Treatment Plant (WWTP) (Section 12.1.2.3.2 and Figure 9), which could hypothetically hold waters with residues of tetracyclines. Tetracyclines are well known to degrade rapidly in sunlight (photolysis) in the presence of catalysts (iron and hydrogen peroxide, both of which can occur naturally in sunlit water) where degradation of tetracycline was complete after 1 minute (Bautitz and Nogueira 2007). The rate of degradation is dependent on the initial concentration and the pH of the water. It is also reported that in natural water samples the rate of photo-degradation is higher than in pure waters due to aquatic matrix effects (Lopez-Penalver et al. 2010). Homem and Santos (2011) report that with tetracyclines over 80% reduction can be rapidly achieved by photo-degradation using advanced oxidation processes (1-300 minutes depending on whether a catalyst was used and the pH of the reaction). These data have largely been generated from examination of tetracycline levels from wastewater treatment plants and their downstream flow as they are expected to have particularly high levels, along with the efficiency of removal of tetracyclines during treatment. This is likely an overestimate for *Ae. aegypti* as waste water treatment environments are not typical *Ae. aegypti* larval habitats (Tun-Lin et al. 1995; Hribar et al. 2001). Typical environments include artificial containers such as used car tires, flower vases, water storage vessels, and discarded materials in the domestic/peri-domestic environments *id.*

From a review of the accessible environments (Section 12.1), there are no apparent sources of high concentrations of environmental tetracyclines, as there are no commercial farming (land based or marine) enterprises, including citrus groves, or hospitals in the immediate vicinity of the proposed release site. The nearest hospital/clinic is over 300 m away from the proposed release site separated by an inlet comprised of sea water and vegetation. The inlet with the sea water and the vegetation bordering it provides a geophysical barrier to dispersal of released mosquitoes through spontaneous flight (Hemme et al. 2010; Maciel de Freitas et al. 2010), especially as there are/would be sufficient breeding sites (ovitrap) in the release site, so the male mosquitoes would not need to fly far to find females with which to mate.

Potential sources of tetracycline in and around residences in the TA would be highly unlikely to affect OX513A survival. Pet or human food derived from sources with potential tetracycline residues would not affect survival for several reasons. First, animal-derived food products must have residue levels below established tolerance levels of 2 ppm in muscle, 6 ppm in liver, and 12 ppm in fat and kidney (21 CFR 556.720), and plant-derived food products must have residue levels below 0.35 ppm on apples, peaches, and pears (40 CFR 180.337) which is not sufficiently high to affect OX513A survival because

levels of tetracycline would likely have to be close to 1 µg/ml or higher in water to have an effect on eclosion and adult OX513A survival. To achieve sustained µg/ml tetracycline levels in water from a tetracycline residue at the tolerance levels noted above, all the tetracycline in the animal-derived food would have to leach out into the water so that 50%, 16.7%, and 8.33% of the drinking water was muscle, liver, and fat/kidney respectively. An even higher percentage of the drinking water would need to comprise plant-based food to reach the concentration of tetracycline necessary to affect OX513A survival. Secondly, any tetracycline or tetracycline derivative in the food would also be subject to photodegradation by exposure to light resulting in lower effective concentrations in any potential mosquito habitat. Additionally, such food would have to be left out continuously for 5-7 days and the container holding such food would need to contain sufficient fresh water throughout this time for the aquatic phase of the mosquito life cycle to be completed, allowing adults to eclose. The combined probability of all these events occurring at once is very low and, therefore, the risk of GE mosquitoes surviving, mating, producing eggs that survive, develop, and eclose, and resulting in the trait persisting in the environment is negligible.

The dose-response study presented in Table 3 has demonstrated that tetracycline concentrations at and below 1 ng/mL do not increase the fitness of OX513A larvae, i.e., do not increase the proportion of functional adults. The overall mean percentage of functional OX513A adults reared with no effect from the tetracycline (concentrations 0 to 1 ng/mL) was 3.7% (CI 3.24%-4.18%). The complete study is provided in *Appendix C*. Full rescue of the OX513A individuals (the maximum number surviving to functional adults) was also shown in this data to require tetracycline concentrations that were 746 to 2,500 times greater than the maximum value we found in the literature for environmental tetracyclines.

#### **12.2.1.1.2 Conclusion**

***Tetracycline concentrations above the rescue level of 1 ng/mL are very unlikely to be found in the typical breeding sites of Ae. aegypti such as man-made containers or uncovered stored water near homes. There are no commercial farms, aquaculture facilities, or hospitals in the immediate vicinity of the proposed release site that have the potential to provide sufficient levels of tetracycline residues. Data from the literature regarding environmental presence of tetracyclines and the data reported in Table 3 indicate that OX513A larvae would need to encounter environmental tetracycline concentrations 746 -2500 times greater than the maximum value we found reported in the literature to fully rescue the non-lethal phenotype. Even if the level of tetracycline in the environment was high enough to increase survival of any mosquito carrying at least one copy of the #OX513 rDNA construct, the resulting adults would still have no greater fitness than wild-type Ae. aegypti and would die in 2-3 days in the field. If these OX513A mosquitoes mated, a majority of their progeny that inherited the lethality trait would die prior to eclosion in the event they were not exposed to environmental tetracycline. Additionally in the case of any inadvertently released OX513A female that were to mate with an OX513A male and lay her eggs in water containing a sufficient concentration of tetracycline that allowed some progeny to develop and emerge, then all of these resulting progeny would carry the #OX513 rDNA construct, meaning that >95% offspring from their mating would die if they didn't encounter sufficient environmental tetracycline again (Harris et al. 2011). As Ae. aegypti prefers to lay eggs in different containers (a phenomenon known as skip oviposition (Rey and O'Connell 2014))***

***the probability that all the oviposition containers contain tetracycline of sufficient quantity to increase survival is very low.***

#### **12.2.1.2 Longevity of OX513A reared on/off tetracycline**

The longevity of the line (adult males and females) has been evaluated in the laboratory. Longevity is significant, in part, because it is an important component of vectorial capacity (i.e., ability to transmit disease).

The homozygous OX513A line used for field trials in Brazil was outcrossed to wild-type of the “Latin” background to generate hemizygous eggs. These eggs were hatched and reared in the absence of the antibiotic tetracycline that is required for survival of most OX513A individuals. Emerged, flying adults were collected and housed in single-sex groups. The longevity of these individuals was assessed over a period of more than 12 weeks alongside that of non-transformed insects of the same background reared with tetracycline (1 µg/mL) in the rearing water, and wild-type individuals.


Rearing in the absence of tetracycline mimics the conditions that hemizygous offspring of OX513A males will encounter in the wild. The 1 µg/mL dose was selected because it is the minimum dose needed to give rise to the maximum percentage of flying adults (see *Appendix C*), yet well over the amounts of tetracycline OX513A mosquitoes might encounter in the field as described above. Longevity of homozygous OX513A individuals reared on the standard tetracycline dose of 30 µg/mL was also assessed.

These experiments therefore examine the longevity of the two types of OX513A female that most plausibly would be present in the field – homozygous females inadvertently co-released with homozygous males, and hemizygous progeny of released males that have mated with wild females and survive as a consequence of incomplete penetrance of the lethality trait. The lifespan of OX513A homozygotes and hemizygotes reared on tetracycline was found to be no longer than that of the wild-type comparators and the median lifespan of OX513A females was significantly shorter than the wild-type comparators (65 days vs. 72). As longevity is an important component of vectorial capacity (i.e., ability to transmit disease), shorter lifespan implies reduced vectorial capacity, especially for hemizygous females reared without tetracycline (with a median lifespan of two days relative to a wild-type median lifespan of 68 days). The full report is available in *Appendix F*.

Additionally, environmental factors are known to reduce daily survival compared to in the laboratory (Joy et al. 2012) because in a laboratory, experiments are carried out under ideal and constant conditions and do not account for adverse or fluctuating conditions (such as temperature isotherms, temperature fluctuations, humidity, photoperiod, diet, and inter- and intraspecific competition) that OX513A mosquitoes would face in the environment (Brady et al. 2013). This reduction in longevity due to environmental factors also implies that the mean fitness of hemizygous OX513A males and females reared without tetracycline is even lower than one would estimate simply by considering survival to adulthood alone.

#### **12.2.1.2.1 The evaluation of the potential for changes in penetrance of the introduced traits on exposure to high doses of tetracycline in blood feeding**

As there is a potential for small numbers of female mosquitoes to be released or result from progeny of mating with OX513A males, a study was conducted to test the hypothesis that providing high doses of dietary tetracycline to adult female *Ae. aegypti* (either homozygous OX513A females mated to wild-type males, or wild-type females mated to homozygous OX513A males) has no effect in the penetrance of the OX513A lethal phenotype observed in their hemizygous offspring. As tetracycline is an antibiotic used as a therapeutic and/or prophylactic agent in human and veterinary medicine, it is possible that a female mosquito could feed on a person or animal that had recently received a dose of tetracycline and carries some level of this antibiotic in the bloodstream. In vertebrates, the concentration of tetracycline in the blood usually reaches peak 2-6 hours following an oral or injected dose, and then gradually declines due to the body's metabolic activity (Agwuh and MacGowan 2006). In both humans and livestock, the peak concentration of tetracycline in blood (plasma) following standard therapeutic doses normally remains below 10 µg/ml (Agwuh and MacGowan 2006; Bimazubute et al. 2011). The highest apparent concentration of tetracycline recorded in vertebrate blood is ~20 µg/mL (a level observed in pigs that received unusually high intra-muscular doses as part of experimental treatments) (Bimazubute et al. 2011). There are no livestock farms in Key Haven, although companion animals and humans may be on therapeutic doses of tetracyclines. In the study, Oxitec used concentrations of tetracycline approximately 10 times higher than the highest dose found in the blood of humans treated with tetracycline, and five times higher than the highest dose found in the blood of animals treated with tetracycline (Figure 12).



**Figure 12. Summary of results of tetracycline-loaded blood study.**

No significant difference for any parameter was observed between the non-tetracycline-loaded control group (A) and any of the treatment groups (B-E). Significant differences were only observed in pupation between groups B and E ( $p < 0.01$ ), and in the number of flying adults between groups C and E ( $0.01 < p < 0.05$ ). Values for the ON-tet control groups (F and G) are shown for reference. NTL: Non tet-loaded. TL-50: Tetracycline loaded, 50  $\mu\text{g}/\text{mL}$ . TL-100: Tetracycline loaded, 100  $\mu\text{g}/\text{mL}$ . WT ♀: Female of parental cross was wild-type. OX513A ♀: Female of parental cross was genetically engineered. OFF-tet: Larvae reared without tetracycline. ON-tet: Larvae reared with tetracycline added to the rearing water.

Oxitec's results (Figure 12) indicate no significant differences in any parameter observed between the non-tetracycline control group and any of the treatment groups, but significant differences were observed in pupation and the numbers of flying adults between two of the treatment groups. The complete study is included in *Appendix G*. These results indicate that the penetrance of the OX513A phenotype in hemizygous offspring of female mosquitoes that have ingested high doses of tetracycline is not significantly different from that observed in the offspring of females that were not provided with tetracycline in their diet. Therefore, there would be no increased survival of the OX513A mosquito in the event that a surviving hemizygous female offspring takes a blood meal from an individual (human or

animal) that has recently received a therapeutic dose of tetracycline which could still be at a high concentration in their blood.

#### **12.2.1.2.2 Conclusion**

***Based on the results of this tetracycline-loaded blood study, together with the longevity data described in 12.2.1.2, FDA concludes that the ability of the OX513A line to survive outside the laboratory is unlikely to be affected by environmental exposure to exogenous tetracycline sources.***

#### **12.2.1.3 Susceptibility to chemical insecticides**

Susceptibility to chemical insecticides is an important feature for OX513A, as chemical insecticides can be used as part of a risk management strategy for rapid elimination of the OX513A line from the environment, and standard mosquito control would continue to be used during the duration of the proposed field trial (see Section 11). Furthermore, were the OX513A mosquito to contain any genes that impart resistance to insecticides, and those genes introgress into wild populations of *Ae. aegypti* via sexual reproduction, deployment of OX513A could result in increased resistance to current chemical controls which could compromise overall *Ae. aegypti* control in the trial location. Therefore, in 2011 Oxitec commissioned a study (performed by the Liverpool School of Tropical Medicine, LSTM) to evaluate the susceptibility of OX513A mosquitoes to insecticides (*Appendix E*).

The 2011 study tested the susceptibility of the OX513A line to five commonly used insecticides (temephos, permethrin, deltamethrin, bendiocarb, and malathion) and screened the OX513A mosquitoes for the presence of knock-down (kdr) mutations 1016 and 1534, which are associated with resistance to pyrethroids and DDT. A susceptible laboratory strain (*Ae. aegypti* New Orleans) was used as control for the study. Standard WHO procedures and discriminating doses<sup>38</sup> were used, and 100 insects were assayed in each treatment. Temephos (which is a larvicide) was tested on 4<sup>th</sup> instar larvae, and all other insecticides were tested on 2-3 day old adult female mosquitoes. Mortality was recorded 24 hours after exposure. The results are summarized in Table 4.

---

<sup>38</sup> [http://whqlibdoc.who.int/hq/2006/WHO\\_CDS\\_NTD\\_WHOPES\\_GCDPP\\_2006.3\\_eng.pdf](http://whqlibdoc.who.int/hq/2006/WHO_CDS_NTD_WHOPES_GCDPP_2006.3_eng.pdf) [Accessed June 15, 2016].

**Table 4. Mosquito mortality recorded 24 hours after exposure to insecticide.**

Insecticide	Dose	OX513A No. tested	OX513A No. alive	OX513A No. dead	OX513A % mort.	NEW ORLEANS No. tested	NEW ORLEANS No. alive	NEW ORLEANS No. dead	NEW ORLEANS % mort.
temephos	0.012 mg/L	102	0	102	100	n/d	n/d	n/d	n/d
permethrin	0.75%	100	0	100	100	63	0	63	100
deltamethrin	0.05%	100	0	100	100	41	0	41	100
bendiocarb	0.10%	200	106	94	47	100	49	51	51
malathion	0.80%	100	0	100	100	n/d	n/d	n/d	n/d

OX513A line was found to be susceptible to discriminating doses of temephos, permethrin, deltamethrin, and malathion, and it showed significant resistance to bendiocarb. The level of resistance to bendiocarb in OX513A was comparable to that seen in the NEWORLEANS (control) strain.

The NEWORLEANS strain is a long-standing laboratory strain that is considered susceptible to all known insecticides; the original colony was established by the CDC. The NEWORLEANS strain is an accepted standard in susceptibility assessments and continues to be widely used throughout the world.

For the NEWORLEANS strain, none of the observed test results other than those for bendiocarb deviated from the values expected when assessing a fully-susceptible strain using the World Health Organization’s recommended discriminating concentrations (i.e., 100% mortality). Therefore, there was no reasonable justification for suspecting that the integrity of the NEWORLEANS strain had been compromised (as results would likely have been skewed for more than just a single compound). In addition, the fact that the bendiocarb results observed for both OX513A and NEWORLEANS strains remained equal, the most plausible explanations are that either the recommended doses for bendiocarb are inappropriate for this species (as suggested in the report in Appendix E), or that variation associated with such tests (for example, due to inaccurately prepared or old pesticide solutions, inconsistent dosing, inaccurate endpoint timing, climatic conditions, etc.) had resulted in a corresponding shift in responses of both strains.

Given the above, the key metric of a comparison between the levels of mortality observed in OX513A with those of the accepted susceptible standard remains valid i.e., no significant difference for all compounds. As previously mentioned, the OX513A line was also genotyped for two *kdr* mutations that

are associated with pyrethroid and DDT resistance, in the same study. Results showed that these mutations were absent in the OX513A line.

A separate study on susceptibility to insecticides was conducted in Malaysia by Nazni et al. (2009b). This study compared the susceptibility of the line MyRIDL-513A<sup>39</sup> and the laboratory line MyWT; seven insecticides (DDT, Fenitrothion, Malathion, Propoxur, Permethrin, Lambda-cyhalothrin, and Cyfluthrin) were tested following standard WHO methods. All of the insects used were 3-5 day old females, and there were 25 adults in each test. There were slight differences in the susceptibility of insecticides between the two strains that were tested, as the MyWT was tolerant to propoxur and fenitrothion, whereas the MyRIDL513A strain was fully susceptible to both chemicals. Additionally, some level of resistance to DDT was detected in both strains, which the authors of the study attributed to the Malaysian genetic background shared by both strains (since use of DDT in the past in Malaysia caused the dissemination of resistance alleles in *Ae. aegypti* populations).

Taken together these studies provide evidence that OX513A is no more resistant to insecticides than the comparator wild-type strain.

#### 12.2.1.4 Temperature

Temperature is a key abiotic factor in the consideration of the survivability of *Ae. aegypti* OX513A, although this can be complicated by the interaction with diet and larval density dependent effects (Courret et al. 2014). Except in East Africa, where it is native, *Ae. aegypti* is a non-native tropical species with a cosmopolitan habitat extending from 40° N to 40° S latitude. *Ae. aegypti* has an ecological temperature range of 14-30 °C [ $\sim$ 57- 86° F] (Brady et al. 2013; Brady et al. 2014; Kraemer et al. 2015). The effect of temperature on larval development of *Ae. aegypti* has been well studied. Larval development is a function of temperature, which affects adult size, dry weight, and ovariole number, all of which fall as the temperature rises (Christophers 1960; Rueda et al. 1990). High temperatures alone (>40°C [104°F]) are unlikely to limit the species but low temperatures are limiting with the threshold being around the 15°C [59°F] isotherm. At temperatures lower than 15°C, *Ae. aegypti* become torpid, unable to fly, or move their limbs only slowly (Christophers 1960; Rowley and Graham 1968; Yang et al. 2009). Lower temperatures can slow development time to such a degree (where egg-to-adult cycles are longer than 45 days) that the species is prevented from establishing itself in the environment.

Global historical collections and laboratory experiments on this well-studied vector have suggested its distribution is limited by the 10°C [ $\sim$ 50°F] winter isotherm<sup>40</sup> (Christophers 1960), while a more recent and complex stochastic population dynamics model analysis suggests the temperature's limiting

---

<sup>39</sup> The MyRIDL-513A strain was generated by out-crossing the original OX513A line to the Malaysian MyWT strain. The resulting offspring (strain MyRIDL-513A) contains the genetic modifications associated with OX513A in a Malaysian genetic background.

<sup>40</sup> An isotherm is a line on a map or chart of the earth's surface connecting points having the same temperature at a given time or the same mean temperature for a given period.

value to be more towards the 15°C [~59 °F] yearly isotherm (Otero et al. 2006). Low temperatures below 10°C [~50°F] are therefore likely to severely limit the geographical range of *Ae. aegypti*, although the protection provided by human habitations may afford some protection from lower temperatures. Scholte et al. (2010) indicated that *Ae. aegypti* could not survive winter temperatures in Northern Europe. In a recent study, Thomas et al. (2012) found that a tropical strain of *Ae. aegypti* eggs could only survive at a threshold of -2°C [~28 °F] for 24 hours before hatching broke down completely. Based on available scientific evidence, survival at temperatures below freezing is therefore extremely unlikely; however, these are not temperatures likely to be encountered in the Florida Keys.

#### **12.2.1.4.1 Study on the temperature response of OX513A**

The temperature response of the OX513A line has been evaluated in the laboratory. In such a study, *Ae. aegypti* larvae hemizygous for the OX513A construct were reared at five temperatures ranging between and including 9°C [~48°F] and 37°C [98.6°F]. Larvae were reared in the absence of tetracycline, which as a dietary supplement in the laboratory allows survival of OX513A individuals. Latin wild-type (WT) larvae, the background strain of the OX513A line, were reared under the same conditions as a control. Five repetitions were conducted for each temperature point. Oxitec found that both OX513A larvae and Latin WT larvae died before pupation when reared at 9°C and 37°C (*Appendix D*).

These results demonstrate that the presence of the OX513A insertion does not extend the viable temperature conditions for *Ae. aegypti* such that they can develop to functional adults at these temperatures under laboratory conditions. Therefore, there is no indication that OX513A might be able to spread beyond the current temperature-bounded range of wild *Ae. aegypti*. OX513A larvae reared at intermediate temperatures within this range did not show a higher than expected proportion (<5%) of individuals surviving from first instar larvae (L1) to functional adult (range 0-2%) (*Appendix D*). Together, these studies demonstrate the phenotype of OX513A is stable over the range of temperatures that larvae would be likely to encounter in the field and that they would be extremely unlikely to expand the habitable geographic range of *Ae. aegypti*.

The geophysical containment of the species is also discussed in Section 15.3.

#### **12.2.1.4.2 Conclusion**

***Ae. aegypti has a distinctive global distribution which is limited by a number of abiotic factors such as temperature and availability of breeding sites containing fresh water. Survivability of the OX513A line is impacted by sensitivity to temperature, the antibiotic tetracycline and its analogues used to control the repressible lethality of the line, and susceptibility to insecticides.***

***Laboratory studies have indicated that the genetic engineering has not altered the mosquitoes' response to temperatures across a biologically relevant range, and consequently, no increased distribution of the mosquito is anticipated. Similarly, the sensitivity of the line to tetracyclines has been examined in laboratory conditions. Studies conclude there is no increased survival of the OX513A mosquito from blood meals spiked with high concentrations of tetracycline from doses that are higher than would be given to humans or animals therapeutically. Therefore, it is unlikely that a surviving hemizygous female offspring taking a blood meal from an individual (human or animal) that***

***has recently received a therapeutic dose of tetracycline will imbibe sufficient tetracycline to allow the survival of the mosquito. Therefore, it is highly unlikely that OX513A mosquitoes would encounter tetracycline levels sufficient for survival in the environment or in human or animal blood (in the unlikely event that a female OX513A mosquito was to bite a human or animal therapeutically treated with tetracycline).***

***Two studies have shown that the genetic engineering did not affect susceptibility of the OX513A line to currently used insecticides.***

***In conclusion, the response of OX513A to abiotic factors is likely to be the same as non-genetically engineered *Aedes aegypti*.***

## **12.2.2 Biotic factors affecting survivability**

### **12.2.2.1 Reproduction**

In *Ae. aegypti*, reproduction is sexual with internal exchange of gametes. Mating occurs in aerial swarms, which form around the blood-meal host (Hartberg 1971). These aggregations are primarily composed of males, with females entering the swarm singly. Pheromones are also involved in swarming behavior (Fawaz et al. 2014). Mating occurs in flight, where males and females meet, form a “copula” in mid-air, and mate in a matter of seconds (Hartberg 1971; Moore 1979). Key mating behaviors, such as males resonating their antennae to a certain pitch, which the females reproduce by beating their wings at the same specific frequency, are essential to successful coupling between males and females (Cator et al. 2009; Cator and Harrington 2011).


The average adult lifespan is 3-6 days for male mosquitoes (Clements 2000) although this is highly dependent on temperature, being shorter in tropical regions and longer in more temperate climates, with male mosquitoes not being sexually mature until up to 24 hours post-emergence from the pupal case. The average adult lifespan is 8-15 days for female mosquitoes. The female’s behaviors are dependent on her gonotrophic cycle, i.e., response to the host and finding a bloodmeal, digestion of the blood and formation of mature oocytes or eggs, which are then fertilized and oviposited (laid). Although females may go through several gonotrophic cycles in their lifespan, once inseminated, females store enough spermatozoa to fertilize a number of egg batches. They are therefore largely regarded to mate only once during their lifetime (Pascini et al. 2012). Seminal fluid proteins transferred with that original mating render females unreceptive and more refractory to further copulation (Sirot et al. 2008; Avila et al. 2011; Helinski et al. 2012).

The role of male mosquitoes in the reproductive cycle is the insemination of the females. Male reproductive success is dependent on insemination success and reproductive output. During mating, male mosquitoes transfer not just sperm, but also seminal fluid proteins, as described above, that may have profound effects on mated female biology and behavior. Size of male mosquito also influences mating success, with larger males having greater reproductive success than smaller males, mostly likely due to sperm depletion (Helinski and Harrington 2011). Nonetheless, even small males appear to

transfer sufficient seminal fluid proteins to prevent further mating of the female (Dickinson and Klowden 1997).

### 12.2.2.1.1 Insemination capacity of OX513A males

The insemination capacity of males (i.e., the number of females a male is capable of inseminating over the course of his lifetime), and the cost of investing in courtship and mating on longevity were evaluated for a wild-type strain of Malaysian origin ('WT') and the OX513A line of mosquitoes. Experimental details and the results of this study have been published (Bargielowski et al. 2011a).



**Figure 13. Insemination capacity of OX513A males (from (Bargielowski et al. 2011a)).**

Results summarized in Figure 13 show distinct differences in the insemination capacity and the cost of mating in males of the genetically engineered OX513A and the WT line. Genetically engineered males inseminated just over half as many females (on average 6.6) as the WT males (on average 11.5) during their lifetime. Providing days of rest from mating had no significant effect on the total number of females inseminated by males of each line, yet it did increase their longevity. The reduced insemination capacity observed in this study may be evidence of a slight fitness penalty in the OX513A compared to the wild-type, likely to be a result of mass-rearing, as it is known that mass-rearing can have an adverse impact on fitness parameters relative to wild counterparts (Peters and Barbosa 1977; Dominiak et al. 2008; Benedict et al. 2009; Rull et al. 2012; Rao et al. 2014).


#### **12.2.2.2 Mating competitiveness of the OX513A *Ae. aegypti* mosquito**

In mosquitoes, mating is extremely species-specific. For example, in different species, the wing beat frequency can be used for mate detection with the sexes matching their wing beat tones (Cator et al. 2009). In *Ae. aegypti*, the male and female wing beat tone converges and they mate in flight. The ability of OX513A male mosquitoes to mate with the wild female mosquitoes at the release site is essential to effect population suppression. Therefore, extensive testing of the OX513A line mating competitiveness in a range of environments has been carried out. This includes studies in laboratory cages and in open field release in the Cayman Islands (Harris et al. 2011; Harris et al. 2012) and Brazil (Carvalho et al. 2015).

##### **12.2.2.2.1 Mating competitiveness in the laboratory**

Mating competitiveness studies against wild-type strains from around the world have been carried out in a wide variety of laboratory settings. If the OX513A male were equally attractive to the female as a wild-type male, mating competitiveness would be equal to 0.5 (Figure 14). The OX513A line performed successfully against all the wild-type strains tested regardless of the genetic background as none of the mating competitiveness estimates differ significantly from 0.5. For comparison, based on information from International Atomic Energy Agency's (IAEA) irradiated sterile insect technology (SIT) program for the medfly (*Ceratitis capitata*), mating competitiveness of 0.2 is considered acceptable for a successful SIT program (FAO/IAEA/USDA 2003).

**Summary of mating competitiveness results against wild type (WT) strains worldwide**



**Figure 14. Summary of mating competitiveness results against wild-type *Ae. aegypti* strains worldwide in the laboratory.**

The dotted line represents a mating competitiveness of 0.2 for irradiated SIT and the solid line represents equal mating competitiveness i.e., 0.5.

**12.2.2.2.2 Mating competitiveness in the field**

Mating competitiveness ( $C$ ) is defined as the relationship between the numerical density of wild-type ( $N$ ) and sterile ( $S$ ) insects and the relative mating success, such that  $C = PN/S(1 - P)$  where  $P$  is the proportion of sterile matings, i.e., proportion of fluorescent larvae (Mayer et al. 1998; Vreysen 2005). The 95% confidence intervals were obtained by running a bootstrap statistical analysis (Davison and Hinkley 1997; Manly 2007) on the relative mating success and numerical density of wild-type and sterile insects. All the sustained field releases of OX513A males conducted to date have enabled the estimation of their mating competitiveness. Mating competitiveness is increased when the insects are sexually competitive and of high quality. The process of mass rearing can impact the quality of the insects. The very first releases in the Cayman Islands, which were aimed at demonstrating the proof of principle that Oxitec could produce competitive males, used low rearing densities which gave a mating competitiveness estimate of 0.56 (95% CI: 0.032-1.97, (Harris et al. 2011)). In the following studies the objective was to achieve local *Ae. aegypti* population suppression and, with increased mass

production to provide sufficient insects for the trial, mating competitiveness ranged from 0.0004 to 0.059 (Harris et al. 2012; Carvalho et al. 2015). This range is not unexpected given that mating competitiveness as measured by this approach includes any effect of mass rearing, handling and distribution, and in the environment, the effect of migration both of pre-mated females into the area and of released males and mated females out of the area. In addition it may be that, at relatively low local *Ae. aegypti* population densities, a significant proportion of the released OX513A males are released in areas that have few or no females. This may further depress the apparent mating competitiveness of the released OX513A males relative to wild males, which are likely to have a similar initial distribution as wild females. This may have been the case in the five latest estimates for the Itaberaba, Brazil study, where the local *Ae. aegypti* population had already been suppressed during that period (Carvalho et al. 2015).

Relatively few estimates of mating competitiveness under open-field conditions have been published, despite the long history of sterile-male methods. In large-scale, successful SIT programs, field competitiveness of sterile males was estimated at 0.1 for New World screwworm (*Cochliomyia hominivorax*) (Mayer et al. 1998; Vreysen 2005) and <0.01 for Mediterranean fruit fly (*Ceratitidis capitata*) (Rendón et al. 2004; Shelly et al. 2007). Therefore the mating competitiveness range seen over a variety of different environments with OX513A is predominantly within the reported range of commercial sterile insect programs. The outlying value of 0.0004 is likely due to releases in areas that are with only low numbers or no females, which depresses the apparent mating competitiveness as described above.

**Table 5. Summary of mating competitiveness evaluation of the Oxitec OX513A males in the wild.**

	Cayman Islands 2009	Cayman Islands 2010	Itaberaba, Brazil, June 2011	Itaberaba, Brazil, July 2011	Itaberaba, Brazil, Aug. 2011	Itaberaba, Brazil, Sep. 2011	Itaberaba, Brazil, Nov. 2011	Itaberaba, Brazil, Jan. 2012	Itaberaba, Brazil, Apr. 2012	Itaberaba, Brazil, May 2012	Itaberaba, Brazil, June 2012	Itaberaba, Brazil, July 2012	Itaberaba, Brazil, Aug. 2012	Itaberaba, Brazil, Sep. 2012	Mandacaru, Brazil 2012
<b>Mating Competitiveness</b>	0.560	0.059	0.031	0.013	0.037	0.025	0.047	0.013	0.003	0.006	0.0004	0.006	0.006	0.023	0.012
-95%CI from bootstrap	0.032	0.011	0.0254	0.0089	0.0223	0.0138	0.0399	0.0104	0.0016	0.0031	0.000	0.0039	0.0031	0.0139	0.005
+ 95% CI from bootstrap	1.970	0.210	0.0361	0.0174	0.0546	0.0391	0.0549	0.0152	0.0036	0.0097	0.0008	0.0085	0.0104	0.0352	0.021

The data provided in Table 5 are from three different types of typical environments for *Ae. aegypti*. The Cayman Islands data (Harris et al. 2011; Harris et al. 2012) represent a site that was isolated and untreated with conventional insect control measures; the Brazilian Itaberaba site data reported for various individual months (Carvalho et al. 2015) represent a densely populated environment with a high degree of immigration of *Ae. aegypti* from other areas; and the Brazilian Mandacaru environment data represent a rural, isolated population with low housing density. This data therefore suggests that there are unlikely to be differences in mating behaviors of OX513A with the local population of *Ae. aegypti*, across different backgrounds and environments.

#### 12.2.2.2.3 Conclusions

***The successful mating of OX513A with wild-type Ae. aegypti under different conditions and in different housing densities suggests that the insertion of tTAV and DsRed2 at the insertion site in the OX513A line does not exert positional effects including alterations in the ability of OX513A to react to specific mating signals from wild-type Ae. aegypti i.e., the mating competitiveness of OX513A. This leads us to conclude that the highly species-specific nature of mosquito reproduction is not compromised by insertion of the #OX513 rDNA construct. Successful mating of OX513A males with wild-type Ae. aegypti females results in progeny that carry a repressible lethality trait and will consequently die before reaching functional adulthood. Based on reproductive behavior of Ae. aegypti, the transmission of the inserted genetic trait by sexual reproduction is limited to the species Ae. aegypti only.***

### 12.3 Dispersion

#### 12.3.1 Dispersal of the OX513A *Ae. aegypti* mosquito

Spontaneous flight of adult *Ae. aegypti* is limited to around 200 m depending on availability of breeding sites, and hosts from which to take a blood meal (Suwonkerd et al. 2006; Maciel-de-Freitas and Lourenço-de-Oliveira 2009; Maciel de Freitas et al. 2010; Valerio et al. 2012), although there are reports of females travelling further, even in urban environments (Halstead 2012). Roads, water courses, and vegetation represent significant barriers to the movement of *Ae. aegypti* (Maciel-de-Freitas and Lourenço-de-Oliveira 2009; Hemme et al. 2010), which is adapted to live in close proximity to human habitations.

The species can also be dispersed by human activities such as passive transport on boats, trains, automobiles, etc. (Lounibos 2002; Gubler 2006). Damal et al. (2013) reported that human-aided activity, namely the availability of containers that serve as breeding sites, the presence of human hosts, and human mediated passive transport are the predominant means of dispersal of *Ae. aegypti* in Florida. For example, due to passive transport, it was recently reported that *Ae. aegypti* has been detected for the first time in California and that it had likely come from the Southeastern U.S. (Gloria-Soria et al. 2014). As a result of this potential for passive transport, International Sanitary Regulations (WHO 2005) require ports and airports to establish programs to control *Ae. aegypti* and other insect disease vectors for at least 400 m from point of entry facilities.

Altitude is thought to affect distribution, with an elevation of 6,000-8000 feet likely to be limiting to the species in the tropics and even lower elevations in temperate latitudes. In an extensive survey of mosquito species in the Andes, Navarro et al. (2010) did not record the presence of *Ae. aegypti* at any location over 2,000 m. The slope of the elevation could also be an influencing factor, with plateaus being more preferable as habitat than steep slopes.

However, elevation is not a consideration for affecting dispersal of mosquitoes in Monroe County and Key Haven as the majority (>90%) of the land mass is around or just above sea level<sup>41</sup>.

Other factors affecting distribution/dissemination of *Ae. aegypti* include the presence and type of water storage, as the mosquito is rare in deserts and desert-like conditions without human habitation. Conversely in parts of these arid regions where there are human habitations, there is also likely to be stored water, and this can substantially increase the presence of the mosquito (Sharma et al. 2008; Hayden et al. 2010). High temperatures common in desert areas alone, however, are unlikely to limit distribution but the combination of high temperature and low humidity with lack of shade and breeding sites are contributory factors. Landscape or geophysical barriers to movement of *Ae. aegypti* include saltwater, rivers, roads, areas of vegetation without human habitation, and altitude as these locations have fewer potential hosts for blood meals and present harsh environment for mosquitoes (Maciel-de-Freitas and Lourenço-de-Oliveira 2009; Hemme et al. 2010; Maciel de Freitas et al. 2010; Navarro et al. 2010).

Climate (specifically temperature), urbanization (including ease of host availability), water storage and the availability of breeding sites, are therefore the main factors that influence the distribution, survival and establishment of *Ae. aegypti*.


### **12.3.2 Data obtained from field release on dispersal of OX513A**

Data on dispersal of the line has been obtained from previous field trials with OX513A in Malaysia (Lacroix et al. 2012). Adult male mosquitoes were released into an uninhabited forested area of Pahang, Malaysia. Their survival and dispersal was assessed by use of a network of traps. Two lines were used, OX513A back-crossed from the original Rockefeller strain into the My1 strain for 5 generations (OX513A-My1) and the My1 wild-type laboratory strain (Jinjang, Malaysia), to give both absolute and relative data about the performance of the engineered mosquitoes. The two strains had similar maximum dispersal distances (220 m), but mean distance travelled by the OX513A line was lower (52 vs. 100 m) than that for the wild-type comparator used. Life expectancy was similar (2.0 vs. 2.2 days). Recapture rates were high for both strains, possibly because of the uninhabited nature of the site. Neira et al. (2014) reported that in Panama marked, released WT males had a daily survival probability of 2.3 days, so OX513A is similar in terms of its survival.

---

<sup>41</sup> <https://www.google.com/maps/place/Raccoon+Key/@24.5747095,-81.7357574,3591m/data=!3m1!1e3!4m5!3m4!1s0x88d1b18002287e7b:0x445a14e3e77aff8!8m2!3d24.5818125!4d-81.7348125>

Longevity of released males is closely associated with their dispersal ability, as dispersal will generally increase with time. It was anticipated that the dissemination of OX513A genes into the environment should be limited to the dispersal of released males and their subsequent mating with local wild-type females. Inclusion of a heritable marker (DsRed2) as part of the genetic engineering enabled the evaluation of dissemination of OX513A genes resulting from the release of OX513A males. Oxitec assessed the dissemination of OX513A genes into the environment by analyzing the distribution of OX513A eggs recovered from ovitraps in an area adjacent to a site that received sustained release of OX513A males. The mean distance travelled (dissemination) of OX513A genes into the untreated area was estimated at 64 m (95%CI; 55-74) and 79 m (95% CI; 74-86) for the two periods evaluated. This differed little for the dispersal of OX513A and males of the comparator strain (recently colonized *Ae. aegypti*) observed at the same site (mean distance travelled = 39-75 m) and falls in the mid-range of those reported in the scientific literature (mean distance travelled = 12-288 m) for dispersal of *Ae. aegypti*, see Figure 15.



**Figure 15. Review of reported mean distance travelled (m) for wild-type and OX513A *Ae. aegypti* and observed dissemination of #OX513 rDNA construct from male release.**

References for Figure 15: McKemey Brazil (Carvalho et al. 2015);(Reuben and Panicker 1975; McDonald 1977; Trpis and Hausermann 1986; Reiter et al. 1995; Reiter 1996; Muir and Kay 1998; Ordonez-Gonzalez et al. 2001; Tsuda and Takagi 2001; Getis et al. 2003; Harrington et al. 2005; Russell et al. 2005; Maciel-de-Freitas et al. 2007; Maciel-de-Freitas and Lourenço-de-Oliveira 2009; Lacroix et al. 2012)

### 12.3.3 Conclusion

***The OX513A line shows a similar dispersal pattern to the wild-type comparator strain in dispersal experiments and falls within the midrange of the flight distances of Ae. aegypti reported in the scientific literature. The daily survival probability is in the order of 1-3 days, which is consistent with the literature for released male Ae. aegypti.***

## 13 Evaluation of Potential Impacts

This environmental assessment addresses the potential for significant environmental impacts as the result of the conduct of the proposed field trial. The potential impacts include the following:

- Direct or indirect effects on non-target organisms
- Increase in invasiveness or persistence in the environment
- Potential impact on ecosystem function
- Potential increase in disease transmission
- Potential for loss of biodiversity
- Potential adverse effects on humans
- Potential for escape from the HRU
- Potential for gene movement and changes in phenotypes of recipient organisms via sexual and non-sexual transfer of genetic material

The impacts are evaluated based on their likelihood to occur and the potential consequences if they were to occur. When considering the likelihood of potential impacts, consideration is given to appropriate non-GE, wild-type comparators; i.e., the existing mosquito control measures and their consequences on the environment as well as the existing wild-type *Ae. aegypti* mosquito population and its consequences on human health.

### 13.1 What is the likelihood for inadvertent release of OX513A mosquitoes outside of the proposed trial site?

The following section examines the potential for escape from the HRU and the associated activities and measures that are in place to prevent such an escape.

#### 13.1.1 Containment measures

The main pathway for potential impacts is via inadvertent release outside of the intended rearing or trial sites, namely at the HRU site in Marathon and/or during transport of mosquitoes to the release site in Key Haven.

Eggs of the OX513A line of *Ae. aegypti* would be hatched and reared to adulthood at the HRU (Section 10.4.2). There would be life stages of both female and male mosquitoes in the HRU, although the females would be sorted to ensure accuracy of the sorting does not exceed a maximum of 0.2% females

and sorted females would be killed at the larvae/pupae stage, which would be conducted in the containment facility. Therefore, the chance of all life stages of OX513A mosquitoes escaping is extremely low. OX513A mosquitoes would be maintained with multiple levels of physical containment (primary rearing containers, the HRU, and the building housing the HRU) in accordance with ACL2 requirements and those of the U.S. agencies (CDC and USDA APHIS) permitting the import (Sections 10.4.1.6 and 15.1). Every effort would be made to avoid inadvertent release by following established procedures and implementing staff training. FDA verified physical and procedural containment implemented at the HRU during an inspection. FDA inspectors were accompanied by a subject matter expert from CDC. No Form 483<sup>42</sup> was issued at the conclusion of the inspection.

The most likely threat that could lead to a breach of containment is a hurricane and/or flooding following a storm surge. These are natural events that could potentially cause an inadvertent release. The building housing the HRU is a Category 4 hurricane-protected building. In the case of a hurricane, there is a hurricane preparedness policy for the HRU that aims to minimize inadvertent release. The policy calls for killing mosquitoes within 36 hours of a hurricane strike warning issued by the U.S. National Weather Service. The decision to implement these measures would be made by the FKMCD program manager and the study director, in accordance with the hurricane management plan.

Oxitec performed an analysis of the likelihood of potential impacts during transport of their GE mosquitoes along with potential control measures. The results of the analysis are summarized in Table 6 below. Potential impacts are categorized as being “low”, “moderate,” or “likely.”

---

<sup>42</sup> FDA issues a Form 483 to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the FD&C Act and related Acts.

**Table 6. Potential routes for impacts, consequences, and control strategies for the transport of OX513A mosquitoes from the HRU to the release site.**

Potential route of impact	Consequence	Control Measures(s)	Potential likelihood for adverse impact to human health or environment
Release of mosquitoes during transport to trial site.	GE mosquito released to environment outside release area.	Secure, shatterproof double containers would be used for mosquito transfer. Insects cannot establish in the environment due to intrinsic biological containment (reliance on presence of tetracycline). Insecticide treatment can be applied if required.	LOW
Vehicular accident during transport to trial site.	GE mosquito released to environment outside release area.	Secure, shatterproof double containers would be used for mosquito transfer. Insects cannot establish in the environment due to intrinsic biological containment (reliance on presence of tetracycline). Insecticide treatment can be applied if required.	LOW
Transport boxes inadvertently lost.	GE mosquito released to environment.	Containers would be in FKMCD or Oxitec staff custody throughout journey, any loss of boxes would be reported immediately, and every effort would be made to recover the boxes/mosquitoes. A chain of custody would be in place for all transport. Even if not located, insects cannot establish in the environment due to intrinsic biological containment (reliance on presence of tetracycline).	LOW
Boxes dropped during loading for transport.	GE mosquito released to environment.	Secure, shatterproof double containers would be used for mosquito transfer. Insects cannot establish in the environment due to intrinsic biological containment (reliance on presence of tetracycline).	LOW
Boxes stolen.	GE mosquito released to environment.	Boxes would be accompanied by FKMCD or Oxitec staff at all times. Any loss of boxes would be reported immediately and appropriate authorities would be informed of the theft. Insects cannot establish in the environment due to intrinsic biological containment (reliance on presence of tetracycline).	LOW
Mosquitoes passively transported away from trial area (trapped in vehicles etc.).	GE mosquito release to environment outside of release area.	Insects cannot establish in the environment due to intrinsic biological containment (reliance on presence of tetracycline). Insecticides can be used if necessary.	LOW
Release of GE mosquitoes during unpacking.	GE mosquito released to environment.	Staff trained in safe handling procedures, unpacking would only be done within the trial site area, and insects cannot establish in the environment due to intrinsic biological containment (reliance on presence of tetracycline).	LOW

### 13.1.2 Conclusions

Based on our evaluation of the physical containment measures and procedures implemented for the rearing and transportation of OX513A mosquitoes, FDA concludes that, should the field trial proceed, the likelihood that OX513A mosquitoes would be inadvertently released outside of the intended field trial site is low.

#### 13.2 What is the likelihood for establishment of OX513A mosquitoes at the proposed trial site?

There is the potential for a significant environmental impact if an animal spreads and establishes in the environment in which it is released. NRC (2002) identified three variables as important in determining the likelihood of establishment of the GE animal in the environment:

1. The effect of the rDNA construct on the fitness of the animal for the ecosystem into which it was released
2. The ability of the animal to escape and disperse into diverse communities
3. The stability and the resiliency of the receiving environment

Overall concern is a product of all three variables, not the sum and, therefore, if the risk of any one of the variables is negligible the overall concern would be extremely low. An examination of the life-cycle parameters of the OX513A mosquito in comparison to a wild-type control strain mosquito contribute to assessment of the overall fitness of the OX513A line. Fitness of OX513A mosquitoes should be considered within the context that the intended effect of the expression of the rDNA construct is to confer dominant conditional lethality to the line, i.e., a competitive disadvantage, and the line will die without access to the tetracycline antidote in its diet.

This section focuses on the fitness of the line, as the ability of OX513A mosquitoes to escape and disperse into diverse communities is covered in Section 12.3. The stability and resiliency of the receiving environment is described in Section 12.1 on accessible environments.

Fitness is comprised of reproductive potential, mating success, and survival. Of these components, survival has been evaluated in Section 12.2 and will not be addressed here further.

#### 13.2.1 Lifecycle parameters

The lifecycle parameters of the OX513A *Ae. aegypti* have been examined in a study by Lee et al. (2009b). Comparative lifecycle parameters of a wild-type laboratory strain of *Ae. aegypti* (WT) and OX513A *Ae. aegypti* (in this study called LA513, although this represents only a name change and not a strain difference) were studied in the laboratory. The following parameters were statistically indistinguishable in both strains: the number of eggs laid, the number of unhatched eggs, the egg-hatching rate, the duration of larval period in all four instars, larval survivorship, pupation, adult eclosion rate, gonotrophic cycle, adult fecundity, adult lifespan, and offspring sex ratio. These results indicate that under permissive conditions (i.e., in the presence of tetracycline), the basic lifecycle parameters and growth

rate of the OX513A *Ae. aegypti* were not affected by the genetic engineering and its mating competitiveness was sufficient to enable the successful use of this technology.

Bargielowski et al. (2011b) compared the life history characteristics of the OX513A line and a wild-type strain of *Ae. aegypti* in response to increasing larval rearing density in the presence of a constant amount of food per larva. Parameters examined were larval mortality, developmental rate (i.e., time to pupation), adult size, and longevity under permissive conditions (i.e., in the presence of tetracycline). Only two statistically significant differences were found between the strains: the OX513A *Ae. aegypti* larval survival was 5% lower than that of the wild-type and OX513A adult longevity was lower than that seen in the wild-type (20 days OX513A vs 24 days wild-type mean lifespan). The OX513A line pupated approximately one day sooner than wild-type *Ae. aegypti* resulting in smaller adults than the unmodified line. This effect was more pronounced in females than in males.

These life-cycle characterization studies between the investigational product and its conventional counterpart have been used to establish whether unintended changes in the GE mosquito have occurred as a result of the genetic engineering. The results of this comparative safety assessment demonstrated that the only difference of biological relevance identified between the OX513A *Ae. aegypti* line and the wild-type *Ae. aegypti* mosquito is the expression of the intended proteins (tTAV and DsRed2) and a small fitness disadvantage.

### 13.2.2 Mating competitiveness

Mating competitiveness is a key parameter in the assessment of the fitness of the OX513A mosquito. Data in Figure 14 indicate that in the laboratory, the GE mosquitoes performed as well as the WT, and none of the mating competitiveness estimates differ significantly from 0.5.<sup>43</sup> As a point of comparison, the International Atomic Energy Agency considers a mating competitiveness of 0.2 to be acceptable for a successful sterile insect technology (SIT) program (Section 12.2.2.2.1).

Bargielowski et al. (2011a) (Figure 13), however, indicated that the insemination capacity of OX513A males was significantly reduced versus the wild-type Malaysian strain of *Ae. aegypti* used as a comparator in this study. The authors hypothesized that the reduced insemination capacity of OX513A males may be potentially attributed to a slight loss of fitness in the GE mosquito compared to the wild-type, likely due to the effects of mass-rearing (Section 12.2.2.1.1).

It is not clear whether the difference in results described in the Bargielowski et al. (2011a) study and the survey of strains illustrated in Figure 14 is due to differences in the measured endpoint (mating competitiveness vs. insemination capacity) or some other factor. Nonetheless, the weight of evidence seems to indicate that there are no biologically relevant differences in the relative ability of OX513A males to mate with WT *Ae. aegypti* females in the laboratory and suggests that the insertion of the rDNA construct has not affected reproductive behavior of OX513A mosquitoes. In addition, the ability of

---

<sup>43</sup> For OX513A males, mating competitiveness of 0.5 indicates that wild-type *Ae. aegypti* females are equally attracted to OX513A and wild-type *Ae. aegypti* males.

the mosquito to react to the specific mating signals from other *Ae. aegypti* mosquitoes has similarly not been affected. Mating competitiveness has also been assessed in field studies in the Cayman Islands (Harris et al. 2011; Harris et al. 2012) and Brazil (Carvalho et al. 2015) which demonstrate that there are unlikely to be differences in mating behavior of OX513A mosquitoes compared with the local wild-type population of *Ae. aegypti* across different backgrounds and environments.

### 13.2.3 Conclusions

The OX513A line of *Ae. aegypti* mosquitoes carries a repressible dominant lethality trait that prevents progeny inheriting the #OX513 rDNA construct from surviving to functional adulthood in the absence of tetracycline. Although it appears that the introduced lethality trait did not affect mating competitiveness of OX513A males, data demonstrating hemizygous females reared without tetracycline have a median lifespan of two days relative to a wild-type median lifespan of 68 days indicate a further reduction in the likelihood of survival of OX513A mosquitoes and their progeny. FDA therefore concludes it is highly unlikely that OX513A mosquitoes and their progeny would be able to establish at the proposed trial site. Nevertheless, Oxitec would monitor ovitraps for a period of time that covers a full mosquito season after the conclusion of the trial in order to detect any persistence of OX513A mosquitoes.

### 13.3 What is the likelihood of dispersal of OX513A mosquitoes and their progeny from the proposed trial site?

The effect of the introduced traits on the dispersal ability of OX513A mosquitoes is discussed in Section 12.3. In a study of OX513A mosquitoes in Malaysia, Lacroix et al. (2012) showed that the *mean distance traveled (MDT)* for the OX513A-My1 line of mosquitoes was significantly lower than that of their wild-type comparator, My1 line (52 m and 100 m respectively) (Section 12.3.2). Nonetheless, the *maximum distance traveled* was similar for both lines of mosquitoes. This indicates that, in general, the population of OX513A mosquitoes is not expected to exhibit dispersion *greater than* wild-type *Ae. aegypti*.

The location of the proposed field trial site would further limit the spread of released OX513A mosquitoes and their progeny due to various barriers to movement including roads, dense vegetation, and other natural obstacles (Hemme et al. 2010; Maciel de Freitas et al. 2010). The proposed field site is located in Key Haven, which is surrounded by salt water on three sides (Figure 9). The closest island is located more than 250 m away. This will considerably limit the spread of mosquitoes from the proposed field trial site because the *MDT* for OX513A mosquitoes is approximately 200 m (Lacroix et al. 2012; Winskill et al. 2015). In addition, the shoreline of both islands is covered with dense vegetation and will further limit the spread of mosquitoes. Although mosquitoes can potentially be dispersed passively by boats and cars, the likelihood that large numbers of mosquitoes would be dispersed in this way is low. The island is connected to Highway 1 via a single road, with no through traffic passing through the area (especially the TA). Additionally, the TA is located at the end of the peninsula that is furthest away from Highway 1 and is residential with no major commercial venues. Taken together, these factors considerably limit the potential spread of mosquitoes from the proposed field study site.

During the trial, FKMCD would continue standard mosquito control practices at the proposed trial site. These practices include container dumping and removal (source reduction), container treatment with

larvicides, and adulticide treatment. These practices are also expected to limit the dispersion of OX513A mosquitoes. The description of FKMCD activities and chemicals used to control mosquitoes is included in Section 8.1.

While the spread of OX513A mosquitoes beyond the proposed trial site is unlikely for the reasons described above, Oxitec would nevertheless monitor during and after the trial for such spread through ovitraps placed outside the trial area and at the highway entrance to Key Haven. If any OX513A mosquitoes are detected outside the trial area, Oxitec will inform FDA within three days of confirmation of such detection.

### **13.3.1 Conclusions**

Based on our analysis of data available in the literature, dispersal of OX513A mosquitoes appears to be adversely affected as measured by *MDT* but not by *maximum distance traveled*, indicating that in general, the population of OX513A mosquitoes is not expected to exhibit dispersion greater than wild-type *Ae. aegypti*. The location of the proposed trial site and mosquito control measures implemented by FKMCD would considerably limit the dispersion of OX513A mosquitoes as well. FDA therefore concludes that, should the trial proceed, it is highly unlikely that OX513A mosquitoes and their progeny would be able to spread beyond boundaries of the proposed field trial site.

## **13.4 What is the likelihood that the rDNA construct could be transferred to humans or other organisms?**

### **13.4.1 Likelihood of sexual transfer of rDNA construct**

*Ae. aegypti* does not form part of a species complex (i.e., a group of insects of similar form that are often indistinguishable at the species level) and matings with closely related mosquito species do not produce viable offspring (Leahy and Craig 1967; Harper and Paulson 1994; Nazni et al. 2009a). Nazni et al. (2009a) forced laboratory matings between wild-type *Ae. aegypti* and *Ae. albopictus* that yielded eggs in all cases; however, these eggs were not viable, and when bleached were shown to have no embryos.<sup>44</sup> A more recent study (Tripet et al. 2011) showed that there is cross species insemination in the field between *Ae. aegypti* and *Ae. albopictus* but these interspecific matings encounter many barriers and only low frequencies of this type of mating appear to occur. (A single *Ae. albopictus* was found to have *Ae. aegypti* sperm in this study, and three *Ae. aegypti* females were inseminated by *Ae. albopictus* but no viable progeny resulted.) Movement of the genetic elements in OX513A by vertical or sexual transfer to other mosquito species is therefore likely to be only a rare event in nature, and even if movement does occur this is unlikely to produce viable offspring. This is corroborated by the examination of the dispersion of the fluorescent marker gene as described in Section 12.3.2.

---

<sup>44</sup> Lee et al. (2009a) also showed that there was no evidence for successful interspecific mating of OX513A *Ae. aegypti* with wild-type *Ae. albopictus*.

### 13.4.2 Likelihood of non-sexual transfer of the rDNA construct

Non-sexual transfer (NST) of genetic material describes the movement of genes between independent co-existing organisms from different species. It does not include the transfer of genes through sexual reproduction mechanisms i.e., breeding<sup>45</sup>. Non-sexual transfer of genetic material between certain bacteria and other single-celled (prokaryotic) organisms can occur at a detectable frequency and bacteria have obtained a significant proportion of their genetic diversity from distantly related organisms (Ochman et al. 2000). NST from multicellular (eukaryotic) organisms such as plants or insects to other organisms is remarkably rare, occasionally being detected under optimized laboratory conditions, but at frequencies expected to be lower than background rates in natural or field conditions (Keese 2008; Crisp et al. 2015).

Specifically, with regard to the OX513A mosquito, it has been shown that sexual transfer to other species is unlikely to produce viable offspring due to both complex mating barriers and the lack of release of gamete materials (Section 12.2.2). These mating barriers have the effect of restricting the genes to that species, in contrast to many other higher organisms that release genetic material into the surrounding environment, such as plants releasing pollen, fungi releasing spores, or milt in fish.

The potential for the introduced genes to be transferred to other organisms through oral ingestion of the mosquitoes by predators, as well as the potential that genes could be transferred if a female mosquito bites a human or an animal, is assessed below:

#### 13.4.2.1 Acquisition of genes through oral ingestion or biting

It is highly unlikely that the rDNA construct could be transferred to humans or other animals through biting. As discussed in Section 9.2.1, the rDNA construct is stably integrated into the mosquito genome and is not capable of re-mobilization due to altered ITR sequences even when treated with appropriate transposases. Nordin et al. (2013) did not find evidence of non-sexual transfer of the engineered traits through oral ingestion in *Toxorhynchites* fed solely on a diet of OX513A larvae (raised both on and off-tetracycline) and assayed using PCR (approximately 52,000 events i.e. possible occurrences of NST of sequences from #OX513<sup>46</sup> in 121 adults tested). Further, mosquitoes have been feeding on humans and other mammals for millennia, estimated to be more than 100 million years. Complete genome sequences are now available for several mammalian species including humans, and several mosquito species including *Ae. aegypti*; there is no evidence of gene transfer via biting. Even if this hypothetically were to occur, even at extremely low frequencies, one would see DNA sequences from humans in

---

<sup>45</sup> Non-sexual transfer of genetic material is sometimes referred to as horizontal gene transfer, most correctly when discussing transfer of genetic material between bacteria or other microorganisms.

<sup>46</sup> Nordin et al. (2013) describes PCR analysis performed on genomic DNA from 121 adult *Toxorhynchites* which they estimate consumed on average 432 OX513A larvae during their lifetime resulting in a minimum of 52,000 (i.e. 121 X 432) chances for NST to occur. So they determine that the PCR tested a pool of at least 52,000 possible NST “events” in these adults.

human-feeding mosquitoes, from birds in bird-feeding mosquitoes, and *vice versa* under the even more implausible hypothesis of DNA transfer from mosquito to host.

More generally, in the case of birds eating mosquitoes (and humans unintentionally swallowing them), animals do not incorporate DNA from their food into their genome. Because nucleic acids, including DNA, are present in the cells of every living organism (including every plant and animal used for food by humans and animals), they are presumed safe for consumption (FDA 1992). Accordingly, there is no direct food consumption risk associated with exposure to the endogenous *Ae. aegypti* DNA or the #OX513 rDNA construct itself.

Further, several studies have addressed the fate of ingested DNA in mammals and birds, including studies that have attempted to detect rDNA in chicken (Khumnirdpetch et al. 2001) or cows (Klotz and Einspanier 1998) fed with glyphosate tolerant soybean and studies that have attempted to detect rDNA in pigs (Weber and Richert 2001; Klotz et al. 2002), dairy cows, beef steers, and broiler chicken (Flachowsky et al. 2000; Einspanier et al. 2001), all fed with recombinant *Bacillus thuringiensis* corn. In the aforementioned studies, recombinant DNA was not detectable by PCR in various samples. Additionally, in reviews on the detection and fate of both recombinant DNA and protein in animals given feed derived from GE crops, Alexander et al. (2007), Flachowsky et al. (2012), and Van Eenennaam and Young (2014) concluded that there were no health or productivity (differences in compositional and nutritional value) effects on the livestock.

If an organism does acquire a gene through NST, the acquisition might not have any measureable effect on the environment. To have an impact, a significant number of organisms must acquire this new gene to be able to compete with organisms in the environment and establish (NRC 2002). The likelihood of that depends on the rate of NST, the nature of the gene, the incorporation of the gene into heritable cells, and environmental influences (NRC 2002).

Although NST between prokaryotes (e.g., simple organisms such as bacteria) is well-documented, the rate of NST in those populations is extremely rare, occurring at very low frequencies (Thomas and Nielsen 2005). The occurrence of NST between prokaryotes and eukaryotes is more controversial, very difficult to detect, and likely happens on an evolutionary time scale only (Kurland et al. 2003; Dunning Hotopp et al. 2007; Dunning Hotopp 2011; Boto 2014). In a recent study, Crisp et al. (2015) carried out a detailed analysis of 26 species including 10 primates, 12 *Drosophila* species, and four *Caenorhabditis* genomes and simplified analysis of additional 14 species for the evidence of NST between bacteria and metazoans (more complex eukaryotic organisms including animals whose bodies are composed of cells differentiated into tissues). Their results suggest that in humans and primates, for example, NST events appear to be ancient and more likely occurred sometime in one of their common ancestors and support the notion that NST events occur at extremely low rates, on an evolutionary timescale. Therefore, it is highly unlikely for an NST mediated event related to OX513A mosquitoes to occur within the relatively short timescale of the proposed investigational study.

Another theoretical impact could result from insect gut bacteria acquiring antibiotic resistance genes as the mosquitoes' aquatic life stages are reared in the presence of tetracyclines in the laboratory, then

spreading those genes to other organisms in the environment upon their release. However, there is no causal pathway for this to occur as gut bacteria are lost during mosquito metamorphosis from larvae to adults (Demaio et al. 1996; Moll et al. 2001). Larvae are treated with tetracycline, but as described above the gut bacteria are lost during the pupal stage (e.g., stay in the rearing water), pupae and adults are not subsequently treated with tetracycline during the rearing, and pupae are washed in fresh water several times during the sorting process. The possibility of superficial bacteria present on the body surface of eclosed adults acquiring antibiotic resistance genes due to OX513A eggs and larvae being raised in tetracycline containing water is very low. There is no causal pathway for this to occur because pupae would be washed several times in fresh water during sorting, the pupae would be raised in fresh water, and the adults eclosing from these pupae would not have extensive enough contact with the pupal case or the water surface for acquisition of bacteria that could be harbouring antibiotic resistance genes. Additionally, bacteria would need to be present in the rearing trays, acquire tetracycline resistance genes, and spread those acquired resistance traits across the general bacterial population which would have to persist in the fresh water used to maintain sorted pupae. The combined probability of all these events happening is very low.

It is also highly unlikely that the rDNA construct could be transferred to microorganisms (e.g., bacteria in the intestine of OX513A mosquitoes, humans, or other animals; bacteria present in soil and involved in decomposition of organic matter). Every organism has a number of physical, biochemical, and genetic barriers to restrict non-sexual horizontal gene transfer (Thomas and Nielsen 2005). Despite the fact that prokaryotes are exposed to an abundance of genetic material from eukaryotic organisms, the presence of eukaryotic genes in the genome of prokaryotes is extremely limited and suggests the existence of functional and selective barriers that limit the acquisition of eukaryotic genes by bacteria (Andersson 2005).

### **13.4.3 Conclusions**

Based on evaluation of data and information submitted by Oxitec, FDA determined that the #OX513 rDNA construct is stably integrated in the OX513A mosquito genome and completely refractory to remobilization, even when deliberately re-exposed to the *piggyBac* transposase used for insertion into the mosquito genome. Should the proposed field trial proceed, FDA considers that it is highly unlikely that the #OX513 rDNA construct could be transmitted to other closely related species by inter-breeding, as *Ae. aegypti* mating behavior is highly species-specific. Horizontal or non-sexual transfer of the rDNA construct to humans and other animals is also highly unlikely due to a number of physical, biochemical, and genetic barriers. Mosquitoes have been feeding on humans and other animals for millennia with no evidence of DNA transfer between humans and mosquitoes.

### **13.5 What is the likelihood that release of OX513A mosquitoes would have an adverse effect on non-target species at the proposed trial site?**

*Ae. aegypti* is considered uniquely domestic amongst the mosquito species, being closely associated with human habitations. It is a non-native species in the U.S. present predominantly in the Gulf Coast States (Lounibos 2002), and has therefore not co-evolved with other organisms in the ecosystem and

does not represent a keystone species on which other organisms rely for food. It is continually suppressed by control methods such as the use of insecticides and breeding site source reduction. These methods already reduce the *Ae. aegypti* population to low levels, with an average reduction by chemical intervention of 27.2% (Ballenger-Browning and Elder 2009) and 50% as reported by FKMCD<sup>47</sup> but are increasingly ineffective due to the buildup of resistance mechanisms to the chemicals in use (Marcombe et al. 2011; Maciel-de-Freitas et al. 2014). The use of chemical control methods may also be considered to have a greater environmental impact on other organisms than the result of the suppression of *Ae. aegypti* using OX513A. For example, pyrethroid based sprays are considered a potential toxicity hazard to aquatic organisms (Pierce et al. 2005) and as they are non-discriminatory may harm beneficial insect species as well. Recent research however indicates that this risk may have been overstated (Phillips et al. 2014). In a recent risk assessment conducted for the release of *Ae. aegypti* carrying the intracellular bacterium, *Wolbachia*, a group of experts concluded that *Ae. aegypti* was unlikely to have interactions with natural ecosystems, and it was unlikely that the other species rely heavily or even moderately on *Ae. aegypti* as a food item or provider of ecosystem services (Murphy et al. 2010). Reduced *Ae. aegypti* populations are already achieved as a result of current mosquito control practices. Consequently interactions with other organisms in the environment are already extremely limited and therefore have only been briefly addressed below.

### **13.5.1 Competition with other mosquito species (conspecifics)**

Several species of mosquito can co-occur in the same water-filled containers (aquatic breeding sites), where they are competing for resources such as food. Larval competition, inter- or intraspecific, may have important effects on the growth, survivorship, and reproductive success of these species (Juliano and Lounibos 2005). Therefore, conditions for larval growth and development may have a significant impact on overall container-breeding insect population growth. Those species that can maintain positive population growth under interspecific conditions of greater density or lower resource availability than a competitor are likely to be more successful in their breeding. The effect of the OX513A conditional lethality trait expression occurs towards the fourth instar and pupal life stages and therefore enables the developing larvae to compete with conspecifics for resources. By competing for breeding sites and resources in this way and not dying earlier, for example at the egg stage, this has the effect (as it would for other conspecific mosquitoes not carrying the rDNA construct) of reducing the overall numbers of mosquitoes in the breeding environment.

Adult male mosquitoes will actively compete with one another to mate with females in the environment. The proposed releases would involve a higher number of OX513A males released in relation to the local *Ae. aegypti* male population at the trial site, which would enable the Oxitec mosquitoes to attain over 50% of the matings. Continued release of Oxitec males is then anticipated to

---

<sup>47</sup> <http://keysmosquito.org/wp-content/uploads/2015/05/2015-06-23-Reg-Mtg-Minutes.pdf> [Accessed March 4, 2016].

result in population suppression at the release site. The numbers of mosquitoes released would be adapted during the course of the trial to maintain over 50% of the female matings with OX513A.

### 13.5.2 Predators of *Ae. aegypti*

In the aquatic environment, the larvae have a number of predators including other invertebrates, tadpoles, and fish. Aquatic invertebrate predators from the Coleoptera (beetles), Diptera (flies), Hemiptera (true bugs), and Odonata (dragonflies) orders are known to prey on all mosquito larvae in the same environment (Shalan and Canyon 2009). Because *Ae. aegypti* usually uses man-made containers such as gutters, water containers, cans, and tires as breeding sites, there appears to be no specific predator that preys on *Ae. aegypti* but rather predators that are generally opportunistic and feed on larvae if and when they encounter them. Predators can significantly affect the survival, development, and recruitment levels of mosquitoes in their aquatic breeding sites. There is some evidence that the presence of predators affects oviposition by *Ae. aegypti* in a positive fashion (Albeny-Simoes et al. 2014), where *Ae. aegypti* mosquitoes are attracted to oviposition sites that have high bacterial activity due to animal-derived organic materials produced by other predator species feeding on their prey and *Ae. aegypti*, therefore, lay their eggs at these sites. Mogi (2007) reviewed mosquito invertebrate predators and concluded that they are usually absent or sparse in man-made containers in residential areas, which is where the investigational trial is proposed.

Potential routes of exposure involve different ecological guilds<sup>48</sup> of organisms. These guilds are summarized in Table 7.

**Table 7. Summary of guilds potentially exposed to the OX513A *Ae. aegypti*.**

Terrestrial	Aquatic
Predators	Predators
Parasitoids	Decomposers
Pollinators	
Decomposers	

In the consideration of the possible ecological consequences of mosquito control using OX513A, a key issue is whether *Ae. aegypti* provide any ecological role in the environment. *Ae. aegypti* mosquito is an urban or domestic mosquito closely associated with human habitations. Non-target organisms in these areas are not usually threatened or endangered, and there is no habitat overlap for these species with the domestic environment based on the analysis of the threatened and endangered species (Appendix B). From a review of the scientific literature conducted in PubMed, no papers were identified in which a predator was found to be dependent on *Ae. aegypti* alone as a food source. Additionally, *Ae. aegypti* is a

---

<sup>48</sup> Ecological guilds are a group of species that exploits the same kinds of resources in comparable ways. These can be unrelated species competing for the same resources e.g., insects that pollinate plants compete for the same nectar sources.

non-native insect (Slosek 1986) and is regularly subjected to other control methods such as insecticide treatment and source reduction. Therefore, it is highly unlikely any predator species is dependent on *Ae. aegypti*'s presence in the food chain for its survival and as a consequence there is likely to be negligible impact on non-target organisms.

Nonetheless, in consideration of possible impacts of the release of OX513A, non-target organisms are included in the risk analysis below. Non-target organisms may include invertebrate species such as *Toxorhynchites spp.*, dragonflies, spiders, water-borne Crustaceans such as *Mesocyclops*, amphibians, such as frogs, lizards and geckos, fish, insect feeding birds, and bats. It should be noted, however, that the scientific literature frequently indicates that mosquito predators are regarded as generalized predators (Blum et al. 1997; USFWS 2004; Shaalan and Canyon 2009).

#### **13.5.2.1 Predatory mammals**

Insectivorous bats are often anecdotally regarded to be a significant predator of mosquitoes and are thought to eat large quantities of mosquitoes. In the case of bats, there is temporal separation between the diurnal (daily) habits of bats and *Ae. aegypti* mosquitoes. *Ae. aegypti* mosquitoes are active in the day (Gubler and Clark 1995) whereas bats are crepuscular. Furthermore, a study conducted on bats found that mosquitoes were not always available as food to bats and therefore make up only a small fraction of their diet. This was due to their small size, poor detectability by low frequency echolocation, and variable field metabolic rates (Gonsalves et al. 2013). The American Mosquito Control Association (AMCA) also reviews the role of bats for mosquito control on its website,<sup>49</sup> indicating that although bats do eat mosquitoes, mosquitoes comprised less than 1% of the gut contents of wild caught bats in the studies reviewed to date, and other insects, such as moths provide better nutritional value. An analysis of the diet through stomach content analysis or fecal pellet analysis shows that bats are opportunistic feeders; Whitaker and Lawhead (1992) analyzed the brown bat fecal pellets and showed 71% small moths, 16.8% spiders and 1.8% mosquitoes while the diet of the big brown bat was dominated by beetles and caddisflies (reviewed by Agosta (2002)). This is also confirmed by a study from Feldhamer and Carter (2009) where the prey of eight different insectivorous bats was analyzed. Therefore, due to the temporal separation in activity periods and the likelihood that the mosquito would form only a small part of the bat diet, it is unlikely that *Ae. aegypti* OX513A would significantly impact insectivorous bats.

#### **13.5.2.2 Predatory birds**

The consumption of insects by insectivorous birds can depend on the abundance of the insect population itself; where there are abundant insects, then consumption is likely to increase (Glen 2004). However, even if the consumption increases in times of abundant insect populations, the birds remove an extremely small proportion of the insects. Perhaps the most frequently anecdotally cited bird as a consumer of mosquitoes is the Purple Martin (*Progne subis*), the largest species of martin in North

---

<sup>49</sup> <http://www.mosquito.org/faq> [Accessed June 20, 2016].

America; however both the AMCA and the Purple Martin Conservation Association<sup>50</sup> declare that this is not supported by scientific fact. The facts are that there is temporal isolation between the Purple Martin and the mosquito flight patterns, with the birds and mosquitoes not flying at the same times or altitudes, and that they form only a small part of the overall diet of the birds (Johnson 1967). An intensive 7-year diet study conducted at PMCA headquarters in Edinboro, PA, failed to find a single mosquito among the 500 diet samples collected from parent martins bringing beakfuls of insects to their young.<sup>51</sup> Therefore, due to the temporal separation in activity periods and that the mosquito is likely to form only a small part of the bird diet, it is unlikely that *Ae. aegypti* OX513A would significantly impact insectivorous birds.

### 13.5.2.3 Predatory amphibians

Amphibian predators, such as frogs, and salamanders, do not interact with *Ae. aegypti* or other adult mosquitoes in sufficient numbers for effective mosquito control.<sup>52</sup> Amphibians do have the capacity to consume mosquito larvae, and a study showed that in the laboratory large numbers (200-400 3<sup>rd</sup> instar larvae of *Culex* species per day) could be consumed by salamander species, but this is where mosquitoes were the only food source and there was no prey choice (DuRant and Hopkins 2008). However, there are unlikely to be salamanders present in the same breeding sites, as *Ae. aegypti* is a container breeding species associated with human habitats and salamanders are associated with seasonal pools and wetlands. Blum et al. (1997) found through a diet analysis of anurans (newts) that mosquitoes made up only 0.16% of the anuran diet's content. Therefore, it is unlikely that OX513A would have a significant impact on predatory amphibians.

### 13.5.2.4 Predatory invertebrates

Invertebrate predators form another group that is known to prey on mosquito larvae, in particular the predator mosquito species *Toxorhynchites*, which has been recognized as a potential biological control organism for *Aedes* species. Their use in biological control has been problematic due to establishment and concurrence of oviposition sites (Collins and Blackwell 2000). *Toxorhynchites rutilus* is present in Florida, most commonly found in tree-holes, bromeliads, and other ephemeral containers. It was reported present in the Florida Keys for the first time in 2013, where 9 specimens were found in Key Largo (Tambasco and Hribar 2013). Ants (Lee et al. 1994), coleopterans (Yang 2006), cockroaches (Russell et al. 2001), and pillbugs (Focks et al. 1993) have also been reported to prey on eggs of *Ae. aegypti* or related species, but they are generalist predators and not reliant on a single species of mosquito as their food source.

---

<sup>50</sup> <http://www.purplemartin.org> [Accessed June 21, 2016].

<sup>51</sup> <http://www.mosquito.org/faq#purple%20martins> [Accessed June 21, 2016].

<sup>52</sup> [http://www.michigan.gov/emergingdiseases/0,4579,7-186-25805\\_25824-75797--,00.html](http://www.michigan.gov/emergingdiseases/0,4579,7-186-25805_25824-75797--,00.html) [Accessed June 21, 2016].

### 13.5.2.5 Studies on mosquito predators

To determine potential impacts on predator species, two studies have been conducted in which the predator species (invertebrate predator *Toxorhynchites* and fish (*Poecilia species*)) were fed OX513A larvae at high levels of dietary incorporation (70-100% of their diet) for extended periods (up to 28 days). These studies showed no adverse effects on either of the non-target predatory species. These studies, and the scientific literature reviewed above, indicate that introduction of the rDNA construct in *Ae. aegypti* is unlikely to impact predators that might eat OX513A in the environment.

#### 13.5.2.5.1 Studies on *Toxorhynchites* species

*Toxorhynchites* species are predatory mosquitoes whose larvae feed on small aquatic organisms. These species have been evaluated for biological control of mosquito larvae (Collins and Blackwell 2000; Nyamah et al. 2011). They are relatively large and are easily reared in the laboratory where they can be fed exclusively on mosquito larvae. To evaluate effects on predatory arthropods feeding exclusively on a diet of OX513A *Ae. aegypti* larvae, two different species of *Toxorhynchites* (*Tx. splendens* and *Tx. amboinensis*) were exclusively fed larvae of OX513A reared in the presence of tetracycline (Nordin et al. 2013). As controls the *Toxorhynchites* species were fed a diet of wild-type *Ae. aegypti* larvae and OX513A *Ae. aegypti* larvae reared without tetracycline, the dietary antidote to the conditional-lethal gene. Single *Toxorhynchites* larvae were placed into individual cups and 20 *Ae. aegypti* larvae were maintained in the cup. Eaten larvae were replaced daily. The duration of the developmental stage of the *Toxorhynchites* spp. was recorded daily. *Toxorhynchites* larvae which survived to pupae were placed into cages; female *Toxorhynchites* mosquitoes were presented with 5-8 males from the stock colony and the number of eggs was recorded daily along with survival. After death, the wing length was recorded to determine the size of the *Toxorhynchites* adults as a proxy for normal development. In both *Toxorhynchites* species, there were significantly more larvae consumed in the group that was not supplemented with tetracycline during their aquatic development phase; *Tx. amboinensis* ( $t = 9.2$ ,  $p < 0.001$ ) and *Tx. splendens* ( $t = 8.3$ ,  $p < 0.001$ ). *Tx. amboinensis* females reared on wild-type larvae consumed significantly more larvae than females fed on OX513A larvae reared in the presence of tetracycline ( $t = -3.3$ ,  $p < 0.002$ ). The reason for the occurrence of these results is unknown but there were no significant differences in any other measured parameters.

There was no evidence that the development, fecundity, or longevity of the two *Toxorhynchites* species were adversely affected by the OX513A larvae. Effects on life history parameters of all life stages were compared to *Toxorhynchites* spp. being fed on wild-type larvae of the same background strain, any significant differences found were attributed to differences between species and there was no evidence of an adverse impact (Nordin et al. 2013).

#### 13.5.2.5.2 Study on fish (*Poecilia* species)

A laboratory toxicity study was conducted by SynTech Research France, under GLP conditions, on guppy fish *Poecilia reticulata* (*Actinopterygii: Poeciliidae*); according to OECD (1984) modified for oral route of exposure (Appendix H). Guppies (20-26mm at the start of the test) were exposed to a mix of freshly defrosted larvae and pupae from OX513A and a non-GE control over a period of 14 days under laboratory conditions. During the study, the fish were fed with OX513A mosquitoes or the non-GE

control mosquitoes, daily, at the rate of 700 g mosquitoes/kg diet, following a range finding study. The natural ratio of insects to other dietary components for this fish species is approximately 50% (500 g insects/kg food). The quantity of diet administered daily did not exceed the amount ingested immediately by the fish and was kept constant during the study duration, i.e., 4% of the initial fish weight. Endpoints assessed were mortality, appearance, size, and behavior of the fish, which were observed daily. A toxic reference substance (potassium dichromate) was included to indicate the relative susceptibility of the test organisms and test system. The OX513A group was analyzed for significant differences compared to the control group using ANOVA ( $p \leq 0.05$ ) and to determine values for the LR50, ER50, Lowest Observable Effect Rate (LOER) and No Observable Effect Rate (NOER). Results are shown in Table 8 below; the study is appended (*Appendix H*).

**Table 8. Summary of *P. reticulata* mortality, length, and weight after 14-day oral exposure to *Aedes aegypti*.**

Endpoint	14-day mortality (%)	14-day length (mm)	14-day weight (mg)
Control (700 g non-GE mosquitoes/kg diet)	10	22.44	198.3
OX513A (700 g GE mosquitoes/kg diet)	0	23.2	212.9
LR 50 / ER50 [g GE mosquitoes/kg diet]	>700	>700	>700
LOER [g GE mosquitoes/kg diet]	>700	>700	>700
NOER [g GE mosquitoes/kg diet]	>700	>700	>700

GE = genetically engineered

The results showed that there was no significant difference between mortality, fish length, weight, appearance and behavior in the control and OX513A fed fish, after 14 days. Hence, the NOER was found to be 700 g GE mosquitoes/kg diet and the LOER and LR50/ER50 were estimated to be > 700 g GE mosquitoes/kg diet.

### 13.5.3 *Ae. aegypti* and parasitoids.

No specific parasitoids are known to be associated with *Ae. aegypti*. The nematodes *Romanomermis culicivorax* and *Strelkovimermis spiculatus* from the family Mermithidae are generalist parasitoids infecting a number of mosquito species. Although these species are known to infect *Ae. aegypti* in the laboratory, they have not been found to infect natural populations (Wise de Valdez 2007).

#### **13.5.4 *Ae. aegypti* as a decomposer.**

*Ae. aegypti* larval development is in an aquatic environment and predominantly man-made breeding sites (such as water containers, plant pots, discarded soda cans), which frequently contain detritus which is metabolized by the microbial communities. Although there is limited research in this area, it is thought that *Ae. aegypti* survive on the micro-organisms that break-down the detritus, and it is the nitrogen, phosphorus, and carbon availabilities that influence relative abundance of *Ae. aegypti* in breeding sites (Otero et al. 2006). As the microorganisms break down the detritus, there are number of metabolites and volatile compounds that act as attractants to gravid mosquitoes and stimulate egg laying in containers which are enriched with bacteria (Ponnusamy et al. 2008). Although *Ae. aegypti* occupy man-made or artificial containers where plant and animal detritus is broken down, it is unlikely that the mosquito itself is contributing to the direct decomposition of the material. However, in one study Yee et al. (2007) showed that animal detritus could be directly consumed by mosquitoes in breeding sites. It is likely that the mosquito mainly acts as a consumer of the elements from the breakdown of detritus by other organisms, rather than as a decomposer.

#### **13.5.5 *Ae. aegypti* as a resource for decomposers.**

A few organisms are known decomposers of *Ae. aegypti*; fungi such as *Metarhizium anisopliae*, a well-known entomopathogenic fungus<sup>53</sup> and *Beauveria bassiana* are capable of infecting *Ae. aegypti* eggs (Leles et al. 2012). Entomopathogenic fungi have been tested as biocontrol agents for the control of *Ae. aegypti* and other mosquitoes (Kanzok and Jacobs-Lorena 2006; Scholte et al. 2007). These fungi are soil dwelling and reported to be in agricultural soils in Florida (Beavers et al. 1983) but are also commercially available as biological control agents that have been tested in the Florida environment for the integrated pest management of orchard crops (Lacey and Shapiro-Ilan 2003). No reports have been found of the occurrence of these fungi specifically in the soils of the Florida Keys from an internet search on Google Scholar and PubMed using the key terms of “soil, Florida Keys, *Metarhizium anisopliae*, *Beauveria bassiana*”, but it is possible that they could be present. However soils in the Florida Keys are shallow lying directly on limestone bedrock so are less likely to have high organic matter levels that would encourage soil dwelling fungi.

#### **13.5.6 *Ae. aegypti* as a pollinator.**

Although female *Ae. aegypti* mosquitoes take blood meals from humans in order to obtain protein for ovary development, mosquitoes of both sexes require plant juices as an energy source. Floral nectars are the best-known sources, but mosquitoes also are also known to obtain sugars from extra-floral nectaries, damaged fruits, damaged and intact vegetative tissues, and honeydew (Clements 2000). Some responses of mosquitoes to flower features have been described; for example, *Ae. aegypti* is known to react positively or negatively to different floral scents and to prefer green flowers as reviewed

---

<sup>53</sup> Entomopathogenic fungi are parasitic fungi that can kill or seriously disables insects, usually by infecting them with spores that can bore through the cuticles of insects, killing them.

by Argue (2012). However, details of the relationship between plant species and *Ae. aegypti* specifically was not observed in this study. *Ae. aegypti* are adapted to domestic and urban environments that tend to be low in sugar sources but allow easy and unlimited access to blood meals, such as those around human habitations. It is likely that *Ae. aegypti* males are reliant on sugar sources from potted plants or plant species that are found around houses as part of their preferred existence around humans (Martinez-Ibarra et al. 1997). There is limited information on the pollination of plant species by mosquitoes in general, and no reports that *Ae. aegypti* is a pollinator for any plant species. Despite feeding on plant nectar, it is likely that mosquitoes transfer pollen to some extent although there is little scientific information on this. *Ae. communis* and *Ae. canadensis* are known as pollinators of an orchid in Northern Canada, *Habenaria obtusata* (Thien 1969), a plant species not found in Florida. This lack of pollination activity may be because, as a non-native species, the mosquito has not been present in the ecosystem for sufficient time to develop an essential ecosystem function. Dedicated pollinator species for particular flowers require close evolution for many thousands of years (Patin 2012). Additionally, previous mosquito control efforts in various territories (Elder and Lamche 2004; Wheeler and Petrie 2007; Wheeler et al. 2009; Gubler 2011; Brathwaite Dick et al. 2012; Monteiro et al. 2014) have resulted in the complete eradication of the mosquito from large areas with no reports of any adverse effect on the reproductive capacity of the native or crop plant species documented during this period.

#### **13.5.7 *Ae. aegypti* and threatened and endangered species**

As described in Section 12.1.2.2.1, the Stock Island Snail is the only species located in the physical vicinity of the proposed trial site. We determined that that the proposed investigational use of OX513A mosquitoes would not adversely affect the Stock Island Tree Snail because the Stock Island Tree Snail's habitat (hammock and beach berm) does not overlap with the domestic or peri-domestic environment of *Ae. aegypti* and, therefore, the species are not expected to interact in any manner different from wild-type *Ae. aegypti* present in the environment. Additionally, the proposed investigational trial does not intend to remove or modify the snail's habitat (hammock and beach berm). Therefore, FDA made a "no effect" determination under the ESA, 16 U.S.C. § 1531 *et seq.* The proposed investigational trial, as described in Section 11, would not jeopardize the continued existence of the endangered Stock Island Tree Snail and would not result in the destruction or adverse modification of its critical habitat.

An overview of the wildlife refuges located in Monroe County is provided in Section 12.1.2.2.2. As discussed previously, because all of these refuges are located a considerable distance from the proposed trial site, it is highly unlikely that the proposed trial would have any effects on their environment. Thus, we conclude that the proposed trial would not jeopardize the continued existence of any other endangered species in wildlife refuges located in Monroe County or result in the destruction or adverse modification of other endangered species' critical habitat due to their being located a considerable distance from the proposed trial site.

#### **13.5.8 Introgression of traits from OX513A to local wild-type *Ae. aegypti* at release site**

The short duration of the release coupled with the lethal nature of the integrated trait limits the possibility of introgression of new traits into the local wild-type *Ae. aegypti* population. Further, results

of insecticide testing indicate the absence of traits related to pyrethroid and organophosphate resistance including *kdr* mutations in OX513A mosquitoes. Thus, these traits cannot be introgressed into local mosquito populations. Lastly, *Ae. aegypti* strains continue to move around the globe by piggy backing on human modes of transportation such as cars, trucks, and buses on highways as well as ships and airplanes (Griffitts 1933; Tatem et al. 2006; Guagliardo et al. 2014; Miller and Loaiza 2015). As a result introduction of new, non-native strains is a constant possibility, especially to in an area with a high number of visitors such as the Florida Keys. Thus, new traits could also introgress from these non-native strains that are introduced by humans and, unlike OX513A, go undetected due to the lack of readily observable phenotypic markers (e.g., *DsRed2*) and surveillance. The probability of introgression of traits into the local population related to the proposed release of OX513A mosquitoes is as likely as that from new, non-native strains introduced into the area by other means.

### **13.5.9 Conclusions**

FDA has determined that it is highly unlikely that the presence of OX513A mosquitoes and their progeny and suppression of the local population of *Ae. aegypti* would have any significant effects on the populations of predators, parasitoids, and decomposers at the proposed trial site. No adverse effect on the pollination of local plants is expected as well. Should the proposed field trial proceed, FDA has determined that the proposed trial would not jeopardize the continued existence of Stock Island Tree snails at the trial site and would not result in the destruction or adverse modification of their habitat. Therefore, FDA makes a “no effect” determination under the ESA with regard to the Stock Island Tree Snail. Further, FDA does not expect any adverse effects on other endangered species in wildlife refuges located in Monroe County or destruction and modification of their habitats due to their considerable distance from the proposed trial site.

### **13.6 What is the likelihood that the rDNA expression products in OX513A mosquitoes would have adverse effects on humans or other animals?**

#### **13.6.1 Bioinformatics studies of the novel proteins expressed in OX513A**

Because wild-type *Ae. aegypti* mosquitoes can trigger allergic reactions via bites in humans (Doucoure et al. 2012), and there is the potential to have small numbers of female *Ae. aegypti* carrying the rDNA construct in the environment as a result of survival of progeny from OX513A mating (due to lack of complete penetrance of lethality trait) or a small number of OX513A females being released (due to lack of 100% sorting efficiency), two questions were examined:

1. *Does the tTAV or DsRed2 protein have a degree of homology with proteins that are known to be toxic or allergenic?*
2. *If tTAV or DsRed2 were found to have allergenic potential, would exposure into or through the skin resulting from a mosquito bite represent a greater risk to human health than a bite from an existing wild-type *Ae. aegypti* mosquito?*

The evaluation of the amino acid sequence similarity of novel proteins with known toxins and allergens is the first step in the safety analysis. The Codex Alimentarius Guidelines (Codex 2003; Codex 2009) have been designed to aid with conduct of risk assessments for foods from genetically engineered sources and hence an oral route of exposure.

The argument that that both oral and subcutaneous exposure to known allergens would likely elicit the same immunological response in individuals allergic to these substances is based on the expert opinion of Dr. Ian Kimber, professor of toxicology at the University of Manchester, whose expert opinion is provided in Appendix I. Dr. Kimber states that the properties that make proteins allergenic are independent of the route of exposure, pointing out that chicken ovalbumin, a known food allergen, also has the ability to cause respiratory allergies in workers at poultry plants (James and Crespo 2007). In addition, there are studies (Eifan et al. 2010; Keles et al. 2011; Yukselen et al. 2012) that evaluate the efficacy of sublingual (i.e., oral) and subcutaneous routes in allergen immunotherapy.<sup>54</sup> These studies show that for certain allergens sublingual exposure could be as effective as subcutaneous exposure with regard to the immunological response. Recent FDA approvals of GRASTEK (FDA 2014a), ORALAIR (FDA 2014b), and RAGWITEK (FDA 2014c) for treatment of allergic rhinitis using immunotherapy further support this statement. Thus, the weight of evidence suggests that the properties of proteins to elicit a type of immunological response in some instances may be independent of the route of exposure. Therefore, we consider that the use of the bioinformatics analysis from the Codex guidelines may be a suitable approach to evaluate the potential allergenicity and toxicity of tTAV and DsRed2 proteins from exposure to OX513A mosquitoes.

#### **13.6.1.1 tTAV potential toxicity and allergenicity assessment**

The conditional lethal element, known as the tTA system, which was developed by Gossen and Bujard (1992), and subsequent variants of that system, have been widely used both *in vitro* and *in vivo* for over a decade. Low-level expression of tTA or its variants has been thought to be innocuous; whereas a high level expression is thought to be deleterious to cells, likely due to transcriptional “squenching” (Gill and Ptashne 1988; Lin et al. 2007) and/or interference with ubiquitin-dependent proteolysis. It is the interference of high levels of tTA protein accumulation in the cell that is likely to cause cellular death in the absence of tetracycline. When tetracycline is supplied, the cellular machinery leading to an over accumulation of the tTA protein is turned off.

Although some potential symptoms of toxicity have been reported in transgenic mice expressing high levels of tTA or its variants (Whitsett and Perl 2006), other papers have reported observing no apparent toxicity (Chen et al. 1998; Barton et al. 2002; Zhou et al. 2009).

---

<sup>54</sup> Immunotherapy involves the administration of gradually increasing amounts of allergen over a period of time to desensitize the subject. In sublingual immunotherapy, administration of allergens through oral, gingival, or sublingual mucosa can decrease the allergic response and desensitize the subject.

The potential toxicity and allergenicity of the tTAV and DsRed2 proteins were assessed using a bioinformatics study (conducted independently by Dr. Rick Goodman of the University of Nebraska, a leading expert on allergenicity of products from genetically engineered organisms) with the amino acid sequence and publicly available protein sequences of known toxins according to the Guidelines of Codex Alimentarius (Codex 2003; Codex 2009) (*Appendix J*). The tTAV protein is a synthetic fusion protein and therefore the literature search was broken into component parts relating to the donor organisms from which the synthetic sequences are derived; namely *Escherichia coli* and the VP16 protein from Herpes simplex virus. The study included the following analysis on toxicity and allergenicity in accordance with the Codex Guidelines:

- Scientific literature search strategies in the PubMed database using key search terms “E.coli”, “VP16”, “Herpes”, “allergy” and “allergen”, “toxin” and “toxicity”.
- Amino acid sequence of tTAV and DsRed2 search strategies (FASTA3; BLASTP algorithm) using Allergenonline version 13 and NCBI Entrez protein databases.

The predicted amino acid sequence of tTAV is given in Figure 16 below.

<tTAV

```
MGSRLDKSKVINSALELLNEVGIEGLTTRKLAQKLGVEQPTLYWHVKNKRALLDALAIEM
LDRHHTHFPCLEGESWQDFLRNNAKSFRCALLSHRDGAKVHLGTRPTEKQYETLENQLAF
LCQQGFSLENALYALS AVGHFTLGCVLEDQEHQVAKEERETPTTDSMPPLLRQAIELFDH
QGAEP AFLFGLELIICGLEKQLKCESGSGPAYSRARTKNNYGSTIEGLLDLPDDDAPEEA
GLAAPRLSFLPAGHTRRLSTAPPTDVSLGDELHLDGEDVAMAHADALDDFDLDM LGDGDS
PGPGFTPHDSAPYGALDMADFEFEQMFTDALGIDEYGG
```

**Figure 16. Amino acid sequence of the tTAV protein.**

Potential toxicity was evaluated by comparison of the amino acid sequences of the TetR N-terminal (208 amino acids) and the VP16 C Terminal 129 amino acids against the NCBI database using BLAST and keyword search query limits (“toxin” or “toxic”) in 2011 and repeated in September, 2013 with key word search terms of “toxin” and “toxicity.”

### **13.6.1.2 DsRed2 potential toxicity and allergenicity assessment**

DsRed2 is a marker protein which is expressed constitutively in the developmental life stages of the OX513A mosquito. DsRed is a naturally occurring fluorescent protein which was originally found in various *Discosoma spp.* DsRed2 was developed *in vitro* from native DsRed to enhance the fluorescence and improve the solubility of the protein, which in turn increases the sensitivity of detection (Matz et al. 1999; Lukyanov 2000; CLONTECHniques 2001; Bevis and Glick 2002; Shagin 2004) of cells expressing this

enhanced DsRed2 protein. The DsRed2 DNA sequence used in #OX513 was obtained from Clontech Laboratories (First protein sequence described in Figure 17). The N-terminus of DsRed2 protein expressed by OX513A mosquitoes has three additional amino acids (MAR) from a cloning linker sequence (Second protein sequence described in Figure 17).

**DsRed2 protein sequence (Clontech):**

```
MASSENVITE FMRFKVRMEG TVNGHEFEIE GEGEGRPYEG HNTVCLKVTK GGPLPFAWDI LSPQFQYGSK  
VYVKHPADIP DYKCLSPEEG FKWERVMNFE DGGVATVTQD SSLQDGCIFY KVKFIGVNFP SDGPVMQKKT  
MGWEASTERL YPRDGVKGE THKALKKLDG GHYLVFKSI YMAKKPVQLP GYYYVDAKLD ITSHNEDYTI  
VEQYERTEGR HHLFL
```

**DsRed2 protein sequence (Oxitec):**

```
MARMASSENVITEFMRFKVRMEG TVNGHEFEIEGEGEGRPYEG HNTVCLKVTKGGPLPFAWDILSPQFQYGSK  
VYVKHPADIPDYKCLSPEEG FKWERVMNFE DGGVATVTQD SSLQDGCIFYKVKFIGVNFP SDGPVMQKKT  
MGWEASTERLYPRDGVKGETHKALKKLDGGHYLVFKSIYMAKKPVQLPGYYYVDAKLDITSHNEDYTI  
VEQYERTEGR HHLFL
```

**Figure 17. Amino acid sequences of the DsRed2 protein.**

The DsRed2 marker protein has been evaluated in a New Protein Consultation by the FDA Center for Food Safety and Applied Nutrition (CFSAN) for human safety, and the Center raised no objections to its use in corn plants (Pioneer Hi-Bred International 2006; FDA 2010). This involved an assessment of the amino acid sequence using bioinformatics analyses in accordance with the Guidance provided by Codex (2003), the lability of the protein in simulated gastric fluid (SGF) and an examination of the gene source and history of exposure, as well as the toxicity of the protein using bioinformatics analysis (Pioneer Hi-Bred International 2006). Additional information on the lack of toxicity of DsRed2 is presented in reviews by Millwood et al. (2010) and Stewart (2006), including oral studies in rats (Richards et al. 2003).

It has been further evaluated in an EA by the United States Department of Agriculture, Animal Plant Health Inspection Service (APHIS) on a GE corn variety,<sup>55</sup> which concluded that the corn transformation event (event DP-32138-1) that contained the DsRed2 gene was unlikely to become a plant pest risk. APHIS conducted an additional EA on a GE pink bollworm expressing fluorescent genes similar to DsRed2<sup>56</sup> that concluded in a Finding of No Significant Impact on the environment. Furthermore, DsRed2 and members of the related Green Fluorescent Protein family have been widely used in many organisms for non-invasive *in vivo* and *in vitro* monitoring of disease states and pathways and they appear to be well tolerated.

---

<sup>55</sup> [http://www.aphis.usda.gov/brs/aphisdocs/08\\_33801p\\_dpra.pdf](http://www.aphis.usda.gov/brs/aphisdocs/08_33801p_dpra.pdf) [Accessed June 21, 2016].

<sup>56</sup> <http://www.gpo.gov/fdsys/pkg/FR-2006-04-19/html/E6-5878.htm> [Accessed June 21, 2016].

### 13.6.1.3 Bioinformatics assessment results

The potential allergenicity assessment examined the presence of known allergenic sequences in the tTAV and DsRed2 proteins. Oxitec performed several bioinformatic analyses as per Codex Alimentarius guidelines (2003) to determine potential IgE binding epitopes as well as the potential for cross-reaction with other known allergens. The use of Codex guidelines is appropriate as they provide a robust risk assessment paradigm for both food and non-food exposure to the two proteins as there is no single predictive criterion for the potential allergenicity of newly expressed proteins particularly with regard to oral exposure. A search of allergenic sequences in Version 13 of the Food Allergy Research and Resource Program (FARRP) Allergenonline.org using the complete sequences of tTAV and DsRed2 did not yield any cross matches that had greater than 35% amino acid identity. The same results were returned for an 80 amino acid sliding window sequence homology search of the same Allergenonline database. A third search for any known allergens in the Allergenonline database for any match of any eight contiguous amino acid segments was also negative. There were also no matches with more than 50% identity over the full sequence length of both proteins. BLASTP searches of NCBI Entrez using DsRed2 protein sequence and the keyword allergen returned 6 proteins with E scores <10 and all had either low identity and/or short regions of alignment making the matches highly unlikely to cause cross reactivity in humans. When a similar BLASTP search was conducted using full length tTAV protein sequence only one match with a sequence length of 20 amino acids and 55% identity was returned. Typically short regions of identity suggest that the overall structure of the query is unlikely to match in its entirety to any known allergenic epitopes of the proteins in the database.

Although Codex Guidelines are primarily intended to evaluate food safety concerns from GE organisms (mucosal route of administration), the risk assessment paradigms recommended by Codex are applicable to other routes of exposure such as bites and mosquito saliva. Mosquito saliva proteins introduced via mosquito bites are known to elicit an allergic response in some humans. OX513A saliva is not expected to differ from that of wild-type *Ae. aegypti* in its overall composition irrespective of the presence of the #OX513 rDNA construct in its genome. Therefore, irrespective of current allergic status to mosquito saliva proteins, OX513A saliva is expected to have no additional impact on the response of humans to mosquito bites. Severe anaphylactic reactions to mosquito bites that could be life threatening are rare and the multiple levels of protection described above make it extremely unlikely that humans would be exposed to these two proteins via a mosquito bite and that this would result in a serious anaphylactic reaction. Additionally, an independent food safety assessment for DsRed2 indicates that it should be rapidly digested by gastric enzymes if orally ingested.<sup>57</sup> Taken together these data suggest that there are unlikely to be epitopes that are known to cause allergenic reactions in the general human population.

---

<sup>57</sup> Independent food safety assessment for DsRed2 protein-  
<http://www.fda.gov/downloads/Food/Biotechnology/Submissions/UCM219002.pdf>

Based on these results, no convincing evidence was found to suggest tTAV or DsRed2 proteins expressed in OX513A mosquitoes represent risks of allergy to humans or toxicity to humans or other mammals, if the well-defined Codex oral allergy assessment approach is used (*Appendix J*). For the reasons stated above (Sections 13.6.1.1 and 13.6.1.2), we believe that this analysis is appropriate for both oral and non-oral routes of exposure. Because risk is a function of both exposure and hazard, Oxitec provided a study on whether the introduced proteins can be detected in OX513A female mosquito saliva (i.e., possible exposure).

### **13.6.2 Analysis of expression of the introduced proteins in female mosquito saliva**

Saliva from *Aedes* species mosquitoes contains secreted proteins that play a role in sugar and blood feeding (Grossman and James 1993; Ribeiro 1995). These have been characterized by proteomic studies of saliva itself (Chisenhall et al. 2014), as well as by studies of the sialome (the set of messages and proteins expressed in salivary glands) (Racioppi and Spielman 1987; Valenzuela et al. 2002). There is an amino acid signal sequence typically associated with proteins that are secreted into saliva. In addition, Capurro et al. (2000) confirm that a mosquito secretory signal sequence, fused to the upstream region of the coding sequence, is required in order to secrete engineered short chained variable fragment (scFV) antibodies into saliva for functional expression in mosquitoes. This signal sequence is cleaved during the process of protein secretion into saliva in mosquitoes (e.g., (James et al. 1991; Stark and James 1998)). Neither tTAV nor DsRed2 contain such a signal sequence for secretion nor do they have any sequences with homology to such signal sequences; therefore, tTAV and DsRed2 proteins are not anticipated to be found in the saliva of OX513A. In order to present a potential risk to human health, tTAV protein would have to (a) be expressed in salivary glands, (b) be secreted into the saliva, and (c) be toxic or otherwise hazardous to humans if injected in relevant quantities. Of these, (a) and (b) relate to potential exposure, while (c) relates to potential hazard. Evidence from the bioinformatics analysis in Section 13.6.1.3 shows that no potential hazard was identified.

#### **13.6.2.1 Study on detection of tTAV and DsRed2 in the saliva of OX513A females**

Oxitec conducted a study to determine whether tTAV and DsRed2 proteins would be detectable in the saliva of OX513A female mosquitoes and to determine the limit of detection (LOD) for each of the proteins. Homozygous adult female *Ae. aegypti* expressing the #OX513 rDNA construct were reared to adulthood in the presence of doxycycline. Saliva was collected from these insects as well as from comparator non-GE *Aedes aegypti* females and two pools (OX513A and WT, respectively) were created that were used for the entire study. Western blot analysis using polyclonal tTAV (anti-VP16 tag antibody) and polyclonal DsRed2 antibodies was carried out, using an Enhanced Chemiluminescence (ECL) approach. Sample integrity was confirmed using an antibody to Aegyptin, a secreted salivary protein found in mosquitoes. Aegyptin detection was also used to determine that equivalent amounts of salivary proteins were loaded in all saliva samples tested.

LODs for tTAV and DsRed2 on the western blots were determined using recombinant tTAV and recombinant DsRed2. tTAV and DsRed2 proteins purified directly from OX513A could not be used as sufficient quantity could not be extracted from the insects. The LOD for recombinant tTAV (rtTAV) was

determined to be 0.8 ng and the LOD for recombinant DsRed2 (rDsRed2) was determined to be between 2.5 and 5.0 ng.

The engineered proteins, tTAV and DsRed2 were not detected in OX513A female *Aedes aegypti* saliva at and above these LODs in the 5 µl of saliva analysed. In this study 5 µl of OX513A saliva corresponded to the volume of saliva collected from approximately 5.5 female adult mosquitoes (270 µl of pooled saliva collected from approximately 300 homozygous OX513A *Ae. aegypti* adult females). The study report is provided in *Appendix K*.

### **13.6.3 Conclusions**

Based on the Western immuno-blot assays performed by Oxitec, we conclude that the levels of tTAV and DsRed2 proteins in saliva of OX513A *Ae. aegypti* females homozygous for the #OX513 rDNA construct are below the limit of detection for that assay. Therefore, we consider that it is highly unlikely humans or other animals would be exposed to these proteins even if they were to be bitten by OX513A female mosquitoes. A stepwise approach, evaluating the toxic and allergenic potential of tTAV and DsRed2 proteins based on Codex guidelines and a scientific literature search, did not identify any evidence suggesting the allergenicity or toxicity of tTAV and DsRed2 proteins. Bioinformatics analysis of amino acid sequences of tTAV and DsRed2 proteins did not identify any similarities with known toxins or allergens. Therefore, FDA concludes that tTAV and DsRed2 proteins lack any toxic or allergenic potential and do not pose any significant risks to humans or non-target animals.

## **14 What are the likely consequences to, or effects on the environment of the U.S. associated with the proposed investigational use of OX513A mosquitoes?**

Potential impacts associated with the proposed release of OX513A mosquitoes would depend on the general fitness of the released OX513A males, their role in ecosystem, their interaction with other species in the ecosystem, and potential for dispersal and establishment. Therefore, potential adverse effects associated with the release of OX513A mosquitoes may be divided into two broad categories: consequences for the environment and consequences for human/animal health, which are discussed below.

### **14.1 Consequences for the environment**

Potential impacts on the environment are summarized in Table 9 and include interbreeding with related mosquito species, effects of tetracycline on ecological services, effects on flora, effects on predators, effects on decomposers, effects on endangered or threatened species, development of resistance to insecticides, and persistence or establishment of OX513A mosquitoes at the trial site.

It is highly unlikely that OX513A males would interbreed with other, related mosquito species present at the proposed trial site. Studies show that *Ae. aegypti* matings with closely related mosquito species do not produce viable offspring (Lee et al. 2009a; Nazni et al. 2009a; Tripet et al. 2011). This question is discussed in greater detail in Section 13.4.1. Further, in the highly unlikely event that OX513A male

mosquitoes do mate with other closely related mosquito species, it is equally unlikely that the rDNA construct would spread in the population of these mosquitoes due to the lethality phenotype conferred by this rDNA construct. Therefore, the likelihood of OX513A mosquitoes breeding with other mosquito species would be extremely low, as would be the case for survival of any potential progeny produced as a result of such matings.

It is highly unlikely that the use of tetracycline in the production of OX513A mosquitoes would have any adverse effects on the environment. The levels of tetracycline in the HRU waste water would be low (grams/week). Moreover, these low levels are expected to be rapidly broken down in the environment as tetracycline is sensitive to light (as described in Section 15.3.4). The use of tetracycline and its fate in the environment was reviewed by Sarmah et al. (2006), and the study found that tetracycline rapidly degrades (with the bulk of degradation taking place on day 1) and has a short half-life in the environment (15-30 days in water and up to 9 days in animal manure). The fate of tetracycline and its derivatives in the environment is discussed further in Sections 12.2.1.1.1 and 15.3.4. Therefore, the likelihood of adverse effects associated with the use tetracycline for production of OX513A mosquitoes would be expected to be extremely low.

It is highly unlikely that the release of OX513A male mosquitoes will have any adverse effects on the populations of predators, decomposers, threatened or endangered species or flora at the proposed trial site. As discussed in Section 13.5.2, due to the unique habitat occupied by *Ae. aegypti*, they are subject only to opportunistic predators that prey on *Ae. aegypti* larvae and adults if and when they encounter them. The anthropophilic behavior of *Ae. aegypti* mosquitoes limits the probability of encounter with potential predatory species and, therefore, we identified no species that would rely on these mosquitoes in its diet. Further, with the exception of generalist parasitoids infecting a number of mosquito species, we did not identify any specific parasitoid species associated with *Ae. aegypti* (Section 13.5.3). No adverse effects on decomposers were identified as well. Decomposer organisms are often opportunistic, feeding on detritus when it is found. Biodiversity in soil ecosystems is generally high with a range of organisms assisting in the breakdown of organic matter. These complex interactions involve many species, which exist both above and below ground; many of these species are microscopic and would be extremely difficult to monitor effectively. A number of decomposers that could be involved in the breakdown of *Ae. aegypti* were identified (including but not limited to organisms from classes of *Oligochaeta*, *Diplopoda*, *Isopoda*, *Nematoda*, *Collembola*, and *Acari* as well as species of Protozoa, Fungi, and Bacteria) but none of them are specifically involved in decomposition of *Ae. aegypti* (Section 13.5.5). Further, it is highly unlikely that *Ae. aegypti* mosquitoes play any significant role in pollination because, being non-native species, *Ae. aegypti* mosquitoes have not been present in the Florida ecosystem sufficiently long to develop such a function (Section 13.5.6). With respect to threatened and endangered species (Section 12.1.2.2.1), we established that the proposed trial is not likely to adversely affect the Stock Island Tree Snail whose habitat is in the vicinity of the proposed trial site. Further, it is highly unlikely that the proposed trial would have any significant effects on wildlife refuges located in Monroe County due to a considerable distance from the proposed trial site and the lack of overlap of habitats for any endangered species (Section 12.1.2.2.1). Therefore, the likelihood of adverse effects on

the populations of predators, parasitoids, decomposers, and threatened and endangered species or flora is expected to be extremely low.

In addition, it is highly unlikely that released OX513A mosquitoes would introduce insecticide resistance to the local *Ae. aegypti* mosquito population. Insecticide resistance studies have shown that OX513A mosquitoes are susceptible to insecticides used for mosquito control (Section 12.2.1.3). Therefore, the likelihood of adverse effects associated with introduction of insecticide resistance into the local population of *Ae. aegypti* is expected to be extremely low.

As discussed in Section 13.2, it is highly unlikely that the OX513A mosquitoes would be able to establish at the proposed trial site. The OX513A line of *Ae. aegypti* mosquitoes carries a repressible dominant lethality trait that prevents progeny inheriting the #OX513 rDNA construct from surviving to functional adulthood in the absence of tetracycline. Data and information provided in Section 12.2.1.1.1 and peer-reviewed scientific journals (Phuc et al. 2007; Harris et al. 2012; Carvalho et al. 2015) indicate that more than 95% of OX513A progeny die before reaching viable adulthood if reared without tetracycline. Our evaluation did not identify any sources at the proposed trial site that potentially could have sufficiently high levels of tetracycline to allow survival of OX513A progeny in the environment (Sections 12.2.1.1 and 15.3.4). Although the introduced lethality trait does not appear to have a significant effect on the mating competitiveness of OX513A males, it does appear to have a significant impact on longevity by reducing their fitness (Section 12.2.1.2). Dispersal of OX513A mosquitoes also appears to be adversely affected as measured by mean distance traveled, but not by maximum distance traveled, indicating that, in general, the population of OX513A mosquitoes is not expected to exhibit geographical dispersion significantly different from wild-type *Ae. aegypti*. The location of the proposed field trial site would also limit dispersion because of its relative isolation and existing natural geophysical barriers. Further, given that this trial would be carried out concurrently with the existing FKMCD integrated vector control program currently in place, it is unlikely that OX513A mosquitoes would disperse beyond the trial site (Sections 12.3 and 15.3). Therefore, the likelihood of adverse effects associated with establishment of OX513A at the proposed trial site is extremely low.

In addition, the proposed trial would include continuous monitoring of the mosquito population by different (egg and adult) trapping and molecular methods. This would allow for monitoring of the continued expression of the traits in the population as well as the detection of other mosquito species that may come into the area opportunistically or via niche expansion. See Section 14.2.

#### **14.2 Consequences for human and non-target animal health**

Potential impacts on human or non-target animal health are summarized in Table 9 and include potential toxic effects in humans or non-target animals or allergenic effects in humans, transfer of the rDNA construct to humans or non-target animals, increase in transmission of dengue or other diseases transmitted by mosquitoes, increase in population of other mosquitoes that may contribute to the increase of disease, development of antimicrobial resistance, inadvertent release of OX513A females at the trial site, and a failure of the introduced traits in OX513A mosquitoes.

The risk to human health due to allergenicity of novel proteins can be assessed in a stepwise manner with the final pathway to harm resulting from the multiplication of the probability of occurrence of each step.

The first step is the presence in the local environment of adult GE female mosquitoes that are capable of flying, locating human hosts, and taking a blood meal from these human hosts. The investigational field trial proposes to release primarily male GE mosquitoes. Because male mosquitoes do not bite, they are not a hazard in terms of allergenicity from salivary proteins injected during blood feeding. As described in Section 10.4.2.1, the trial protocol calls for use of a sex sorting method based on the size difference between male and female pupae with quality control processes that ensure accuracy of the sorting does not exceed a maximum of 0.2%. Thus, the overall probability of an OX513A female mosquito being released during the investigational trial is very low (0.2% at most) and the probability of this released female locating a human host and taking a blood meal is also low based on the limited total human population in the trial area (approximately 460 residents in the TA (Section 11.1)). As described in Section 11.1, the actual number of GE mosquitoes released during the trial depends on the initial level of infestation in the trial area, duration of the trial, overflooding ratio, and adaptive management-related adjustments in numbers. Under high initial infestation levels, the total number of OX513A females that would be released is estimated at <29,000 over 104 weeks or 0.6 female mosquitoes per person per week at the highest initial infestation levels and no adaptive management.

The second step is for the recombinant proteins to be expressed in the salivary glands of the OX513A female mosquitoes and be secreted into the mosquito's saliva so that these proteins could be injected into the human host during blood feeding. As described above (Section 13.6.2), results from western immunoblot assays performed by Oxitec indicate the LOD to be 0.8 ng and 2.5-5 ng for tTAV and DsRed2 respectively when four times the amount of salivary protein injected in a bite was used per sample (i.e., at approximately 0.2 and 0.625-1.25 ng for the amount of protein in a single bite). Expert opinion provided by Dr. Jose Ribeiro (NIAID) (see Appendix M) states that saliva volume is not a relevant estimator of hazard during biting, as saliva volume is dependent on active flow of water through the cells in response to serotonin during blood feeding. Rather, total protein content in the salivary gland before and after blood feeding is a better estimator of hazard. In general, an adult *Aedes* female mosquito has ~3 µg of total protein in the salivary gland of which ~1.5 µg is injected and ~0.75 µg is re-ingested into its gut during blood feeding, resulting in a net ~0.75- 1 µg of salivary protein remaining in the bitten host. Additionally, *Aedes* saliva contains about 100 polypeptides with a wide variation in relative abundance. The most highly expressed salivary protein, Aegyptin, is no more than 30% of total salivary protein or ~300 ng, with the least expressed proteins being less than 1 ng. Known allergenic proteins in mosquito saliva are expressed in the dozens or hundreds of ng range and the least expressed proteins in mosquito saliva are expressed at the single ng level. Because both tTAV and DsRed2 proteins were undetectable by this assay the data supports the hypothesis that, if they are expressed and secreted in saliva at all, these proteins are likely expressed below or close to the 1 ng range per *Aedes* female bite. tTAV and DsRed2 are, therefore, highly unlikely to cause an allergic response in a human host that is bitten by an OX513A female because the protein level would be close to or below the level

at which Dr. Ribeiro indicates mosquito saliva proteins that have been identified as human allergens are present.

The third step is the presence of known allergenic sequences in the tTAV and DsRed2 proteins. As discussed in Section 13.6.1.3, Oxitec performed several bioinformatics analyses as per Codex (2003) guidelines to determine potential IgE binding epitopes as well as the potential for cross-reaction with other known allergens. Taken together these data suggest that there are unlikely to be epitopes that are known to cause allergenic reactions in humans.

In addition, it is highly unlikely that the rDNA construct could be transferred to humans or non-target animals. Our evaluation of the possibility for such transfer focused on two potential pathways (Section 13.4.2). First, we evaluated the possibility of #OX513 rDNA construct transfer to humans or animals via biting. We determined that it is highly unlikely the #OX513 rDNA construct could be transferred to humans or animals via biting because the rDNA construct is stably integrated in the mosquito genome and is not capable of re-mobilization even when treated with appropriate transposases due to altered ITR sequences (Section 9.2.1). Also, there is no known pathway for naked, full length #OX513 DNA to be present in saliva. Additionally, mosquitoes have been feeding on humans and other animals for millennia but there is no evidence of DNA transfer between mosquitoes and humans or animals. We also evaluated the possibility of #OX513 rDNA construct transfer to microorganisms (e.g., bacteria in the intestine of OX513A mosquitoes, humans, or other animals; bacteria present in soil and involved in decomposition of organic matter) (Section 13.4.2.1). We determined that such transfer is highly unlikely due to a number of physical, biochemical, and genetic barriers that restrict horizontal gene transfer. Despite the fact that prokaryotes are exposed to an abundance of genetic material from eukaryotic organisms, the presence of eukaryotic genes in the genome of prokaryotes is extremely limited and suggests the existence of functional and selective barriers that limit the acquisition of eukaryotic genes by bacteria. Therefore, the likelihood of adverse effects associated with a potential transfer of the rDNA construct to humans or other non-target animals is extremely low.

It is highly unlikely that the release of OX513A mosquitoes would result in an increase in transmission of dengue or other diseases transmitted by mosquitoes. OX513A male mosquitoes do not bite and, consequently, do not transmit diseases. A small number of females may be co-released with OX513A male mosquitoes or be present at the site of the proposed release as a result of incomplete penetrance of the introduced lethality trait. However, there is no evidence to suggest that OX513A females are fitter than wild-type *Aedes aegypti* (Lee et al. 2009b). There is also no evidence that OX513A females have increased vector competence than wild-type *Ae. aegypti*. In fact, evidence suggests OX513A females have a decreased vector competence because any inadvertently released OX513A females will die in 2-3 days time, as the lack of tetracycline in the environment will turn on the lethality trait, resulting in a lifespan too short to vector viral disease. This is because the short lifespan of the OX513A females is too brief for arboviruses such as dengue and Zika to cross the mosquito midgut barrier, reach the salivary glands, and multiply sufficiently (this period is defined as the external incubation period, EIP) to be transmitted to a human host at a subsequent blood feeding. Disease transmission by female mosquitoes requires that they can locate a human host that is infected with a sufficient titer of virus and blood feed

adequately, that the EIP is sufficiently long to allow virus multiplication and secretion into saliva, and that the female lives long enough to blood feed again after the EIP is complete, thereby transmitting the virus to a human host. EIP for dengue is estimated at 10-14 days. Further, as noted by (Cook et al. 2007), “[l]ong-lived vectors contribute most to pathogen transmission and small decreases in vector life expectancy can cause large reductions in transmission rates” (Cook et al. 2007). All of these factors combined suggest that, if anything, OX513A females would have a lower overall vectorial capacity as compared to wild-type *Ae. aegypti*. Moreover, OX513A mosquitoes are produced under disease-free conditions that further limit the possibility of transmitting any diseases (Section 10.4.1.5). Therefore, the likelihood of adverse effects associated with an increase in transmission of dengue or other diseases transmitted by mosquitoes is extremely low.

It is highly unlikely that the release of OX513A mosquitoes would lead to an increase in the population of other mosquito species that might contribute to an increase in disease transmission at the proposed trial site. A suppression field trial using OX513A in Panama resulted in an 82% suppression of *Ae. aegypti* over an 84-day period without an increase in *Ae. albopictus* at the same site (Gorman et al. 2016). This suggests that a short term field trial as proposed for Key Haven, FL should not have an effect on local *Ae. albopictus* populations via niche expansion. Additionally, *Ae. aegypti* is found more frequently in areas that are coastal and at low altitude, while *Ae. albopictus* is more likely to be present in locations that are inland and at higher altitude (Gratz 2004; Honorio et al. 2009). Because the proposed trial site is in a coastal, low altitude location, it is a more likely habitat for *Ae. aegypti* than *Ae. albopictus*, further lessening the likelihood of *Ae. aegypti* replacement with *Ae. albopictus*. Additionally, the wild-type *Ae. aegypti* population would be expected to recover to pre-trial numbers after the cessation of OX513A mosquito releases. Therefore, the likelihood of adverse effects associated with increase in population of other mosquito species that may contribute to the increase of diseases at the proposed trial site is extremely low.

The likelihood that the production and release of OX513A mosquitoes would lead to development of antimicrobial resistant prokaryotes is extremely low. This is in part because resistant bacteria, even if present in the larval or pupal stages, would be highly unlikely to be present in adult OX513A mosquitoes due to the fact that gut bacteria are lost during mosquito metamorphosis from larvae to adults. Antimicrobial resistance arising in bacteria in the rearing water and the subsequent transfer of this trait to other bacteria that could cause food or water-borne diseases would also be highly unlikely due to the short duration of the mosquito life cycle as well as the trial in general. Waste water from the HRU is treated at a local waste water treatment facility in accordance with existing local and state laws, further precluding the exposure of humans and animals to mosquito larvae-contaminated water. Also, process controls that would be implemented at the HRU (e.g., use of personal protective equipment) would eliminate the potential for transfer of antibiotic resistant bacteria to personnel involved in the production of OX513A mosquitoes (Section 15.1.1). Therefore, the likelihood of the adverse effects associated with development of anti-microbial resistance is extremely low.

Inadvertent release of OX513A females is highly unlikely due to SOPs and quality control procedures that Oxitec would implement (Section 10.4.2). In the highly unlikely event that a person were bitten by

an OX513A female inadvertently released at the trial site or by the female OX513A progeny that survived, the immunological response to these bites in humans and animals would not be expected to differ from the immunological response to bites by wild-type *Ae. aegypti* mosquitoes as discussed above. In fact, we anticipate that it would pose less risk in several respects: (1) released mosquitoes would be maintained in conditions and with procedures that prevent contamination with virus, and (2) dengue virus takes a long time to develop in a mosquito to the point when it can be transmitted (EIP-Section 14.2), shorter-lived females such as the OX513A females are less likely to pass on diseases. Male mosquitoes do not bite humans. Therefore, the likelihood of the adverse effects associated with the release of OX513A females at the trial site is expected to be extremely low.

It is highly unlikely that the failure of the introduced traits in OX513A male mosquitoes would lead to any adverse effects. The stability of the #OX513 rDNA construct was confirmed over multiple generations of OX513A mosquitoes (Section 9.2.4). In the highly unlikely event that the introduced lethality trait is compromised, resulting in a loss of function of the tTAV lethality trait, these mosquitoes would be functionally no different than existing wild-type *Ae. aegypti*. Oxitec would monitor the performance of OX513A mosquitoes during the investigational trial (Section 11) and would be able to detect the failure of the traits and stop the trial. Therefore, the likelihood of the adverse effects associated with the failure of the introduced traits is expected to be extremely low.

### **14.3 Conclusions**

Data and information on the consequences of release, survival, establishment, and spread of OX513A in the environment indicate that the proposed investigational use of OX513A *Ae. aegypti* mosquitoes would not be expected to have any significant adverse impacts on the environment or human and non-target animal health beyond those caused by wild-type mosquitoes.

### **14.4 Consequences of the No Action Alternative**

As described earlier (Section 8.1), the no action alternative would be for Oxitec not to carry out the field trial in Key Haven, Florida. As a result, Oxitec could continue development and commercialization of the product at locations outside of the United States with no intent to conduct a field trial in the United States, or they could select another location in the United States to conduct a field trial. With respect to the former, there would be no consequences or potential environmental impacts arising from that scenario – as there would be no trial in Key Haven, Florida. With respect to the latter, Oxitec would prepare a new environmental assessment evaluating potential environmental impacts associated with that investigational release at another location.

### **14.5 Cumulative Impacts**

As defined by regulation, cumulative impacts are “the impact on the environment which results from the incremental impact of the action when added to other past, present, and reasonably foreseeable future actions regardless of what agency (Federal or non-Federal) or person undertakes such other actions. Cumulative impacts can result from individually minor but collectively significant actions taking place over a period of time.” 40 CFR 1508.7. As part of the environmental assessment, we have

evaluated the environmental impacts of complete population suppression of *Ae. aegypti* at the proposed trial site, including effects on predatory animals, potential for niche expansion and risk of disease transmission. See Sections 13.5.2 and 14.2. Moreover, there are not expected to be any “incremental impacts” seen over time as a result of the proposed trial given that the local population of *Ae. aegypti* should revert to pre-trial levels once the experiment has stopped. Therefore, we have determined there would be no significant environmental impacts caused by the use of OX513A coupled with the continued use of insecticides and other vector control methods employed at the proposed trial site and in the surrounding area that have not already been evaluated. Consideration of any future field trials at this time would be purely speculative. Thus, there are no cumulative impacts from this proposed action that would result in a significant environmental impact for which an EIS would be needed.

## 15 Measures used to minimize potential impacts

### 15.1 Physical containment

Physical containment measures would be implemented at HRU to prevent unintentional or inadvertent escape from contained facilities in accordance with measures proposed by the Arthropod Containment Guidelines level 2 (ACL2).<sup>58</sup> These include both primary and secondary level containments and are summarized below and in Figure 18.

#### 15.1.1 ACL2: Standard practices

The following information is from the ASTMH Committee on Medical Entomology ACL2 Guidelines for safe working practices for the use of infected, uninfected, and genetically engineered arthropod species in contained use. Oxitec relies upon these Guidelines in running its insectaries and external entities, such as the CDC, use them when conducting insectary inspections for import permits under 9 CFR 71.54.<sup>59</sup>

- *Location of Arthropods.* Furniture and incubators containing arthropods (e.g., mosquitoes) are located in such a way that accidental contact and release by laboratory personnel, custodians, and service persons is unlikely. This is achieved by locating any arthropods in dedicated rooms, closets, and incubators out of the traffic flow or similar measures.
- *Supply Storage.* The area is designed and maintained to enhance detection of escaped arthropods. Equipment and supplies not required for operation of the insectary should not be located in the insectary. All supplies for insect maintenance that must be kept within the

---

<sup>58</sup> These Guidelines were produced by the American Committee on Medical Entomology and published in 2002. These Guidelines describe safe working practices for the use of infected, uninfected and genetically engineered arthropod species in contained use. They are followed broadly both inside and outside the USA by arthropod researchers and CDC inspects premises holding vectors in accordance with them. They are available at <http://www.astmh.org/subgroups/acme#arthropod> [Accessed June 21, 2016].

<sup>59</sup> [http://www.cdc.gov/od/eaipp/inspection/docs/Import\\_Permit\\_Checklist\\_ACL-2.pdf](http://www.cdc.gov/od/eaipp/inspection/docs/Import_Permit_Checklist_ACL-2.pdf) [Accessed June 17, 2016]

insectary are located in a designated area and closed storage is used where possible. Doors and drawers are opened only for access. Insect diet is kept in sealed containers.

- *General Arthropod Elimination.* Accidental sources of arthropods from within the insectary are eliminated. This is accomplished by cleaning work surfaces after a spill of materials, including water that might contain viable eggs. Pools of water are mopped up immediately.
- *Primary Container Cleaning and Disinfestation.* In addition to cleaning cages and containers to prevent arthropod escape, practices are in place such that arthropods do not escape by inadvertent disposal in primary containers. Cages and other containers are appropriately cleaned to prevent arthropod survival and escape (e.g., heated to over the lethal temperature or killed by freezing). Autoclaving or incineration of primary containers is recommended for containers.
- *Primary Container Construction.* Cages used to hold arthropods are non-breakable and screened with mesh of a size to prevent escape. Containers are preferably autoclavable or disposable. Openings designed to prevent escape during removal and introduction of arthropods are used.
- *Disposal of Arthropods.* Living arthropods are not to be disposed of. All wastes from the insectary (including arthropod carcasses, and rearing medium) are transported from the insectary in leak-proof, sealed containers for appropriate disposal in compliance with applicable institutional or local requirements. All life stages of arthropods are killed before disposal. Material is killed with hot water or freezing before flushing down drains that are fitted with sieves. All waste from the insectary is frozen at below  $-15^{\circ}\text{C}$  prior to disposal via incineration.
- *Primary Container Identification and labelling.* Arthropods are identified adequately. Labels giving species, strain/origin, date of collection, responsible investigator, and so on are firmly attached to the container). Vessels containing stages with limited mobility (e.g., eggs, pupae) are securely stored.
- *Prevention of Accidental Dispersal on Persons or via Sewer.* Before leaving the insectary and after handling arthropods, personnel wash their hands, taking care not to disperse viable life stages into the drainage system. If materials are disposed of via the sewer, all material is destroyed by heat or freezing followed by incineration. Air curtains are used as appropriate.
- *Pest Exclusion Program.* A program to prevent the entrance of wild arthropods (e.g., houseflies, cockroaches, spiders) and rodents effectively precludes predation, contamination.
- *Escaped Arthropod Monitoring.* Investigators assess whether escapes are occurring by instituting an effective arthropod trapping program to monitor the escape prevention

program. Oviposition traps, ground-level flea traps, oil-filled channels surrounding tick colonies, light traps for mosquitoes and so on are recommended. The Guidelines also recommend exterior monitoring particularly in the case when exotic arthropods are used. Records of exterior captures are maintained.

- *Source and Harborage Reduction.* Harborage and breeding areas are eliminated. Furniture and racks in the insectary are minimized and can be easily moved to permit cleaning and location of escaped arthropods. Equipment in which water is stored or might accumulate (e.g., humidifiers) is screened to prevent arthropod access, or contains chemicals to prevent arthropod survival.
- *Notification and Signage.* Persons entering the area are aware of the presence of arthropod vectors. The hazard warning sign identifies the arthropod species, lists the name and telephone number of the responsible person(s), and indicates any special requirements for entering the insectary (e.g., the need for immunizations or respirators).
- *Procedure Design.* All procedures are carefully designed and performed to prevent arthropod escape.
- *Safety Manual.* A safety manual is prepared, approved by the IBC or senior management, and adopted. The manual contains emergency procedures, standard operating procedures, waste disposal and other information necessary to inform personnel of the methods for safe maintenance and operation of the insectary.
- *Training.* Laboratory personnel are advised of special hazards and are required to follow instructions on practices and procedures contained in the safety manual. Adherence to established safety procedures and policies is made a condition of employment and is part of the annual performance review of every employee. Personnel receive annual updates and additional training as necessary for procedural or policy changes. Records of all training are maintained.
- *Access Restrictions.* Routine access is limited to trained persons and accompanied guests.
- Service persons are made aware of the hazards present and the consequences of arthropod release and contact with agents that may be present. Transfer of arthropods between manipulation and holding areas is in non-breakable secure containers.
- *Escaped Arthropod Handling.* Loose arthropods must be killed and disposed of, or recaptured and returned to the container from which they escaped.
- *Accidental Release Reporting.* An accidental release procedure is in place. This includes contacts and immediate mitigating actions. Accidents that result in release of GE arthropods from primary containment vessels must be reported immediately to the

insectary director who is responsible for ensuring that appropriate and documented action is taken to mitigate the release and written records are maintained.

- *Movement of Equipment.* All equipment must be appropriately decontaminated and disinfested before transfer between rooms within the insectary, and before removal from the insectary.

#### **15.1.1.1 Safety equipment (Primary barriers)**


- *Eye and Face Protection.* Appropriate face/eye and respiratory protection are worn by all personnel entering the insectary.
- *Gloves.* Gloves are worn when handling blood, and associated equipment and when contact with potentially infectious material is unavoidable.
- *Torso Apparel.* White laboratory coats, gowns, and/or other protective equipment are worn at all times in the insectary.
- *Personal Clothing.* Clothing should minimize the area of exposed skin (e.g., skirts, shorts, open-toed shoes, sandals, tee shirts are inadvisable since this can increase the risk of attracting and being bitten by a loose arthropod).

#### **15.1.1.2 Facilities (Secondary barriers)**

- *Location of Insectary.* The insectary is separated from areas that are open to unrestricted personnel traffic within the building by at least two self-closing doors that prevent passage of the arthropods.
- *Insectary Doors.* Entrance to the insectary is via a double-door vestibule that prevents flying and crawling arthropod escape. The two contiguous doors must not be opened simultaneously.
- *Additional barriers.* Potential points of egress, such as air ventilation units are screened with insect proof mesh.
- *Insectary Window.* The insectary windows are sealed shut where present, and are of hurricane rated glass.
- *Interior Surfaces.* The insectary is designed, constructed, and maintained to facilitate cleaning and housekeeping. The interior walls are light-colored so that a loose arthropod can be easily located, recaptured, or killed. Gloss finishes, ideally resistant to chemical disinfectants and fumigants, are recommended. Floors are light colored, smooth and uncovered. Ceilings are as low as possible to simplify detection and capture of flying insects.
- *Floor Drains.* Floor drains are modified to prevent accidental release of arthropods by use of metal screens small enough for the trapping of all arthropod stages (e.g., mosquito larvae).
- *Plumbing and Electrical Fixtures.* Internal facility appurtenances (e.g., light fixtures, pipes, ducting) are minimal since these provide hiding places for loose arthropods. Penetrations of walls, floors, and ceilings are minimal and sealed/caulked. Light fixtures are sealed, and

accessed from above. HVAC Ventilation is appropriate for arthropod maintenance, but does not compromise containment of the arthropod. Appropriate filter/barriers are installed to prevent escape of arthropods; air curtains are located in vestibules to the laboratory.

- *Sink*. The facility has a hand-washing sink with hot water and with suitable plumbing to prevent arthropod escape.
- *Illumination*. Illumination is appropriate for arthropod maintenance but does not compromise arthropod containment, impede vision, or adversely influence the safety of procedures within the insectary. Lighted (or dark) openings that attract escaped arthropods are avoided.



**Figure 18. Summary schematic of containment measures for egg production facility in the U.S.**

## 15.2 Biological containment

Any potential escapees from the HRU would be homozygous for the OX513A insertion and, because the integrated rDNA lethality trait is >95% penetrant in the laboratory, it is anticipated that >95% would die in the environment as there is no access to the required concentration of tetracycline to allow survival. Laboratory conditions represent optimal conditions; the survival in the environment is expected to be lower due to the harsher environmental conditions encountered. However, even if 5% of the progeny survive, they will not live any longer than wild-type *Ae. aegypti* because they are functionally no more fit

than the wild-type. Some evidence of this has been obtained from experiments conducted in Malaysia and the Cayman Islands. Mark, release, recapture studies with OX513A males were conducted in Malaysia (Lacroix et al. 2012) and the Cayman Islands (Winskill et al. 2014) to assess the longevity of released OX513A males. Decay in recapture rate of males over time allowed estimation of daily survival probability (DSP), from which average life expectancy can be calculated as  $-1/\text{Log}_e(\text{DSP})$ .

In the Malaysian study, OX513A mosquito average life expectancy was 2.0 (DSP=0.611) days and 2.3 (DSP=0.646) days for the non-GE comparator and, therefore, OX513A average life expectancy did not differ significantly from the non-GE laboratory mosquito strain co-released as part of a comparative evaluation. In the Cayman study, four separate mark, release, recapture studies were conducted with resulting estimates of average life expectancy that were shorter than observed in Malaysia, ranging between 0.1 (DSP=0.001) to 1.6 (DSP = 0.53) days for the OX513A mosquito. No comparator non-GE strain was co-released in this study.

### **15.2.1 Potential for the failure of the biological containment**

It is theoretically possible that non-specific mutations or alterations in the genome of the OX513A mosquito alters the expression of the lethality trait, which could result in the failure of the lethality trait to act in the absence of tetracycline, and in the survival of offspring between OX513A males and wild-type female crosses. In the event such mutations were to occur, resulting in a loss of function of the tTAV lethality trait, these mosquitoes would be functionally no different than existing wild-type *Ae. aegypti*. Additionally, a loss of tTAV function in the field (i.e., in released adults) as opposed to in the rearing process in the HRU will not affect future batches of OX513A adults produced and released as live mosquitoes from the field are not returned to the production facility and cannot influence the genetics of the production stock. Further, the insertion of the rDNA construct in OX513A has remained stable over many generations even under mass rearing conditions. Therefore, any re-arrangements or movements of the rDNA construct that could lead to the failure of the biological containment are highly unlikely.

Another theoretical possibility is that environmental concentrations of tetracycline are sufficient to rescue the phenotype from the lethality trait. This has been addressed in Section 15.3.4.

The efficacy of the lethality trait expression is assessed by comparing the mortality of the OX513A mosquito (scored by fluorescence and confirmed by PCR) and wild-type progeny, as described in the Section 11. If these results indicate that there is no statistically significant difference in mortality, then the lethality trait will be regarded as not having the desired efficacy. Lack of efficacy has not been seen in any previous releases in the Cayman Islands, Panama, or Brazil. However, in the unlikely event that the lethality trait is not effective during the investigational period, it will be detected as described above, the trial will be stopped, and additional mosquito control measures such as larvicides or adulticides can be applied.

### 15.3 Geographical/geophysical containment

*Ae. aegypti* are present in the environment in Florida, where it is regarded as an invasive species by some ((Juliano and Lounibos 2005) and CDC<sup>60</sup>), but for the purposes of this EA *Ae. aegypti* will be referred to as a non-native species. It is the intention of the proposed field trial for OX513A males to mate with wild-type females at the proposed release site. The proposed field trial would include the following geographical/geophysical naturally occurring containment measures:

- Temperature;
- Water storage and rainfall;
- Salinity of the water surrounding the release site; and
- Insufficient tetracycline in the environment and breeding sites that has the potential to reverse the lethality trait in the environment.

Each of these elements and their effect on containment are discussed further below.

#### 15.3.1 Temperature

The effect of temperature on larval development of *Ae. aegypti* has been well studied. Studies showed that larvae have an ecological temperature range of 10-30°C (~50°F -86°F) (Tun-Lin et al. 2000). Larval development is a function of temperature, which also affects adult size, dry weight, and ovariole number, all of which fall as the temperature rises (Clements 2000). High temperatures alone (>40°C)[104°F] are unlikely to limit the species but low temperatures are limiting with the threshold being the 10-15°C (~50-59 °F) isotherm. At temperatures lower than 15°C (59°F), *Ae. aegypti* becomes torpid, unable to fly, or moves its limbs only slowly. Lower temperatures can slow development time to such a degree that the species is prevented from establishing itself because egg to adult cycles of longer than 45 days are likely to prevent establishment. *Ae. aegypti* does not appear to enter a true diapause, although the eggs are able to survive in dry conditions for several months. Low temperatures affect the ability of eggs to hatch with significant decrease in hatching seen between -5°C and -7 °C and no hatching seen when temperatures fell to -10 °C. The duration of exposure to cold temperatures had less effect as temperatures decreased. No *Aedes aegypti* eggs survived and hatched when exposed to -15 °C for even an hour (Thomas et al. 2012). Thus, even brief exposure to -10 °C or lower temperatures can have significant impacts on egg banks and mosquito populations in future seasons.

Temperature sensitivity of the OX513A line has been investigated and is reported in Section 12.2.1.4.

---

<sup>60</sup> <http://www.cdc.gov/dengue/entomologyecology/> [Accessed June 17, 2016].

### 15.3.2 Water storage and rainfall

Dessicated *Ae. aegypti* eggs have the potential to remain viable for several months if environmental conditions are suitable. Access to water will induce egg hatching. Water storage vessels for personal use, such as washing and drinking, can serve as attractive oviposition sites for female mosquitoes if the containers are not covered, or the cover is routinely removed.

In the Florida Keys, there is piped water to houses and, therefore, the only containers that could provide breeding sites are those that are filled with rainwater, or deliberately filled with tap water and left out. FKMCD makes regular surveys of containers in the area and advises residents to tip out water from all containers that they might have on their land (source reduction). Additionally, the larvicide *Bti* is used in any container that is found to be productive for larvae.

### 15.3.3 Salinity of the ocean surrounding the release site

The release site is surrounded by saline ocean waters and inlets. *Ae. aegypti* are reported not to survive in sea water at salinity levels between 14 g/L and 35 g/L, although Ramasamy et al. (2011) showed that they were able to survive to a limited extent in brackish waters with lower saline levels (3 g/L), as described in Section 12.1.1.1. Some of these environments with brackish waters are likely to include standing water in boats, which are expected to be found in the trial area, although these are also the same breeding sites that are targeted for *Aedes* control using conventional means such as insecticides. FKMCD recommends that standing water be removed from boats.<sup>61</sup>

### 15.3.4 Tetracycline in the environment

Tetracyclines in the environment can come from human or animal drugs, or non-drug sources (such as in agriculture) (Section 12.2.1.1.1). Tetracycline was first approved for human use in the United States in 1957. Oral tetracyclines used at that time included tetracycline, oxytetracycline, and chlortetracycline. Many uses of these drugs have been discontinued for use in humans. The forms of tetracycline most commonly used in human medicine today include, for example, doxycycline and minocycline. Both doxycycline and minocycline are prescription drugs. Currently, tetracycline is most frequently used for upper respiratory and skin and soft tissue infection in humans. Tetracycline is used therapeutically in animals. Oxytetracycline and chlortetracycline are used both therapeutically and for production (growth) purposes in food-producing animals, although FDA has issued guidance documents with recommendations for ending production use in feed or drinking water by January 1, 2017 (see Guidance for Industry 209<sup>62</sup> and Guidance for Industry 213<sup>63</sup>). Based on 2014 tetracycline sales data, 6,600,849 kgs

<sup>61</sup> <http://keysmosquito.org/mosquito-protection/> [Accessed June 17, 2016].

<sup>62</sup> [CVM GFI#209 The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals \(PDF - 251KB\)](#) [Accessed June 21, 2016].

<sup>63</sup>

<http://www.fda.gov/downloads/animalveterinary/guidancecompliancenenforcement/guidanceforindustry/ucm299624.pdf> [Accessed June 23, 2106].

of active ingredient were sold that year for use in animals in the U.S.<sup>64</sup> According to the U.S. Pharmacopeia Safety Data Sheet, tetracycline has known environmental toxicity to fish with LC50<sup>65</sup> of 186.9-258.9 mg/L.<sup>66</sup> The sensitivity of the OX513A line has been evaluated in Section 12.2.1.1 and will not be repeated here, but in summary, minimum concentrations of 1 µg/mL are required to fully rescue the phenotype from the lethality trait.

Aquaculture facilities, farms, hospitals, or municipal sewage facilities are the only sources that theoretically could introduce into the environment sufficiently high levels of tetracycline to allow survival of OX513A progeny in the environment. Our survey of the area showed that there are no farms, including aquaculture facilities or citrus groves, or hospitals/medical centers in the proposed trial site.<sup>67</sup> The closest hospital is located on another island, separated from the trial site by more than 250 m of saline water and dense vegetation that prevents the spontaneous dispersion of OX513A mosquitoes. The proposed field trial site has a waste water treatment plant (WWTP) that serves the residents of Key Haven. The WWTP is located at the southern end of Key Haven at the junction of the Buffer and UCA (Figure 9). This site is approximately 400 m away from the TA, which is considerably farther than an average spontaneous flight distance of *Ae. aegypti* mosquitoes. Even if released OX513A mosquitoes were able to reach the WWTP, it is highly unlikely that their progeny would find a suitable concentration of tetracycline in its water to enable rescue of the lethality trait because the WWTP provides services to residential customers only (and therefore would not contain tetracycline waste from commercial facilities).

Further, tetracycline and its derivatives are sensitive to ultra-violet light and degrade quickly when exposed to sunlight (Bautitz and Nogueira 2007). They are strongly adsorbed by soil and clays, which significantly decrease their mobility and bioavailability (Sithole and Guy 1987; Pils and Laird 2007). Curtis et al. (2015) analyzed environmental concentrations of tetracycline and its derivatives in samples from Campinas and Itu, Sao Paulo, Brazil. The samples were collected from three different creeks impacted by sewage or poultry production, one private fish production lake, rain and tap water, and multiple discarded containers that contained larvae at the time of sampling. The analysis showed that the levels of tetracycline, and its analogs oxytetracycline and chlortetracycline were below the limit of quantification for each of the samples.

In general, *Ae. aegypti* prefer man-made containers such as gutters, water containers, and tires that hold rainwater or clean still water for their breeding sites (Tun-Lin et al. 1995; Hribar et al. 2001). It is

---

<sup>64</sup> FDA 2014 Summary Report on Antimicrobials Sold or Distributed for Use in Food Producing Animals, <http://www.fda.gov/downloads/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/UCM476258.pdf> [Accessed June 21, 2016].

<sup>65</sup> LC50 is the lethal dose at which 50% of the test subjects die.

<sup>66</sup> <http://static.usp.org/pdf/EN/referenceStandards/msds/1651009.pdf> [Accessed June 16, 2016].

<sup>67</sup> <https://www.google.com/maps/@24.5821038,-81.7370013,16z> [Accessed June 16, 2016].

highly unlikely that these sites would contain any tetracycline at all for the reasons noted above. Further, it is highly unlikely that *Ae. aegypti* would use sewage waters at the Key Haven WWTP as their breeding site as confirmed by the FKMCD surveillance records (Appendix L). The FKMCD records indicate that no *Ae. aegypti* larvae were found at the Key Haven WWTP during the 2004-2015 period. There have been some reports of *Ae. aegypti* larvae being found in the surface clear water layer of septic tanks (Hribar et al. 2004; Burke et al. 2010), but this is not common and occurs only where the lid is cracked or broken, providing the female access to a novel oviposition site. However, Key West and surrounding areas in Monroe County have eliminated 99.9% of septic tanks<sup>68</sup> and use a public sewage system as the major means of waste disposal.

Additionally, any potential sources of tetracycline in and around residences in the TA due to the presence of food from animal-derived sources with potential tetracycline residues would also have a low probability of affecting OX513A survival (see Section 12.2.1.1.1).

Thus, we conclude that it is highly unlikely that OX513A mosquitoes or their progeny would be exposed to any exogenous tetracycline and its derivatives in the environment that would allow them to establish at the proposed trial site.

## 16 Risk assessment

Our risk assessment approach relies on the environmental risk issues associated with the introduction or escape of GE animals into the environment, which are identified in the 2002 National Research Council (NRC) report entitled “Animal Biotechnology: Science Based Concerns” (NRC 2002). According to the NRC report, risk [R] is the joint probability of exposure [P(E)] and the conditional probability of harm (i.e., adverse effects) given that the exposure to a hazard has occurred [P(H|E)]: Risk = P(E) x P(H|E) or Risk = Exposure x Adverse Effect. Therefore, there must be both exposure and an adverse effect to pose a risk. If one of the components is negligible then the risk would be negligible as well.

Further, the report defined ecological “harm” as “gene pool, species or community perturbation resulting in negative impacts to community stability.” Negative impacts might be direct or indirect such as changes in other factors used or needed by the ecological community. Prioritization of environmental concerns posed by GE animals was considered, determining the likelihood that a GE animal will become established in the receiving community and reported below:

- Fitness -The effect the rDNA construct has on the “fitness” of the animal within the ecosystem into which it is released.

---

<sup>68</sup> Monroe County Engineering Division: Keys Wastewater Plan Nov 2007 <http://www.monroecounty-fl.gov/DocumentCenter/Home/View/478> [Accessed June 9, 2016]

- Increased adaptability -The ability of the GE animal to escape and disperse into diverse communities.
- The stability and resilience of the receiving community.

In order for a GE animal to prove a hazard, it must spread and establish in the community in which it is released; therefore, the NRC report further defines exposure as the establishment of the GE animal in the community. For these reasons, the risk assessment has used this definition of exposure potential.

The risk assessment was conducted using the following steps:

- Identification of potential harms regardless of their likelihood;
- Identification of the hazards that could produce potential harms;
- Likelihood of exposure (using the definition above);
- Likelihood of harm being realized if exposure occurs; and
- Determination of risk by the multiplication of the resulting outcomes on harm and exposure.

In our assessment we identified and evaluated potential hazards, likelihood of exposure and potential consequences (likelihood of adverse effects) associated with the proposed trial.

The potential adverse effects associated with the proposed investigational use of the OX513A *Ae. aegypti* mosquito are summarized in Table 9. These potential adverse effects have been classified as direct or indirect and have been grouped according to their likely area of impact: human or non-target animal health and environmental.

A direct adverse effect refers to the primary effects that the use of the OX513A mosquito could have on the environment, including human health. An indirect adverse effect refers to a causal chain of events being established whereby the harm is reached through mechanisms not directly related to the OX513A mosquito itself, such as interaction with other organisms, transfer of the rDNA construct, or changes in use or management at the release site.

Classifying the adverse effect as direct will facilitate the monitoring activities during the trial. A direct effect refers to a potential adverse effect that would be expected to be seen throughout the period of the release, whereas an indirect effect may not be observed in the release period but might become apparent at a later stage.

The risk assessment is summarized in Table 9 and brings together all the information previously presented in the EA regarding potential hazards, likelihood of exposure and adverse effects along with the data endpoints that have been considered in the analysis.

**Table 9. Risk assessment.**

Risk category	Adverse effect/ consequence	Direct/ indirect	Likelihood of exposure	Likelihood of adverse effects	Estimation of risk	Comments
Human or animal health	Toxic effects in humans or non-target animals or allergenic effects in humans	Direct	Highly unlikely (HUL)	Extremely low (EL)	Negligible (HUL x EL)	Western blot assays demonstrated that the levels of tTAV and DsRed2 proteins in OX513A female saliva are below the LOD. Further, bioinformatics analysis demonstrated the lack of toxic and allergenic potential for humans (Section 13.6). The expressed proteins have been shown to have no homology to known toxins following bioinformatics evaluations carried out according to international guidelines. Therefore, the immunological response to the bites from OX513A female mosquitoes is not expected to be any different from the immunological response to the bites from wild-type <i>Ae. aegypti</i> mosquitoes.
Human or animal health	Transfer of the rDNA construct to humans or non-target animals	Direct	Highly unlikely (HUL)	Extremely low (EL)	Negligible (HUL x EL)	The rDNA construct is stably integrated in the mosquito genome (Section 9.2.1) and is incapable of being transferred through non-sexual means (Section 13.4.2). No adverse effects on predator species were identified when they were fed a diet comprised of OX513A larvae exclusively (Section 13.5.2.5).

Risk category	Adverse effect/ consequence	Direct/ indirect	Likelihood of exposure	Likelihood of adverse effects	Estimation of risk	Comments
Human or animal health	Increase in transmission of dengue or other diseases transmitted by mosquitoes	Direct	Highly unlikely (HUL)	Extremely low (EL)	Negligible (HUL x EL)	Male mosquitoes do not bite or transmit disease. A small number of OX513A females that may be co-released (not to exceed 0.2%) or are present in the environment as a result of incomplete penetrance of the introduced lethality trait would have a relatively short lifespan, which would limit their ability to interact with humans and transmit disease. In the highly unlikely event that an OX513A female feeds on an infected person, the OX513A mosquito would not be able to transmit the infection further because OX513A lifespan is considerably shorter than the EIP required for viral development (Section 14.2).
Human or animal health	Increase in population of other mosquitoes that may contribute to the increase of diseases	Indirect	Unlikely (UL)	Extremely low (EL)	Negligible (UL x EL)	It is highly unlikely that the release of OX513A mosquitoes would lead to an increase in population of other mosquito species that might contribute to an increase of disease transmission at the proposed trial site. A suppression field trial using OX513A in Panama resulted in an 82% suppression of <i>Ae. aegypti</i> over an 84 day period without an increase in <i>Ae. albopictus</i> at the same site. This suggests that a short term field trial should not have an effect on local <i>Ae. albopictus</i> populations via niche expansion. <i>Ae. aegypti</i> is found more frequently in areas that are coastal and low altitude, while <i>Ae. albopictus</i> is more likely to be present in locations that are inland and at higher altitude. The proposed trial site is in a coastal, low altitude location.

Risk category	Adverse effect/ consequence	Direct/ indirect	Likelihood of exposure	Likelihood of adverse effects	Estimation of risk	Comments
Human or animal health	Development of anti- microbial resistance	Indirect	Highly unlikely (HUL)	Extremely low (EL)	Negligible (HUL x EL)	It is highly unlikely that antimicrobial resistant bacteria, even if present in the larval or pupal stages, would be present in adult OX513A mosquitoes because their gut bacteria are lost during mosquito metamorphosis from larvae to adults. It is highly unlikely that any antimicrobial resistance would arise in bacteria in the rearing water and that this trait would be transferred to other bacteria that could cause food or water-borne diseases due to the short duration of the mosquito lifecycle and the trial in general. The process controls implemented at the HRU (e.g., use of personal protective equipment) eliminate the potential for transfer of antibiotic resistant bacteria (if present) to personnel.

Risk category	Adverse effect/ consequence	Direct/ indirect	Likelihood of exposure	Likelihood of adverse effects	Estimation of risk	Comments
Human or animal health	Release of OX513A females	Direct	Highly unlikely (HUL)	Extremely low (EL)	Negligible (HUL x EL)	SOPs and quality control procedures would be in place to ensure accuracy of the sorting does not exceed a maximum of 0.2% OX513A females. Male mosquitoes do not bite. If a person were bitten by an OX513A female inadvertently released at the trial site or by female OX513A progeny that survived, the immunological response to these bites in humans and other animals is not expected to be any different from the immunological response to bites by wild-type <i>Ae. aegypti</i> mosquitoes. Inadvertently released female OX513A mosquitoes would not be likely to transmit any disease because (1) released mosquitoes would be maintained in conditions and with procedures that prevent contamination with virus, and (2) dengue virus takes a long time to develop in a mosquito to the point when it can be transmitted, so that shorter-lived females such as the OX513A females are less likely to pass on diseases.
Human or animal health	Failure of the introduced traits	Direct	Highly unlikely (HUL)	Extremely low (EL)	Negligible (HUL x EL)	Stability of the inserted rDNA construct was confirmed over multiple generations of OX513A mosquitoes. In the highly event that the introduced traits is compromised, mosquitoes could be controlled using alternative techniques. No such instability in the introduced traits has been observed to date over 100 generations.
Environmental	Interbreeding with related mosquito species	Direct	Highly unlikely (HUL)	Extremely low (EL)	Negligible (HUL x EL)	Biological data from experiments conducted and literature shows that cross-species mating results in non-viable progeny (Section 13.4.1).

Risk category	Adverse effect/ consequence	Direct/ indirect	Likelihood of exposure	Likelihood of adverse effects	Estimation of risk	Comments
Environmental	Effect of tetracycline on the environment	Indirect	Highly Unlikely (UL)	Extremely low (EL)	Negligible (HUL x EL)	The levels of tetracycline in the waste water are expected to be relatively low and would be quickly degraded or adsorbed in the environment (Section 12.2.1.1.1).
Environmental	Effect on flora	Direct/ indirect	Highly unlikely (HUL)	Extremely low (EL)	Negligible (HUL x EL)	There are no reports that <i>Ae. aegypti</i> is a pollinator for any plant species. It is highly unlikely that the rDNA construct could be transferred to other species that may be involved in pollination of plants.
Environmental	Effect on predators	Direct	Highly unlikely (HUL)	Extremely low (EL)	Negligible (HUL x EL)	The <i>Ae. aegypti</i> mosquito lives in and around human habitation in artificial breeding containers such as flower pots and water storage containers. The mosquito is a non-native species and is not known as the sole food source for any one organism although larval stages could be eaten by amphibians or other species living in the domestic. In some instances the larvae could be consumed by fish in the environment. Adult mosquitoes are poor fliers and females are generally found in or around houses, adult mosquitoes are most likely to be eaten by spiders or amphibians although it is possible that some adults could be opportunistically eaten by bats or birds.
Environmental	Effect on decomposers	Direct	Unlikely (UL)	Extremely low (EL)	Negligible (UL x EL)	No decomposers that are specifically involved in decomposition of <i>Ae. aegypti</i> were identified (Section 13.5.5). No adverse effects have been identified in open releases conducted in Malaysia, Cayman Islands, Panama and Brazil.

Risk category	Adverse effect/ consequence	Direct/ indirect	Likelihood of exposure	Likelihood of adverse effects	Estimation of risk	Comments
Environmental	Development of resistance to insecticides in the local population of <i>Ae. aegypti</i>	Indirect	Highly unlikely (HUL)	Extremely low (EL)	Negligible (HUL x EL)	OX513A are susceptible to insecticides used for mosquito control.
Environmental	Persisting or establishing at the trial site	Direct	Highly unlikely (HUL)	Extremely low (EL)	Negligible (HUL x EL)	It is highly unlikely that OX513A mosquitoes and their progeny would be able to establish in the environment due to selective disadvantage conferred by the lethality trait and compromised fitness.
Environmental	Effect on endangered or threatened species	Direct	Highly unlikely (HUL)	Extremely low (EL)	Negligible (HUL x EL)	With the exception of the Stock Island Tree Snail, there is no habitat overlap of OX513A mosquitoes with threatened or endangered species as <i>Ae. aegypti</i> is a mosquito closely associated with human habitats. The trial is not likely to adversely affect the Stock Island Tree Snail as it does not propose removal or modification of its habitat. National wildlife refuges are located considerable distance away from the proposed trial site and would not be affected by the proposed trial.

## 16.1 Uncertainties in the risk assessment

Uncertainty in the risk assessment can come from a variety of sources, such as variability in parameters and the limitations of their understanding. The risk assessment presented here is qualitative, relying on published information and scientific study. In qualitative risk assessments, judgment by professionals in the field is used to estimate the degree of uncertainty. For the risk questions posed below the uncertainty has been evaluated:

- What is the likelihood of inadvertent release of OX513A mosquitoes outside of the proposed trial site?

There is a high degree of confidence in the containment measures at the HRU. Rearing would be conducted in accordance with ACL2 containment levels and the facility has been inspected for compliance by the appropriate federal authorities (e.g., FDA, CDC). Staff working at the HRU would be Oxitec staff with a high degree of experience in handling OX513A and other GE insects in contained conditions. Staff from FKMCD working in the HRU would be trained in the procedures for the rearing of OX513A by Oxitec staff.

Some uncertainty exists for the occurrence of adverse weather conditions being encountered during the course of the trial and preventing rearing or release. For rearing, this is minimized by the HRU being located in a Category 4 hurricane rated building<sup>69</sup> and a Hurricane Preparedness Policy being in place, where adult and larval insect life stages would be killed within 36 hours of a hurricane warning being issued by NOAA or State Authorities. Even if some OX513A were to escape the containment, they would not live longer than their short lifespan and the introduced lethality trait and the dependence on the presence of tetracycline for survival would prevent establishment in the environment.

- What is the likelihood of dispersal of OX513A mosquitoes and their progeny from the proposed trial site?

There is a high degree of confidence that OX513A released males would have limited dispersal, based on results from previous trials of OX513A in other countries and information from the published literature, the location and features of the proposed trial site, and in-trial as well as post-trial monitoring of the site for #OX513-containing *Ae. aegypti*.

- What is the likelihood for establishment of OX513A mosquitoes at the proposed trial site?

---

<sup>69</sup> A Category 4 hurricane rated building is capable of withstanding a Category 4 strength hurricane on the Saffir-Simpson Hurricane Wind Scale (this is defined as “winds of 130-156 mph; Catastrophic damage will occur: Well-built framed homes can sustain severe damage with loss of most of the roof structure and/or some exterior walls. Most trees will be snapped or uprooted and power poles downed. Fallen trees and power poles will isolate residential areas. Power outages will last weeks to possibly months. Most of the area will be uninhabitable for weeks or months” (NOAA 2015)).

Sufficient information from previous field releases of OX513A, where the lifespan of the released insects was approximately 1-3 days (Lacroix et al. 2012) and the fact that more than 95% of progeny die before reaching adulthood as well as evidence from the scientific literature on potential sources of tetracycline provide a high degree of certainty that the OX513A would be unlikely to establish in the environment.

## 17 Conclusions

Based on the foregoing, FDA concludes that the investigational use of OX513A *Ae. aegypti* mosquitoes in Key Haven, Florida would not result in significant impacts on the environment. The agency's conclusions are summarized below:

- What is the likelihood of inadvertent release of OX513A mosquitoes outside of the proposed trial site?

FDA concludes that the likelihood of inadvertent release of OX513A mosquitoes outside of the proposed trial site is low due to the physical containment measures and standard operating procedures implemented for the rearing and transportation of OX513A.

- What is the likelihood of establishment of OX513A mosquitoes at the proposed trial site?

The OX513A line of *Ae. aegypti* mosquitoes carries a repressible dominant lethality trait that prevents progeny inheriting the #OX513 rDNA construct from surviving to functional adulthood in the absence of tetracycline. Although it appears that the introduced lethality trait did not affect mating competitiveness of OX513A males, data demonstrating hemizygous females reared without tetracycline have a median lifespan of two days relative to a wild-type median lifespan of 68 days further reduce the likelihood of survival of OX513A mosquitoes and their progeny. FDA therefore concludes that it is highly unlikely that OX513A mosquitoes and their progeny would be able to establish at the proposed trial site.

- What is the likelihood of dispersal of OX513A mosquitoes and their progeny from the proposed trial site?

Based on our analysis of data available in the literature, we conclude that dispersal of OX513A mosquitoes appears to be adversely affected as measured by *MDT*, but not by *maximum distance traveled*, indicating, that in general, the population of OX513A is not expected to exhibit dispersion greater than wild-type *Ae. aegypti*. The location of the proposed trial site and mosquito control measures implemented by FKMCD would considerably limit the dispersal of OX513A mosquitoes as well. FDA therefore concludes that it is highly unlikely that OX513A mosquitoes and their progeny would be able to establish at the proposed field trial site, or spread beyond its boundaries, should the trial proceed.

- What is the likelihood that the rDNA construct could be transferred to humans or other organisms?

Based on evaluation of data and information submitted by Oxitec, FDA determined that the #OX513 rDNA construct is stably integrated in the OX513A mosquito genome and completely refractory to remobilization, even when deliberately re-exposed to *piggyBac* transposase. Should the proposed field trial proceed, FDA considers that it is highly unlikely that the #OX513 rDNA construct could be transmitted to other closely related species by inter-breeding, as *Ae. aegypti* mating behavior is highly species-specific. Horizontal or non-sexual transfer of the rDNA construct to humans and other animals is also highly unlikely due to a number of physical, biochemical, and genetic barriers. Mosquitoes have been feeding on humans and other animals for millennia with no evidence of DNA transfer between humans and mosquitoes.

- What is the likelihood that release of OX513A mosquitoes would have an adverse effect on non-target species at the proposed trial site?

FDA has determined that it is highly unlikely that the presence of OX513A mosquitoes and their progeny and suppression of the local population of *Ae. aegypti* would have any significant effects on the populations of predators, parasitoids, and decomposers at the proposed trial site. No adverse effect on the pollination of local plants is expected as well. Should the proposed field trial proceed, FDA has determined that the proposed trial would not jeopardize the continued existence of Stock Island Tree snails found in the vicinity of the proposed trial site and would not result in the destruction or adverse modification of their habitat. Therefore, FDA makes a “no effect” determination under the ESA with regard to the Stock Island Tree Snail. Further, FDA does not expect any adverse effects on other endangered species in wildlife refuges located in Monroe County or destruction and modification of their habitats due to their considerable distance from the proposed trial site

- What is the likelihood that the rDNA expression products in OX513A mosquitoes would have adverse effects on humans or other animals?

Based on the Western immuno-blot assays performed by Oxitec, we conclude that the levels of tTAV and DsRed2 proteins in saliva of OX513A *Ae. aegypti* females homozygous for the #OX513 rDNA construct are below the limit of detection for that assay. Therefore, we consider that it is highly unlikely that humans or other animals would be exposed to these proteins even if they were to be bitten by OX513A female mosquitoes. A stepwise approach evaluating the toxic and allergenic potential of tTAV and DsRed2 proteins and a scientific literature search did not identify any evidence suggesting the allergenicity or toxicity of tTAV and DsRed2 proteins. Bioinformatics analysis of amino acid sequences of tTAV and DsRed2 proteins did not identify any similarities with known toxins or allergens. Therefore, FDA concludes that tTAV and DsRed2 proteins lack any toxic or allergenic potential and do not pose any significant risks to humans or non-target animals.

- What are likely consequences to, or effects on the environment associated with the investigational use of OX513A mosquitoes?

The consequences of release, establishment, and dispersal of OX513A in the environment have been extensively studied: data and information from these studies indicate that the proposed investigational use of OX513A *Ae. aegypti* mosquitoes is not expected to cause any significant adverse impacts on the environment or human and non-target animal health beyond those caused by wild-type mosquitoes.

In summary, data and information presented and evaluated indicates that the investigational use of OX513A *Ae. aegypti* mosquitoes, as described in this EA, would not result in significant effects on the quality of the human environment.

## **18 Listing of agencies and persons consulted**

U.S. Environmental Protection Agency  
Office of Pesticide Programs  
Biopesticides and Pollution Prevention Division

Centers for Disease Control and Prevention  
Division of Vector-Borne Diseases

National Institutes of Health  
National Institute of Allergy and Infectious Diseases  
Laboratory of Malaria and Vector Research

## 19 References

- Adeleke MA, Adebimpe WO, Hassan AO, Oladejo SO, Olaoye I, Olatunde GO, Adewole T. 2013. Larval habitats of mosquito fauna in Osogbo metropolis, Southwestern Nigeria. *Asian Pac J Trop Biomed* **3**: 673-677.
- Agosta SJ. 2002. Habitat use, diet and roost selection by the Big Brown Bat (*Eptesicus fuscus*) in North America: a case for conserving an abundant species. *Mammal Review* **32**: 179-198.
- Agwuh KN, MacGowan A. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylicyclines. *J Antimicrob Chemother* **58**: 256-265.
- Albeny-Simoes D, Murrell EG, Elliot SL, Andrade MR, Lima E, Juliano SA, Vilela EF. 2014. Attracted to the enemy: *Aedes aegypti* prefers oviposition sites with predator-killed conspecifics. *Oecologia* **175**: 481-492.
- Alexander TW, Reuter T, Aulrich K, Sharma R, Okine EK, Dixon WT, McAllister TA. 2007. A review of the detection and fate of novel plant molecules derived from biotechnology in livestock production. *Animal Feed Science and Technology* **133**: 31-62.
- Andersson JO. 2005. Lateral gene transfer in eukaryotes. *Cell Mol Life Sci* **62**: 1182-1197.
- Ansari MA, Singh KR, Brooks GD, Malhotra PR, Vaidyanathan V. 1977. The development of procedures and techniques for mass rearing of *Aedes aegypti*. *Indian J Med Res* **65 Suppl**: 91-99.
- Arensburger P, Hice RH, Wright JA, Craig NL, Atkinson PW. 2011. The mosquito *Aedes aegypti* has a large genome size and high transposable element load but contains a low proportion of transposon-specific piRNAs. *BMC Genomics* **12**: 606.
- Argue CL. 2012. *The Pollination Biology of North American Orchids: Volume 1*. Springer New York, New York, NY.
- Avila FW, Sirot LK, LaFlamme BA, Rubinstein CD, Wolfner MF. 2011. Insect seminal fluid proteins: identification and function. *Annu Rev Entomol* **56**: 21-40.
- Ball TS, Ritchie SR. 2010. Sampling biases of the BG-sentinel trap with respect to physiology, age, and body size of adult *Aedes aegypti* (Diptera: Culicidae). *J Med Entomol* **47**: 649-656.
- Ballenger-Browning KK, Elder JP. 2009. Multi-modal *Aedes aegypti* mosquito reduction interventions and dengue fever prevention. *Trop Med Int Health* **14**: 1542-1551.
- Bargielowski I, Alphey L, Koella JC. 2011a. Cost of Mating and Insemination Capacity of a Genetically Modified Mosquito *Aedes aegypti* OX513A Compared to Its Wild Type Counterpart. *PLoS ONE* **6**: e26086 doi:10.1371/journal.pone.0026086.
- Bargielowski I, Nimmo D, Alphey L, Koella JC. 2011b. Comparison of life history characteristics of the genetically modified OX513A line and a wild type strain of *Aedes aegypti*. *PLoS One* **6**: e20699.
- Barrera R, Amador M, Diaz A, Smith J, Munoz-Jordan JL, Rosario Y. 2008. Unusual productivity of *Aedes aegypti* in septic tanks and its implications for dengue control. *Med Vet Entomol* **22**: 62-69.
- Barton MD, Dunlop JW, Psaltis G, Kulik J, DeGennaro L, Kwak SP. 2002. Modified GFAP promoter auto-regulates tet-activator expression for increased transactivation and reduced tTA-associated toxicity. *Molecular Brain Research* **101**: 71-81.
- Bautitz IR, Nogueira RFP. 2007. Degradation of tetracycline by photo-Fenton process - Solar irradiation and matrix effects. *J Photochem Photobiol A: Chemistry* **187**: 33-39.
- Beavers JB, McCoy CW, Kaplan DT. 1983. Natural enemies of subterranean *Diaprepes abbrevialis* (Coleoptera: Curculionidae) larvae in Florida. *Environmental Entomology* **12**: 840-843.
- Benedict MQ, Knols BG, Bossin HC, Howell PI, Mialhe E, Caceres C, Robinson AS. 2009. Colonisation and mass rearing: learning from others. *Malar J* **8 Suppl 2**: S4.
- Bevis BJ, Glick BS. 2002. Rapidly maturing variants of the *Discosoma* red fluorescent protein (DsRed). *Nature biotechnology* **20**: 83-87.
- Bimazubute M, Cambier C, Baert K, Vanbelle S, Chiap P, Gustin P. 2011. Penetration of oxytetracycline

- into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs. *J Vet Pharmacol Ther* **34**: 176-183.
- Blake ES, Landesea CW, Gibney EJ. 2011. The deadliest, costliest, and most intense United States tropical cyclones from 1851 to 2010 (and other frequently requested hurricane facts). *NOAA Technical Memorandum NWS NHC-6*.
- Blum S, Basedow T, Becker N. 1997. Culicidae (Diptera) in the diet of predatory stages of anurans (Amphibia) in humid biotopes of the Rhine Valley in Germany. *J Vector Ecol* **22**: 23-29.
- Boto L. 2014. Horizontal gene transfer in the acquisition of novel traits by metazoans. *Proceedings of the Royal Society of London B: Biological Sciences* **281**.
- Brady OJ, Golding N, Pigott DM, Kraemer MU, Messina JP, Reiner RC, Jr., Scott TW, Smith DL, Gething PW, Hay SI. 2014. Global temperature constraints on *Aedes aegypti* and *Ae. albopictus* persistence and competence for dengue virus transmission. *Parasit Vectors* **7**: 338.
- Brady OJ, Johansson MA, Guerra CA, Bhatt S, Golding N, Pigott DM, Delatte H, Grech MG, Leisnham PT, Maciel-de-Freitas R et al. 2013. Modelling adult *Aedes aegypti* and *Aedes albopictus* survival at different temperatures in laboratory and field settings. *Parasit Vectors* **6**: 351.
- Brathwaite Dick O, San Martin JL, Montoya RH, del Diego J, Zambrano B, Dayan GH. 2012. The History of Dengue Outbreaks in the Americas. *American Journal of Tropical Medicine and Hygiene* **87**: 584-593.
- Brown JE, McBride CS, Johnson P, Ritchie S, Paupy C, Bossin H, Lutomiah J, Fernandez-Salas I, Ponlawat A, Cornel AJ et al. 2011. Worldwide patterns of genetic differentiation imply multiple 'domestications' of *Aedes aegypti*, a major vector of human diseases. *Proc Biol Sci* **278**: 2446-2454.
- Brown KD, Kulis J, Thomson B, Chapman TH, Mawhinney DB. 2006. Occurrence of antibiotics in hospital, residential, and dairy effluent, municipal wastewater, and the Rio Grande in New Mexico. *Science of The Total Environment* **366**: 772-783.
- Burke R, Barrera R, Lewis M, Kluchinsky T, Claborn D. 2010. Septic tanks as larval habitats for the mosquitoes *Aedes aegypti* and *Culex quinquefasciatus* in Playa-Playita, Puerto Rico. *Med Vet Entomol* **24**: 117-123.
- Capurro MdL, Coleman J, Beerntsen BT, Myles KM, Olson KE, Rocha E, Krettli AU, James AA. 2000. Virus-expressed, recombinant single-chain antibody blocks sporozoite infection of salivary glands in *Plasmodium gallinaceum*-infected *Aedes aegypti*. *The American Journal of Tropical Medicine and Hygiene* **62**: 427-433.
- Carvalho DO, McKemey A, Garziera L, Lacroix R, Donnelly CA, Alphey L, Malavasi A, Capurro ML. 2015. Suppression of a field population of *Aedes aegypti* in Brazil by sustained release of transgenic male mosquitoes. *PLoS Neglected Tropical Diseases* **9**: e0003864.
- Carvalho DO, Nimmo D, Naish N, McKemey AR, Gray P, Wilke ABB, Marrelli MT, Virginio JF, Alphey L, Capurro ML. 2014. Mass Production of Genetically Modified *Aedes aegypti* for Field Releases in Brazil. *J Vis Exp* doi:10.3791/3579.
- Cary LC, Goebel M, Corsaro BG, Wang HG, Rosen E, Fraser MJ. 1989. Transposon mutagenesis of baculoviruses: analysis of *Trichoplusia ni* transposon IFP2 insertions within the FP-locus of nuclear polyhedrosis viruses. *Virology* **172**: 156-169.
- Cator LJ, Arthur BJ, Harrington LC, Hoy RR. 2009. Harmonic convergence in the love songs of the dengue vector mosquito. *Science* **323**: 1077-1079.
- Cator LJ, Harrington LC. 2011. The Harmonic Convergence of Fathers Predicts the Mating Success of Sons in *Aedes aegypti*. *Anim Behav* **82**: 627-633.
- CDC. 2010. Locally acquired Dengue--Key West, Florida, 2009-2010. *MMWR Morb Mortal Wkly Rep* **59**: 577-581.

- Chadee DD, Martinez R. 2016. *Aedes aegypti* (L.) in Latin American and Caribbean region: With growing evidence for vector adaptation to climate change? *Acta Trop* **156**: 137-143.
- Chen J, Kelz MB, Zeng G, Sakai N, Steffen C, Shockett PE, Picciotto MR, Duman RS, Nestler EJ. 1998. Transgenic animals with inducible, targeted gene expression in brain. *Mol Pharmacol* **54**: 495-503.
- Chisenhall DM, Christofferson RC, McCracken MK, Johnson AM, Londono-Renteria B, Mores CN. 2014. Infection with dengue-2 virus alters proteins in naturally expectorated saliva of *Aedes aegypti* mosquitoes. *Parasit Vectors* **7**: 252.
- Christophers SR. 1960. *Aedes aegypti* (L.) the yellow fever mosquito: its life history, bionomics and structure. University Press, Cambridge.
- Clark TM, Flis BJ, Remold SK. 2004. Differences in the effects of salinity on larval growth and developmental programs of a freshwater and a euryhaline mosquito species (Insecta: Diptera, Culicidae). *J Exp Biol* **207**: 2289-2295.
- Clements AN. 2000. *The biology of mosquitoes: development, nutrition, and reproduction*. CABI Publishing, Oxford.
- CLONTECHniques. 2001. Living Colors DsRed2 Improved Red Fluorescent Protein for Use in Living Cells. <https://home.ccr.cancer.gov/med/flowcore/DsRed2.pdf>. CLONTECHniques.
- Codex. 2003. Appendix HII, Guidelines for the conduct of food safety assessment of foods derived from recombinant-DNA plants and Appendix HV, Annex on the assessment of possible allergenicity. [www.fao.org/input/download/.../CXG\\_045e.pdf](http://www.fao.org/input/download/.../CXG_045e.pdf). World Health Organization and Food and Agriculture Organization, Rome.
- Codex. 2009. Codex Alimentarius Guidelines. Foods derived from modern biotechnology. [ftp://ftp.fao.org/codex/Publications/Booklets/Biotech/Biotech\\_2009e.pdf](ftp://ftp.fao.org/codex/Publications/Booklets/Biotech/Biotech_2009e.pdf). World Health Organization and Food and Agricultural Organization of the United Nations, Rome.
- Collins LE, Blackwell A. 2000. The biology of Toxorhynchites mosquitoes and their potential as biocontrol agents. *Biocontrol News and Information* **21**: 105N-116N.
- Cook PE, McMeniman CJ, O'Neill SL. 2007. Modifying Insect Population age structure to control vector-borne disease. In *Transgenesis and the management of vector-borne disease*, (ed. S Aksoy). Landes Bioscience.
- Couret J, Dotson E, Benedict MQ. 2014. Temperature, larval diet, and density effects on development rate and survival of *Aedes aegypti* (Diptera: Culicidae). *PLoS One* **9**: e87468.
- Crisp A, Boschetti C, Perry M, Tunnacliffe A, Micklem G. 2015. Expression of multiple horizontally acquired genes is a hallmark of both vertebrate and invertebrate genomes. *Genome Biol* **16**: 50.
- Curtis Z, Matzen K, Oviedo MN, Nimmo D, Gray P, Winskill P, Locatelli MAF, Jardim WF, Warner S, Alphey L et al. 2015. Assessment of the Impact of Potential Tetracycline Exposure on the Phenotype of *Aedes aegypti* OX513A: Implications for Field Use. *Plos Neglected Tropical Diseases* **9**.
- Damal K, Murrell EG, Juliano SA, Conn JE, Loew SS. 2013. Phylogeography of *Aedes aegypti* (yellow fever mosquito) in South Florida: mtDNA evidence for human-aided dispersal. *Am J Trop Med Hyg* **89**: 482-488.
- Davison AC, Hinkley DV. 1997. *Bootstrap methods and their application*. University Press, Cambridge.
- Demaio J, Pumpuni CB, Kent M, Beier JC. 1996. The midgut bacterial flora of wild *Aedes triseriatus*, *Culex pipiens*, and *Psorophora columbiae* mosquitoes. *Am J Trop Med Hyg* **54**: 219-223.
- Devi PJ, R.K. 2013. Ovitrap surveillance of *Aedes* mosquitoes (Diptera: Culicidae) in selected areas of Dehradun District, Uttarakhand, India. *Global Journal of Med Res* **13**: 53-57.
- Dibo MR, Chierotti AP, Ferrari MS, Mendonca AL, Neto FC. 2008. Study of the relationship between *Aedes* (*Stegomyia*) *aegypti* egg and adult densities, dengue fever and climate in Mirassol, state of Sao Paulo, Brazil. *Mem Inst Oswaldo Cruz* **103**: 554-560.

- Dickinson JM, Klownden MJ. 1997. Reduced transfer of male accessory gland proteins and monandry in female *Aedes aegypti* mosquitoes. *J Vector Ecol* **22**: 95-98.
- Dominiak BC, Sundaralingam S, Jiang L, Jessup A, Barchia IM. 2008. Production levels and life history traits of mass reared Queensland fruit fly *Bactrocera tryoni* (Froggatt) (Diptera: Tephritidae) during 1999/2000 in Australia. *Plant Protection Quarterly* **23**: 131-135.
- Doucoure S, Mouchet F, Cornelié S, DeHecq JS, Rutee AH, Roca Y, Walter A, Herve JP, Misse D, Favier F et al. 2012. Evaluation of the human IgG antibody response to *Aedes albopictus* saliva as a new specific biomarker of exposure to vector bites. *PLoS Negl Trop Dis* **6**: e1487.
- Dunning Hotopp JC. 2011. Horizontal gene transfer between bacteria and animals. *Trends Genet* **27**: 157-163.
- Dunning Hotopp JC, Clark ME, Oliveira DC, Foster JM, Fischer P, Munoz Torres MC, Giebel JD, Kumar N, Ishmael N, Wang S et al. 2007. Widespread lateral gene transfer from intracellular bacteria to multicellular eukaryotes. *Science* **317**: 1753-1756.
- DuRant SE, Hopkins WA. 2008. Amphibian predation on larval mosquitoes. *Canadian Journal of Zoology* **86**: 1159-1164.
- Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, Barlan IB. 2010. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. *Clin Exp Allergy* **40**: 922-932.
- Einspanier R, Klotz A, Kraft J, Aulrich K, Poser R, Schwägele F, Jahreis G, Flachowsky G. 2001. The fate of forage plant DNA in farm animals: a collaborative case-study investigating cattle and chicken fed recombinant plant material. *European Food Research and Technology* **212**: 129-134.
- Elder R, Lamche G. 2004. Update on the *Aedes aegypti* mosquito eradication campaign in Tennant Creek, NT. *Northern Territory Disease Control Bulletin* **11**.
- FAO/IAEA/USDA. 2003. Manual for product quality control and shipping procedures for sterile mass-reared tephritid fruit flies. <http://www.naweb.iaea.org/nafa/ipc/public/ipc-mass-reared-tephritid.html>. International Atomic Energy Agency, Vienna, Austria.
- Fawaz EY, Allan SA, Bernier UR, Obenauer PJ, Diclaro JW, 2nd. 2014. Swarming mechanisms in the yellow fever mosquito: aggregation pheromones are involved in the mating behavior of *Aedes aegypti*. *J Vector Ecol* **39**: 347-354.
- FDA. 1992. Statement of policy-Foods derived from new plant varieties. <http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/BioTechnology/ucm096095.htm>.
- FDA. 2010. NPC 000004: Agency Response Letter. <http://www.fda.gov/Food/FoodScienceResearch/GEPlants/Submissions/ucm222920.htm>.
- FDA. 2014a. April 11, 2014 Approval Letter - GRASTEK. <http://www.fda.gov/BiologicsBloodVaccines/Allergens/ucm393185.htm>
- FDA. 2014b. FDA approves first sublingual allergen extract for the treatment of certain grass pollen allergies. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm391458.htm>
- FDA. 2014c. FDA approves Ragwitek for short ragweed pollen allergies. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393820.htm>
- Feldhamer GA, Carter TC. 2009. Prey consumed by eight species of insectivorous bats from Southern Illinois. *American Midland Naturalist* **162**: 43-51.
- Flachowsky G, Aulrich K, Bohme H, Daenicke R. 2000. GMO in animal nutrition: results of experiments at our Institute. In *6th International Feed Production Conference*, (ed. G Piva, F Masoero), pp. 291-307, Piacenza, Italy.
- Flachowsky G, Schafft H, Meyer U. 2012. Animal feeding studies for nutritional and safety assessments of feeds from genetically modified plants: a review. *Journal für Verbraucherschutz und*

- Lebensmittelsicherheit* **7**: 179-194.
- FLDOH. 2012. Mosquito-borne disease alert issued for Miami-Dade County. <http://www.floridahealth.gov/diseases-and-conditions/mosquito-borne-diseases/documents/2012/documents/miami-dade-2degue-alert-11-16-12.pdf>.
- FLDOH. 2013. Martin County dengue outbreak and serosurvey. <http://www.floridahealth.gov/diseases-and-conditions/dengue/documents/mc-dengue-survey-summary-june2014.pdf>.
- Focks DA, Haile DG, Daniels E, Mount GA. 1993. Dynamic life table model for *Aedes aegypti* (Diptera: Culicidae): analysis of the literature and model development. *J Med Entomol* **30**: 1003-1017.
- Getis A, Morrison AC, Gray K, Scott TW. 2003. Characteristics of the spatial pattern of the dengue vector, *Aedes aegypti*, in Iquitos, Peru. *The American journal of tropical medicine and hygiene* **69**: 494-505.
- Gill G, Ptashne M. 1988. Negative effect of the transcriptional activator GAL4. *Nature* **334**: 721-724.
- Glen DM. 2004. Birds as predators of lepidopterous larvae. In *Insect and bird interactions*, (ed. HF Van Emden, M Rothschild), pp. 89-108. Intercep.
- Gloria-Soria A, Brown JE, Kramer V, Hardstone Yoshimizu M, Powell JR. 2014. Origin of the dengue fever mosquito, *Aedes aegypti*, in California. *PLoS Negl Trop Dis* **8**: e3029.
- Gong P, Epton MJ, Fu G, Scaife S, Hiscox A, Condon KC, Condon GC, Morrison NI, Kelly DW, Dafa'alla T et al. 2005. A dominant lethal genetic system for autocidal control of the Mediterranean fruitfly. *Nat Biotech* **23**: 453-456.
- Gonsalves L, Bicknell B, Law B, Webb C, Monamy V. 2013. Mosquito consumption by insectivorous bats: does size matter? *PLoS One* **8**: e77183.
- Gorman K, Young J, Pineda L, Marquez R, Sosa N, Bernal D, Torres R, Soto Y, Lacroix R, Naish N et al. 2016. Short-term suppression of *Aedes aegypti* using genetic control does not facilitate *Aedes albopictus*. *Pest Manag Sci* **72**: 618-628.
- Gossen M, Bujard H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *PNAS* **89**: 5547-5551.
- Gratz NG. 2004. Critical review of the vector status of *Aedes albopictus*. *Med Vet Entomol* **18**: 215-227.
- Griffitts THD. 1933. Air traffic in relation to public health. *American Journal of Tropical Medicine and Hygiene* **s1-13**: 283-290.
- Grossman GL, James AA. 1993. The salivary glands of the vector mosquito, *Aedes aegypti*, express a novel member of the amylase gene family. *Insect Mol Biol* **1**: 223-232.
- Guagliardo SA, Barboza JL, Morrison AC, Astete H, Vazquez-Prokopec G, Kitron U. 2014. Patterns of geographic expansion of *Aedes aegypti* in the Peruvian Amazon. *PLoS Negl Trop Dis* **8**: e3033.
- Gubler DJ. 2006. Dengue/dengue haemorrhagic fever: history and current status. *Novartis Found Symp* **277**: 3-16; discussion 16-22, 71-13, 251-253.
- Gubler DJ. 2011. Prevention and control of *Aedes aegypti*-borne diseases: lesson learned from past successes and failures. *AsPac J Mol Biol Biotechnol* **19**: 111-114.
- Gubler DJ, Clark GG. 1995. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. *Emerg Infect Dis* **1**: 55-57.
- Gubler DJ, Reiter P, Ebi KL, Yap W, Nasci R, Patz JA. 2001. Climate variability and change in the United States: potential impacts on vector- and rodent-borne diseases. *Environ Health Perspect* **109 Suppl 2**: 223-233.
- Gulkowska A, Leung HW, So MK, Taniyasu S, Yamashita N, Yeung LW, Richardson BJ, Lei AP, Giesy JP, Lam PK. 2008. Removal of antibiotics from wastewater by sewage treatment facilities in Hong Kong and Shenzhen, China. *Water Res* **42**: 395-403.
- Halstead SB. 2012. Dengue vaccine development: a 75% solution? *The Lancet* **380**: 1535-1536.
- Handler AM. 2002. Use of the piggyBac transposon for germ-line transformation of insects. *Insect biochemistry and molecular biology* **32**: 1211-1220.

- Handler AM, McCombs SD, Fraser MJ, Saul SH. 1998. The lepidopteran transposon vector, piggyBac, mediates germ-line transformation in the Mediterranean fruit fly. *Proceedings of the National Academy of Sciences* **95**: 7520-7525.
- Harper JP, Paulson SL. 1994. Reproductive isolation between Florida strains of *Aedes aegypti* and *Aedes albopictus*. *J Am Mosq Control Assoc* **10**: 88-92.
- Harrington LC, Scott TW, Lerdthusnee K, Coleman RC, Costero A, Clark GG, Jones JJ, Kitthawee S, Kittayapong P, Sithiprasasna R et al. 2005. Dispersal of the dengue vector *Aedes aegypti* within and between rural communities. *The American Journal of Tropical Medicine and Hygiene* **72**: 209-220.
- Harris AF, McKemey AR, Nimmo D, Curtis Z, Black I, Morgan SnA, Oviedo MN, Lacroix R, Naish N, Morrison NI et al. 2012. Successful suppression of a field mosquito population by sustained release of engineered male mosquitoes. *Nat Biotech* **30**: 828-830.
- Harris AF, Nimmo D, McKemey AR, Kelly N, Scaife S, Donnelly CA, Beech C, Petrie WD, Alpey L. 2011. Field performance of engineered male mosquitoes. *Nat Biotechnol* **29**: 1034-1037.
- Hartberg WK. 1971. Observations on the mating behaviour of *Aedes aegypti* in nature. *Bulletin of the World Health Organization* **45**: 847.
- Hayden MH, Uejio CK, Walker K, Ramberg F, Moreno R, Rosales C, Gameros M, Mearns LO, Zielinski-Gutierrez E, Janes CR. 2010. Microclimate and Human Factors in the Divergent Ecology of *Aedes aegypti* along the Arizona, U.S./Sonora, MX Border. *EcoHealth* **7**: 64-77.
- Helinski ME, Deewatthanawong P, Sirot LK, Wolfner MF, Harrington LC. 2012. Duration and dose-dependency of female sexual receptivity responses to seminal fluid proteins in *Aedes albopictus* and *Ae. aegypti* mosquitoes. *J Insect Physiol* **58**: 1307-1313.
- Helinski MEH, Harrington LC. 2011. Male Mating History and Body Size Influence Female Fecundity and Longevity of the Dengue Vector *Aedes aegypti*. *Journal of Medical Entomology* **48**: 202-211.
- Hemme RR, Tank JL, Chadee DD, Severson DW. 2009. Environmental conditions in water storage drums and influences on *Aedes aegypti* in Trinidad, West Indies. *Acta Tropica* **112**: 59-66.
- Hemme RR, Thomas CL, Chadee DD, Severson DW. 2010. Influence of Urban Landscapes on Population Dynamics in a Short-Distance Migrant Mosquito: Evidence for the Dengue Vector *Aedes aegypti*. *PLoS Neglected Tropical Diseases* **4**: e634.
- Homem V, Santos L. 2011. Degradation and removal methods of antibiotics from aqueous matrices--a review. *J Environ Manage* **92**: 2304-2347.
- Honorio NA, Castro MG, Barros FS, Magalhaes Mde A, Sabroza PC. 2009. The spatial distribution of *Aedes aegypti* and *Aedes albopictus* in a transition zone, Rio de Janeiro, Brazil. *Cad Saude Publica* **25**: 1203-1214.
- Hribar LJ, Smith JM, Vlach JJ, Verna TN. 2001. Survey of Container-Feeding Mosquitoes from the Florida Keys, Monroe County, Florida. *J Am Mosquito Contr Association* **17**: 245-248.
- Hribar LJ, Vlach JJ, DeMay DJ, James SS, Fahey JS, Fussell EM. 2004. Mosquito larvae (Culicidae) and other Diptera associated with containers, storm drains, and sewage treatment plants in the Florida Keys, Monroe County, Florida. *Florida Entomologist* **87**: 199-203.
- HSE. 2014. The genetically modified organisms (contained use) regulations 2014. <http://www.hse.gov.uk/pubns/priced/l29.pdf>. Health and Safety Executive, London.
- Irving-Bell RJ, Okoli EI, Diyelong DY, Lyimo EO, Onyia OC. 1987. Septic tank mosquitoes: competition between species in central Nigeria. *Med Vet Entomol* **1**: 243-250.
- James AA, Blackmer K, Marinotti O, Ghosn CR, Racioppi JV. 1991. Isolation and characterization of the gene expressing the major salivary gland protein of the female mosquito, *Aedes aegypti*. *Mol Biochem Parasitol* **44**: 245-253.
- James JM, Crespo JF. 2007. Allergic reactions to foods by inhalation. *Curr Allergy Asthma Rep* **7**: 167-174.
- Jasinskiene N, Coates CJ, Benedict MQ, Cornel AJ, Rafferty CS, James AA, Collins FH. 1998. Stable

- transformation of the yellow fever mosquito, *Aedes aegypti*, with the Hermes element from the housefly. *Proceedings of the National Academy of Sciences* **95**: 3743-3747.
- Johnson PH, Spitzauer V, Ritchie SA. 2012. Field sampling rate of BG-sentinel traps for *Aedes aegypti* (Diptera: Culicidae) in suburban Cairns, Australia. *J Med Entomol* **49**: 29-34.
- Johnson RF. 1967. Seasonal variation in the food of the Purple Martin *Progne Subis* in Kansas. *IBIS* **109**: 8-13.
- Joy TK, Jeffrey Gutierrez EH, Ernst K, Walker KR, Carriere Y, Torabi M, Riehle MA. 2012. Aging field collected *Aedes aegypti* to determine their capacity for dengue transmission in the southwestern United States. *PLoS One* **7**: e46946.
- Juliano SA, Lounibos LP. 2005. Ecology of invasive mosquitoes: effects on resident species and on human health. *Ecol Lett* **8**: 558-574.
- Kanzok SM, Jacobs-Lorena M. 2006. Entomopathogenic fungi as biological insecticides to control malaria. *Trends Parasitol* **22**: 49-51.
- Keese P. 2008. Risks from GMOs due to horizontal gene transfer. *Environ Biosafety Res* **7**: 123-149.
- Keles S, Karakoc-Aydiner E, Ozen A, Izgi AG, Tevetoglu A, Akkoc T, Bahceciler NN, Barlan I. 2011. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. *J Allergy Clin Immunol* **128**: 808-815 e807.
- Khumnirdetch VU, Intarachote S, Treemanee S, Tragoonroong S, Thummabood S. 2001. Detection of GMOs in the broilers that utilized genetically modified soybean meals as a feed ingredient (Poster 585). In *Plant and Animal Genome IX Conference*, San Diego, CA.
- Klotz A, Einspanier R. 1998. Nachweis von "Novel-Feed" im Tier? Beeinträchtigung des Verbrauchers von Fleisch oder Milch ist nicht zu erwarten. *Mais* **3**: 109-111.
- Klotz A, Mayer J, Einspanier R. 2002. Degradation and possible carry over of feed DNA monitored in pigs and poultry. *European Food Research and Technology* **214**: 271-275.
- Koukidou M, Klinakis A, Reboulakis C, Zagoraiou L, Tavernarakis N, Livadaras I, Economopoulos A, Savakis C. 2006. Germ line transformation of the olive fly *Bactrocera oleae* using a versatile transgenesis marker. *Insect molecular biology* **15**: 95-103.
- Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, Moore CG, Carvalho RG, Coelho GE, Van Bortel W et al. 2015. The global distribution of the arbovirus vectors *Aedes aegypti* and *Ae. albopictus*. *Elife* **4**: e08347.
- Krockel U, Rose A, Eiras AE, Geier M. 2006. New tools for surveillance of adult yellow fever mosquitoes: comparison of trap catches with human landing rates in an urban environment. *J Am Mosq Control Assoc* **22**: 229-238.
- Kurland CG, Canback B, Berg OG. 2003. Horizontal gene transfer: a critical view. *Proc Natl Acad Sci U S A* **100**: 9658-9662.
- Kuwayama H, Yaginuma T, Yamashita O, Niimi T. 2006. Germ-line transformation and RNAi of the ladybird beetle, *Harmonia axyridis*. *Insect molecular biology* **15**: 507-512.
- Labbé GMC, Nimmo DD, Alphey L. 2010. piggybac- and PhiC31-Mediated Genetic Transformation of the Asian Tiger Mosquito, *Aedes albopictus* (Skuse). *PLoS Neglected Tropical Diseases* **4**: e788.
- Lacey LA, Shapiro-Ilan DI. 2003. The potential role for microbial control of orchard insect pests in sustainable agriculture. *Food, Agriculture and Environment* **1**: 326-331.
- Lacroix R, McKemey AR, Raduan N, Kwee Wee L, Nordin O. 2012. Open Field Release of Genetically Engineered Sterile Male *Aedes aegypti* in Malasia. *PLoS ONE* **7**: e42771.
- Le-Minh N, Khan SJ, Drewes JE, Stuetz RM. 2010. Fate of antibiotics during municipal water recycling treatment processes. *Water Research* **44**: 4295-4323.
- Leahy MG, Craig JGB. 1967. Barriers to hybridization between *Aedes aegypti* and *Aedes albopictus*. *Evolution* **21**: 41-58.
- Leal AL, Hribar LJ. 2010. Mosquito Fauna of Wilderness Islands Within the National Key Deer Refuge and

- the Great White Heron National Wildlife Refuge, Monroe County, Florida. *Journal of the American Mosquito Control Association* **26**: 141-147.
- Lee DK, Ghatkar AP, Vinson SB, Olson JK. 1994. Impact of foraging red imported fire ants (*Solenopsis invicta*) (Hymenoptera: Formicidae) on *Psorophora columbiae* eggs. *J Am Mosq Control Assoc* **10**: 163-173.
- Lee HL, Aramu M, Nazni WA, Selvi S, Vasani S. 2009a. No evidence for successful interspecific cross-mating of transgenic *Aedes aegypti* (L.) and wild type *Aedes albopictus* Skuse. *Tropical Biomedicine* **26**: 312-319.
- Lee HL, Joko H, Nazni WA, Vasani S. 2009b. Comparative life parameters of transgenic and wild strain of *Aedes aegypti* in the laboratory *Dengue Bulletin* **33**: 103-114.
- Leles RN, D'Alessandro WB, Luz C. 2012. Effects of *Metarhizium anisopliae* conidia mixed with soil against the eggs of *Aedes aegypti*. *Parasitology Research* **110**: 1579-1582.
- Lin H, McGrath J, Wang P, Lee T. 2007. Cellular toxicity induced by SRF-mediated transcriptional squelching. *Toxicol Sci* **96**: 83-91.
- Locatelli MAF, Sodr e FF, Jardim WF. 2011. Determination of Antibiotics in Brazilian Surface Waters Using Liquid Chromatography–Electrospray Tandem Mass Spectrometry. *Archives of Environmental Contamination and Toxicology* **60**: 385-393.
- Lopez-Penalver JJ, Sanchez-Polo M, Gomez-Pacheco CV, Rivera-Utrilla J. 2010. Photodegradation of tetracyclines in aqueous solution by using UV and UV/H<sub>2</sub>O<sub>2</sub> oxidation processes. *J Chem Tech Biotech* **85**: 1325-1333.
- Lounibos LP. 2002. Invasions by insect vectors of human disease. *Annu Rev Entomol* **47**: 233-266.
- Lukyanov KA. 2000. Natural Animal Coloration Can Be Determined by a Nonfluorescent Green Fluorescent Protein Homolog. *Journal of Biological Chemistry* **275**: 25879-25882.
- Maciel-de-Freitas R, Avendano FC, Santos R, Sylvestre G, Araujo SC, Lima JB, Martins AJ, Coelho GE, Valle D. 2014. Undesirable consequences of insecticide resistance following *Aedes aegypti* control activities due to a dengue outbreak. *PLoS One* **9**: e92424.
- Maciel-de-Freitas R, Codeco CT, Lourenco-de-Oliveira R. 2007. Daily survival rates and dispersal of *Aedes aegypti* females in Rio de Janeiro, Brazil. *Am J Trop Med Hyg* **76**: 659-665.
- Maciel-de-Freitas R, Lourenco-de-Oliveira R. 2009. Presumed unconstrained dispersal of *Aedes aegypti* in the city of Rio de Janeiro, Brazil. *Revista de Saude P blica* **43**: 8-12.
- Maciel de Freitas R, Sousa-Santos R, Codeco CT, Lourenco-de-Oliveira R. 2010. Influence of the spatial distribution of human hosts and large size containers on the dispersal of the mosquito *Aedes aegypti* within the first gonotrophic cycle. *Medical and Veterinary Entomology* **24**: 74-82.
- Mackay AJ, Amador M, Diaz A, Smith J, Barrera R. 2009. Dynamics of *Aedes aegypti* and *Culex quinquefasciatus* in septic tanks. *J Am Mosq Control Assoc* **25**: 409-416.
- Manly BFJ. 2007. *Randomization, bootstrap and Monte Carlo methods in biology*. Chapman and Hall/CRC, Boca Raton, FL.
- Marcombe S, Darriet F, Tolosa M, Agnew P, Duchon S, Etienne M, Yp Tcha MM, Chandre F, Corbel V, Yebakima A. 2011. Pyrethroid resistance reduces the efficacy of space sprays for dengue control on the island of Martinique (Caribbean). *PLoS Negl Trop Dis* **5**: e1202.
- Martinez-Ibarra JA, Rodriguez MH, Arredondo-Jimenez JI, Yuval B. 1997. Influence of plant abundance on nectar feeding by *Aedes aegypti* (Diptera: Culicidae) in southern Mexico. *J Med Entomol* **34**: 589-593.
- Matz MV, Fradkov AF, Labas YA, Savitsky AP, Zaraisky AG, Markelov ML, Lukyanov SA. 1999. Fluorescent proteins from nonbioluminescent Anthozoa species. *Nature Biotech* **17**: 969-973.
- Mayer DG, Atzeni MG, Stuart MA, Anaman KA, Butler DG. 1998. Mating competitiveness of irradiated flies for screwworm fly eradication campaigns. *Preventive veterinary medicine* **36**: 1-9.
- McBride CS, Baier F, Omondi AB, Spitzer SA, Lutomiah J, Sang R, Ignell R, Vossell LB. 2014. Evolution of

- mosquito preference for humans linked to an odorant receptor. *Nature* **515**: 222-227.
- McDonald PT. 1977. POPULATION CHARACTERISTICS OF DOMESTIC Aedes Aegypti (DIPTERA: GULICIDAE) IN VILLAGES ON THE KENYA COAST II. Dispersal within and between villages. *Journal of Medical Entomology* **14**: 49-53.
- McQuillan D, Hopkins S, Chapman TH, Sherrell K, Mills D. 2002. Drug residues in ambient water: Initial surveillance in New Mexico, USA.
- Miller MJ, Loaiza JR. 2015. Geographic expansion of the invasive mosquito *Aedes albopictus* across Panama--implications for control of dengue and Chikungunya viruses. *PLoS Negl Trop Dis* **9**: e0003383.
- Millwood RJ, Moon HS, Neal Stewart C. 2010. Fluorescent Proteins in Transgenic Plants. In *Reviews in Fluorescence 2008*, Vol 2008 (ed. CD Geddes), pp. 387-403. Springer New York, New York, NY.
- Mogi M. 2007. Insects and other invertebrate predators. *J Am Mosq Control Assoc* **23**: 93-109.
- Moll RM, Romoser WS, Modrzakowski MC, Moncayo AC, Lerdthusnee K. 2001. Meconial peritrophic membranes and the fate of midgut bacteria during mosquito (Diptera: Culicidae) metamorphosis. *J Med Entomol* **38**: 29-32.
- Monteiro FA, Schama R, Martins AJ, Gloria-Soria A, Brown JE, Powell JR. 2014. Genetic diversity of Brazilian *Aedes aegypti*: patterns following an eradication program. *PLoS Negl Trop Dis* **8**: e3167.
- Moore DF. 1979. Hybridization and mating behavior in *Aedes aegypti* (Diptera: Culicidae). *J Med Entomol* **16**: 223-226.
- Morato VC, Teixeira Mda G, Gomes AC, Bergamaschi DP, Barreto ML. 2005. Infestation of *Aedes aegypti* estimated by oviposition traps in Brazil. *Rev Saude Publica* **39**: 553-558.
- Muir LE, Kay BH. 1998. *Aedes aegypti* survival and dispersal estimated by mark-release-recapture in northern Australia. *The American Journal of Tropical Medicine and Hygiene* **58**: 277-282.
- Munoz I, Carrillo M, Zanuy S, Gomez A. 2005. Regulation of exogenous gene expression in fish cells: an evaluation of different versions of the tetracycline-regulated system. *Gene* **363**: 173-182.
- Murphy B, Jansen C, Murray J, De Barro P. 2010. Risk Analysis on the Australian Release of *Aedes aegypti* (L.) (Diptera: Culicidae) containing *Wolbachia*
- Naidoo J, Young D. 2012. Gene regulation systems for gene therapy applications in the central nervous system. *Neurol Res Int* **2012**: 595410.
- Navarro JC, Del Ventura F, Zorrilla A, Liria J. 2010. [Highest mosquito records (Diptera: Culicidae) in Venezuela]. *Rev Biol Trop* **58**: 245-254.
- Nazni WA, Dayang HAB, Azahari AH. 2009a. Cross-mating between Malaysian strains of *Aedes aegypti* and *Aedes albopictus* in the laboratory. *Southeast Asian J Trop Med Public Health* **40**: 40-46.
- Nazni WA, Selvi S, Lee HL, Sadiyah I, Azahari AH, Derric N, Vasan S. 2009b. Susceptibility status of transgenic *Aedes aegypti* (L.) against insecticides. *Dengue Bulletin* **33**: 124-129.
- Neira M, Lacroix R, Caceres L, Kaiser PE, Young J, Pineda L, Black I, Sosa N, Nimmo D, Alphey L et al. 2014. Estimation of *Aedes aegypti* (Diptera: Culicidae) population size and adult male survival in an urban area in Panama. *Mem Inst Oswaldo Cruz* **109**: 879-886.
- NOAA. 2015. Saffir-Simpson Hurricane Wind Scale. <http://www.nhc.noaa.gov/aboutsshws.php>.
- Nordin O, Donald W, Ming WH, Ney TG, Mohamed KA, Halim NAA, Winskill P, Hadi AA, Muhammad ZSi, Lacroix R et al. 2013. Oral Ingestion of Transgenic RIDL *Ae. aegypti* Larvae Has No Negative Effect on Two Predator Toxorhynchites Species. *PLoS ONE* **8**: e58805  
doi:10.1371/journal.pone.0058805.
- NRC. 2002. *Animal biotechnology: science-based concerns*. The National Academic Press, Washington, DC.
- Nwoke BE, Nduka FO, Okereke OM, Ehigbibe OC. 1993. Sustainable urban development and human health: septic tank as a major breeding habitat of mosquito vectors of human diseases in south-eastern Nigeria. *Appl Parasitol* **34**: 1-10.

- Nyamah MA, Sulaiman S, Omar B. 2011. Field observation on the efficacy of *Toxorhynchites splendens* (Wiedemann) as a biocontrol agent against *Aedes albopictus* (Skuse) larvae in a cemetery. *Trop Biomed* **28**: 312-319.
- O'Brochta DA. 2003. Gene vector and transposable element behavior in mosquitoes. *Journal of Experimental Biology* **206**: 3823-3834.
- Ochman H, Lawrence JG, Groisman EA. 2000. Lateral gene transfer and the nature of bacterial innovation. *Nature* **405**: 299-304.
- OECD. 1984. *Test No. 204: Fish, Prolonged Toxicity Test: 14-Day Study*. Organisation for Economic Co-operation and Development, Paris.
- Ordóñez-González JG, Mercado-Hernández R, Flores-Suárez AE, Fernández-Salas I. 2001. The use of sticky ovitraps to estimate dispersal of *Aedes aegypti* in northeastern Mexico. *J Am Mosq Control Assoc* **17**: 93-97.
- Otero M, Solari HG, Schweigmann N. 2006. A Stochastic Population Dynamics Model for *Aedes Aegypti*: Formulation and Application to a City with Temperate Climate. *Bulletin of Mathematical Biology* **68**: 1945-1974.
- Palavesam A, Esnault C, O'Brochta DA. 2013. Post-Integration Silencing of piggyBac Transposable Elements in *Aedes aegypti*. *PLoS ONE* **8**: e68454.
- Pascini TV, Ramalho-Ortigao M, Martins GF. 2012. Morphological and morphometrical assessment of spermathecae of *Aedes aegypti* females. *Mem Inst Oswaldo Cruz* **107**: 705-712.
- Patiny S, ed. 2012. *Evolution of plant-pollinator relationships*. Cambridge University Press, Cambridge.
- Peters TM, Barbosa P. 1977. Influence of population density on size, fecundity, and developmental rate of insects in culture. *Annu Rev Entomol* **22**: 431-450.
- Phillips BM, Anderson BS, Voorhees JP, Siegler K, Denton D, TenBrook P, Larsen K, Isorena P, Tjeerdema RS. 2014. Monitoring the aquatic toxicity of mosquito vector control spray pesticides to freshwater receiving waters. *Integr Environ Assess Manag* **10**: 449-455.
- Phuc HK, Andreasen MH, Burton RS, Vass C, Epton MJ, Pape G, Fu G, Condon KC, Scaife S, Donnelly CA et al. 2007. Late-acting dominant lethal genetic systems and mosquito control. *BMC Biol* **5**: 11.
- Pierce RH, Henry MS, Blum TC, Mueller EM. 2005. Aerial and tidal transport of mosquito control pesticides into the Florida Keys National Marine Sanctuary. *Rev Biol Trop* **53 Suppl 1**: 117-125.
- Pils JRV, Laird DA. 2007. Sorption of Tetracycline and Chlortetracycline on K- and Ca-Saturated Soil Clays, Humic Substances, and Clay-Humic Complexes. *Environ Sci Technol* **41**: 1928-1933.
- Pioneer Hi-Bred International I. 2006. Early food safety evaluation for a Red Fluorescent Protein: DsRed2. <http://www.fda.gov/downloads/Food/Biotechnology/Submissions/UCM219002.pdf>.
- Ponnusamy L, Xu N, Nojima S, Wesson DM, Schal C, Apperson CS. 2008. Identification of bacteria and bacteria-associated chemical cues that mediate oviposition site preferences by *Aedes aegypti*. *Proceedings of the National Academy of Sciences* **105**: 9262-9267.
- Racioppi JV, Spielman A. 1987. Secretory proteins from the salivary glands of adult *Aedes aegypti* mosquitoes. *Insect Biochem* **17**: 503-511.
- Radke EG, Gregory CJ, Kintzinger KW, Sauber-Schatz EK, Hunsperger EA, Gallagher GR. 2012. Dengue outbreak in Key West, Florida, USA, 2009. In *Emerg Infect Dis [serial on the Internet]*, doi:DOI: 10.3201/eid1801.110130.
- Ramasamy R, Surendran SN, Jude PJ, Dharshini S, Vinobaba M. 2011. Larval Development of *Aedes aegypti* and *Aedes albopictus* in Peri-Urban Brackish Water and Its Implications for Transmission of Arboviral Diseases. *PLoS Neglected Tropical Diseases* **5**: e1369.
- Ranson H, Burhani J, Lumjuan N, Black IV WC. 2010. Insecticide resistance in dengue vectors. *TropIKA* **1**.
- Rao D, Aguilar-Arguello S, Montoya P, Diaz-Fleischer F. 2014. The effect of irradiation and mass rearing on the anti-predator behaviour of the Mexican fruit fly, *Anastrepha ludens* (Diptera: Tephritidae). *Bull Entomol Res* **104**: 176-181.

- Reiter P. 1996. [Oviposition and dispersion of *Aedes aegypti* in an urban environment]. *Bull Soc Pathol Exot* **89**: 120-122.
- Reiter P, Amador MA, Anderson RA, Clark GG. 1995. SHORT REPORT: DISPERSAL OF AEDES AEGYPTI IN AN URBAN AREA AFTER BLOOD FEEDING AS DEMONSTRATED BY RUBIDIUM-MARKED EGGS. *Am J Trop Med Hyg* **52**: 177-179.
- Rendón P, McInnis D, Lance D, Stewart J. 2004. Medfly (Diptera:Tephritidae) Genetic Sexing: Large-Scale Field Comparison of Males-Only and Bisexual Sterile Fly Releases in Guatemala. *Journal of Economic Entomology* **97**: 1547-1553.
- Reuben R, Panicker KN. 1975. Studies on dispersal and loss rates of male *Aedes aegypti* (L.) in different seasons at Sonapat, India. *J Commun Dis* **7**: 301-312.
- Rey JR, O'Connell SM. 2014. Oviposition by *Aedes aegypti* and *Aedes albopictus*: influence of congeners and of oviposition site characteristics. *J Vector Ecol* **39**: 190-196.
- Ribeiro JM. 1995. Blood-feeding arthropods: live syringes or invertebrate pharmacologists? *Infect Agents Dis* **4**: 143-152.
- Richards HA, Han C-T, Hopkins RG, Failla ML, Ward WW, Stewart CN. 2003. Safety assessment of recombinant green fluorescent protein orally administered to weaned rats. *The Journal of nutrition* **133**: 1909-1912.
- Rowley WA, Graham CL. 1968. The effect of temperature and relative humidity on the flight performance of female *Aedes aegypti*. *J Insect Physiol* **14**: 1251-1257.
- Rueda LM, Patel KJ, Axtell RC, Stinner RE. 1990. Temperature-dependent development and survival rates of *Culex quinquefasciatus* and *Aedes aegypti* (Diptera: Culicidae). *J Med Entomol* **27**: 892-898.
- Rull J, Encarnacion N, Birke A. 2012. Mass rearing history and irradiation affect mating performance of the male fruit fly, *Anastrepha obliqua*. *J Insect Sci* **12**: 45.
- Russell BM, Kay BH, Shipton W. 2001. Survival of *Aedes aegypti* (Diptera: Culicidae) eggs in surface and subterranean breeding sites during the northern Queensland dry season. *J Med Entomol* **38**: 441-445.
- Russell RC, Webb CE, Williams CR, Ritchie SA. 2005. Mark–release–recapture study to measure dispersal of the mosquito *Aedes aegypti* in Cairns, Queensland, Australia. *Medical and veterinary entomology* **19**: 451-457.
- Sarmah AK, Meyer MT, Boxall AB. 2006. A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment. *Chemosphere* **65**: 725-759.
- Scholte EJ, Hartog WD, Dik M, Schoelitz B, Brooks M, Schaffner F, Foussadier R, Braks M, Beeuwkes J. 2010. Introduction and control of three invasive mosquito species in the Netherlands, July-October 2010. *Euro Surveill* **15**: 1-4.
- Scholte EJ, Takken W, Knols BG. 2007. Infection of adult *Aedes aegypti* and *Ae. albopictus* mosquitoes with the entomopathogenic fungus *Metarhizium anisopliae*. *Acta Trop* **102**: 151-158.
- Schonig K, Freundlieb S, Gossen M. 2013. Tet-Transgenic Rodents: a comprehensive, up-to date database. *Transgenic Res* **22**: 251-254.
- Serpa LL, Monteiro Marques GR, de Lima AP, Voltolini JC, Arduino Mde B, Barbosa GL, Andrade VR, de Lima VL. 2013. Study of the distribution and abundance of the eggs of *Aedes aegypti* and *Aedes albopictus* according to the habitat and meteorological variables, municipality of Sao Sebastiao, Sao Paulo State, Brazil. *Parasit Vectors* **6**: 321.
- Sethuraman N, Fraser MJ, Eggleston P, O'Brochta DA. 2007. Post-integration stability of piggyBac in *Aedes aegypti*. *Insect Biochemistry and Molecular Biology* **37**: 941-951.
- Shalan EA, Canyon DV. 2009. Aquatic insect predators and mosquito control. *Trop Biomed* **26**: 223-261.
- Shagin DA. 2004. GFP-like Proteins as Ubiquitous Metazoan Superfamily: Evolution of Functional Features and Structural Complexity. *Molecular Biology and Evolution* **21**: 841-850.

- Sharma K, Angel B, Singh H, Purohit A, Joshi V, others. 2008. Entomological studies for surveillance and prevention of dengue in arid and semi-arid districts of Rajasthan, India. *Journal of vector borne diseases* **45**: 124.
- Sharma VP, Patterson RS, Ford HR. 1972. A device for the rapid separation of male and female mosquito pupae. *Bulletin of the World Health Organization* **47**: 429.
- Shelly TE, McInnis DO, Rodd C, Edu J, Pahio E. 2007. Sterile insect technique and Mediterranean fruit fly (Diptera: Tephritidae): assessing the utility of aromatherapy in a Hawaiian coffee field. *Journal of Economic Entomology* **100**: 273-282.
- Silver JB. 2008. *Mosquito Ecology*. Springer, New York.
- Sirost LK, Poulson RL, Caitlin McKenna M, Girnary H, Wolfner MF, Harrington LC. 2008. Identity and transfer of male reproductive gland proteins of the dengue vector mosquito, *Aedes aegypti*: Potential tools for control of female feeding and reproduction. *Insect Biochemistry and Molecular Biology* **38**: 176-189.
- Sithole BB, Guy RD. 1987. Models for tetracycline in aquatic environments. *Water Air Soil Pollution* **32**: 303-314.
- Slosek J. 1986. *Aedes aegypti* mosquitoes in the Americas: a review of their interactions with the human population. *Soc Sci Med* **23**: 249-257.
- Somers G, Brown JE, Barrera R, Powell JR. 2011. Genetics and morphology of *Aedes aegypti* (Diptera: Culicidae) in septic tanks in Puerto Rico. *J Med Entomol* **48**: 1095-1102.
- Stark KR, James AA. 1998. Isolation and characterization of the gene encoding a novel factor Xa-directed anticoagulant from the yellow fever mosquito, *Aedes aegypti*. *J Biol Chem* **273**: 20802-20809.
- Stewart CN. 2006. Go with the glow: fluorescent proteins to light transgenic organisms. *Trends in Biotechnology* **24**: 155-162.
- Stieger K, Belbellaa B, Le Guiner C, Moullier P, Rolling F. 2009. In vivo gene regulation using tetracycline-regulatable systems. *Adv Drug Deliv Rev* **61**: 527-541.
- Suwonkerd W, Mongkalagoon P, Parbaripai A, Grieco J, Achee N, Roberts D, Chareonviriyaphap T. 2006. The effect of host type on movement patterns of *Aedes aegypti* (Diptera: Culicidae) into and out of experimental huts in Thailand. *Journal of Vector Ecology* **31**: 311-318.
- Swaminathan S, Khanna N, Herring B, Mahalingam S. 2013. Dengue vaccine efficacy trial: does interference cause failure? *Lancet Infect Dis* **13**: 191-192.
- Tabachnick WJ. 1991. Evolutionary Genetics and Arthropod-borne Disease: The Yellow Fever Mosquito. *American Entomologist* **37**: 14-26.
- Tambasco A, Hribar LJ. 2013. First record of *Toxorhynchites rutilus rutilus* (Coquillett) from the Florida Keys. *Studia Dipterologica* **20**: 68-70.
- Tamura T, Thibert C, Royer C, Kanda T, Eappen A, Kamba M, Kômoto N, Thomas J-L, Mauchamp B, Chavancy G et al. 2000. Germline transformation of the silkworm *Bombyx mori* L. using a piggyBac transposon-derived vector. *Nature Biotechnology* **18**: 81-84.
- Tatem AJ, Hay SI, Rogers DJ. 2006. Global traffic and disease vector dispersal. *Proc Natl Acad Sci U S A* **103**: 6242-6247.
- Teets FD, Ramgopal MN, Sweeney KD, Graham AS, Michael SF, Isern S. 2014. Origin of the dengue virus outbreak in Martin County, Florida, USA 2013. *Virology* **1-2**: 2-8.
- Thibault ST, Luu HT, Vann N, Miller TA. 1999. Precise excision and transposition of piggyBac in pink bollworm embryos. *Insect Molecular Biology* **8**: 119-123.
- Thien LB. 1969. Mosquito pollination of *Habenaria obtusata* (Orchidaceae). *American J Bot* **56**: 232-237.
- Thomas C, M., Nielsen K, M. 2005. Mechanisms of, and Barriers to, Horizontal Gene Transfer between Bacteria. *Nature Reviews Microbiology* **3**: 711-721.
- Thomas SM, Obermayr U, Fischer D, Kreyling J, Beierkuhnlein C. 2012. Low-temperature threshold for egg survival of a post-diapause and non-diapause European aedine strain, *Aedes albopictus*

- (Diptera: Culicidae). *Parasit Vectors* **5**: 1-7.
- Tripet F, Lounibos LP, Robbins D, Moran J, Nishimura N, Blosser EM. 2011. Competitive Reduction by Satyrization? Evidence for Interspecific Mating in Nature and Asymmetric Reproductive Competition between Invasive Mosquito Vectors. *American Journal of Tropical Medicine and Hygiene* **85**: 265-270.
- Trpis M, Hausermann W. 1986. Dispersal and other population parameters of *Aedes aegypti* in an African village and their possible significance in epidemiology of vector-borne diseases. *Am J Trop Med Hyg* **35**: 1263-1279.
- Tsuda Y, Takagi M. 2001. Survival and development of *Aedes aegypti* and *Aedes albopictus* (Diptera : Culicidae) larvae under a seasonally changing environment in Nagasaki, Japan. *Environ Entomology* **30**: 855-860.
- Tun-Lin W, Burkot TR, Kay BH. 2000. Effects of temperature and larval diet on development rates and survival of the dengue vector *Aedes aegypti* in north Queensland, Australia. *Medical and Veterinary Entomology* **14**: 31-37.
- Tun-Lin W, Kay BH, Barnes A. 1995. Understanding productivity, a key to *Aedes aegypti* surveillance. *Am J Trop Med Hyg* **53**: 595-601.
- USFWS. 2004. United States Fish and Wildlife Service Report; Appendix –K4: Effects of Mosquito Control. [http://www.fws.gov/cno/refuges/DonEdwards/CCP-PDFs/Appendix-K4\\_EffectsofMosquitoControl.pdf](http://www.fws.gov/cno/refuges/DonEdwards/CCP-PDFs/Appendix-K4_EffectsofMosquitoControl.pdf).
- Valenzuela JG, Pham VM, Garfield MK, Francischetti IMB, Ribeiro JMC. 2002. Toward a description of the sialome of the adult female mosquito *Aedes aegypti*. *Insect Biochemistry and Molecular Biology* **32**: 1101-1122.
- Valerio L, Facchinelli L, Ramsey JM, Bond JG, Scott TW. 2012. Dispersal of male *Aedes aegypti* in a coastal village in southern Mexico. *Am J Trop Med Hyg* **86**: 665-676.
- Van Eenennaam AL, Young AE. 2014. Prevalence and impacts of genetically engineered feedstuffs on livestock populations. *J Anim Sci* **92**: 4255-4278.
- Vreysen MJB. 2005. Monitoring sterile and wild insects in area-wide integrated pest management programmes. In *Sterile insect technique: Principles and practice in area-wide integrated pest management*, (ed. VA Dyck, et al.), pp. 325-361. Springer, Netherlands.
- Watkinson AJ, Murby EJ, Kolpin DW, Costanzo SD. 2009. The occurrence of antibiotics in an urban watershed: from wastewater to drinking water. *Sci Total Environ* **407**: 2711-2723.
- Weber TE, Richert BT. 2001. Grower-finisher growth performance and carcass characteristics including attempts to detect transgenic plant DNA and protein in muscle from pigs fed genetically modified "Bt" corn. Abstract 162. In *American Society of Animal Science Midwestern Section meeting*, Des Moines, IA.
- Wheeler AS, Petrie WD, Malone D. 2009. Reintroduction of *Aedes aegypti* into Grand Cayman. *J Am Mosq Control Assoc* **25**: 260-264.
- Wheeler AW, Petrie WD. 2007. An overview of *Aedes aegypti* and *Aedes albopictus* control in the British Overseas Territory of the Cayman Islands. *Euro Surveill* **12**: E071122-071123.
- Whitaker JO, Lawhead B. 1992. Foods of *Myotis lucifugus* in a maternity colony in Central Alaska. *J Mammalogy* **73**: 646-648.
- Whitsett JA, Perl AK. 2006. Conditional control of gene expression in the respiratory epithelium: A cautionary note. *Am J Respir Cell Mol Biol* **34**: 519-520.
- WHO. 2005. *International sanitary regulations*. World Health Organization, Geneva, Switzerland.
- Williams CR, Long SA, Webb CE, Bitzhenner M, Geier M, Russell RC, Ritchie SA. 2007. *Aedes aegypti* population sampling using BG-Sentinel traps in north Queensland Australia: statistical considerations for trap deployment and sampling strategy. *J Med Entomol* **44**: 345-350.
- Winskill P, Carvalho DO, Capurro ML, Alphey L, Donnelly CA, McKemey AR. 2015. Dispersal of Engineered

- Male *Aedes aegypti* Mosquitoes. *PLoS Negl Trop Dis* **9**: e0004156.
- Winskill P, Harris AF, Morgan SA, Stevenson J, Raduan N, Alphey L, McKemey AR, Donnelly CA. 2014. Genetic control of *Aedes aegypti*: data-driven modelling to assess the effect of releasing different life stages and the potential for long-term suppression. *Parasit Vectors* **7**: 68.
- Wise de Valdez MR. 2007. Predator avoidance behaviour of *Aedes aegypti* mosquito larvae infected with mermithid nematodes (Nematoda: Mermithidae). *J Vector Ecol* **32**: 150-153.
- Yang HM, Macoris ML, Galvani KC, Andrighetti MT, Wanderley DM. 2009. Assessing the effects of temperature on the population of *Aedes aegypti*, the vector of dengue. *Epidemiol Infect* **137**: 1188-1202.
- Yang P. 2006. Laboratory study of predation by *Curinus coeruleus* (Coleoptera: Coccinellidae) on eggs of *Aedes albopictus* (Diptera: Culicidae). *Proc Hawaiian Entomol Soc* **38**: 127-129.
- Yee DA, Kesavaraju B, Juliano SA. 2007. Direct and indirect effects of animal detritus on growth, survival, and mass of invasive container mosquito *Aedes albopictus* (Diptera: Culicidae). *J Med Entomol* **44**: 580-588.
- Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. 2012. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. *Int Arch Allergy Immunol* **157**: 288-298.
- Zhou H, Huang C, Yang M, Landel CP, Xia PY, Liu YJ, Xia XG. 2009. Developing tTA transgenic rats for inducible and reversible gene expression. *Int J Biol Sci* **5**: 171-181.
- Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA. 2002. Tetracycline-controlled transcriptional regulation systems: advances and application in transgenic animal modeling. *Semin Cell Dev Biol* **13**: 121-128.